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ABSTRACT 
 
 Current vascular implant materials poorly interact with smooth muscle cells 
(SMCs) of the media allowing the permanent loss of vascular elastin, eliminated by 
trauma or disease, a crucial element in maintaining the natural biomechanics of the blood 
vessel and overall vascular homeostasis. In addition, these materials insufficiently recruit 
vascular endothelial cells (ECs) to form a normally functional, confluent endothelium 
that acts as the interface between the blood and vascular tissue and regulates numerous 
vital vascular processes. As a result, the restenosis, or re-occlusion, rate within these 
devices has remained fairly high stimulating the investigation of numerous new materials 
capable of providing the necessary stimuli for the regeneration of vascular tissue. Our lab 
has reported extensively on hyaluronic acid (HA) as a vascular regenerative agent. We 
found it beneficially impact two key aspects of vascular regeneration, namely functional 
endothelialization and elastin matrix repair/ regeneration, and that the biologic impact is 
dependant on HA molecular weight. This project was initiated to investigate the size-
specific ability of exogenous HA to promote endothelialization, and then attempted to 
utilize this, and previously acquired information on the HA-dependant upregulation of 
elastogenesis of vascular SMCs, for the development of HA biomaterials, in the form of 
surface coatings and hydrogels, for vascular tissue engineering. 
 Exogenous supplementation of a HA digest (D2) containing a concentrated 
mixture of HA oligomers (0.75–10 kDa) promoted EC proliferation and tube formation, 
but also enhanced platelet attachment, CAM expression, and cytokine release. 
 ii
Conversely, the exogenous addition of HMW HA (HA 1500) inhibited platelet deposition 
on cultured ECs and limited their CAM expression and cytokine release. Upon 
immobilization onto a substrate through derivatization of HA without crosslinking, ECs 
were able to attach on D2, however HA 1500 deterred attachment. As observed with 
exogenous D2, ECs were able to proliferate on D2 substrates similar to cultures on 
fibronectin but also elicited CAM expression. Another HA digest (D1) containing a broad 
mixture of HA oligomers, previously shown to promote elastogenesis of vascular SMCs 
as an exogenous supplement, was also immobilized and stimulated SMCs to upregulate 
synthesis of soluble tropoelastin, and crosslinked matrix elastin similar to the levels 
previously observed with exogenous D1. These surfaces also enhanced elastin 
organization into fibrils and desmosine crosslinking to a greater degree than exogenous 
D1. These HA digests (D2, D1) were then separately embedded within divinyl sulfone 
(DVS) and glycidyl methacrylate (GM) crosslinked HA 1500 hydrogels (DVS-HA, GM-
HA), respectively, and we found the mechanical and physical properties of these 
hydrogels can be modulated by varying the crosslinker and oligomer concentration within 
them. However, the mechanical properties of these gels were too weak to act as 
standalone vascular scaffolding biomaterials and, therefore, must be used as composite 
structures. DVS-HA gels were somewhat cytotoxic stimulating an inflammatory reaction 
in vivo and EC CAM expression in vitro. Yet, the highest amount of EC attachment and 
proliferation was observed on DVS-HA that contained the highest amount of D2. SMCs 
survived encapsulation into the more biocompatible GM-HA gels and D1 incorporation 
elevated elastin levels to 2× the amount within GM-HA without D1. 
 iii
 Overall, we showed that HA oligomers are useful to incorporate within vascular 
biomaterial scaffold, either as surface-immobilized coatings or as hydrogels to promote 
endothelialization and elastic tissue regeneration. Our studies also indicate that 
incorporation of HMW HA is also necessary to temper adverse cell responses to HA 
oligomers (e.g., CAM expression) and provide mechanical stability/ ease of handling to 
the gels. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Engineering Vascular Regenerative Biomaterials  
 With increasing insight into the structural and functional characteristics of living 
organs, researchers have begun to investigate the possibility of designing and 
regenerating tissues, resulting in the development of tissue engineering, a field which 
focuses on the replacement of tissues damaged by disease and trauma. Broadly, tissue 
engineering may be defined as ‘the use of a combination of cells, engineering materials 
or scaffolds, and suitable biochemical factors to improve or replace biological functions 
in an effort to effect the advancement of medicine’ 1 Tissue engineering technologies have 
the potential to regenerate nearly limitless organs and tissues, and treat a wide variety of 
injuries and diseases. However, to date, the successful development of tissue engineering 
products has been limited to relatively simple and actively regenerating tissues, such as 
skin; the more complex and static tissues of the vascular system, are far more difficult to 
regenerate and current tissue engineering techniques have shown limited success in 
creating replacements for such tissues. Therefore, the current strategy is to focus on 
regenerating specific components of the blood vessel. 
 An outstanding problem addressed by this study is the insufficiency of 
conventional vascular biomaterials to stimulate the regeneration of the luminal 
endothelial cell (EC) monolayer and medial elastin matrix of blood vessels. Vascular ECs 
are one of the most complex and sensitive components of the blood vessel in terms of 
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physical structure, cell signaling, and physiologic function. They serve as a semi-
permeable barrier between the two vascular compartments, namely blood and vascular 
connective tissue, controlling the transfer of cellular and non-cellular (e.g., growth factors, 
proteins, cytokines) components between the compartments and thereby influencing 
effective vascular function. Under healthy, non-activated, conditions ECs regulate 
numerous processes that maintain vascular homeostasis but if diseased or physiologically 
injured, they initiate restorative signaling pathways that can be exaggerated and lead to 
further tissue impairment, if prolonged. Moreover the ECs also actively regulate smooth 
muscle cells (SMCs) within the underlying medial layer of the vessel wall by release of 
signaling biomolecules such as nitric oxide (NO) and prostacyclin 2. While SMCs are 
responsible for vasoregulation, they also generate structural matrix proteins (e.g. collagen, 
elastin) within the media, which contributes to the structural integrity of the blood vessel. 
The vascular extracellular matrix (ECM) is composed primarily of collagen and elastin, 
which affect the mechanical behavior of blood vessels in different ways. The initial strain 
applied to blood vessels due to blood flow is accommodated by elastin allowing the 
vessel to expand with minimal resistance. Continued expansion and increased strain is 
eventually strongly resisted by collagen preventing overexpansion and rupture. While 
collagen provides rigidity, elastin allows the connective tissues in blood vessels to stretch 
and then recoil to their original positions 3. Vascular SMCs routinely produce collagen 
throughout adulthood but their capacity for synthesizing elastin vastly decreases. In 
addition to blood vessel mechanics, elastin is crucial to regulating cell-signaling 
pathways 4-7 involved in injury response, and inflammation 8. In light of the vital 
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physiologic significance of these two vascular cell types and their surrounding ECM, 
their injury by chemical agitation, physical trauma, or infections (e.g. bacterial, viral) can 
initiate and progressively lead to the pathology of life threatening complications such as 
atherosclerosis, aneurysm and vasospasms 9,10. Therefore, the regeneration of these two 
components of blood vessels is vital to the viability of a vascular implant material for the 
treatment of vascular disease. 
 
1.2 Clinical Problem and Significance  
 In the United States, cardiovascular disease (CVD) accounts for more annual 
fatalities than any other disease 2, and incurs the national health care system over $448.5 
billion per year as costs for its treatment and management 11. Atherosclerosis, or 
occlusive plaque development within the vessel wall resulting in gradual vessel 
narrowing and loss of patency, is the predominant manifestation of CVD. When severely 
occluded, vessel segments are routinely bypassed with conduits of natural or synthetic 
origin 12. While autologous tissues (e.g., autologous saphenous veins), the current gold 
standard, remain patent in the long-term, they are often unavailable due to prior 
harvesting, or chronic systemic disease 13. In such cases, vascular grafts fabricated from 
synthetic materials (e.g., Dacron; expanded-polytetrofluoroethylene or ePTFE) are 
implanted instead. While synthetic materials remain mostly patent (93% for Dacron and 
95% for ePTFE at 5 years) when integrated into large (> 6 mm diameter) vessels, they are 
not as effective in smaller vessels due to the inherent pre-disposition of such sized vessels 
to re-occlude (43% and 45% patency, respectively) 14-16. The details of this reocclusion 
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process is still poorly understood, however scientists agree it is a direct result of the 
failure of the graft lumens to re-endothelialize completely with functional ECs, the 
exaggerated response of healthy patient cells to the graft material, and a compliance 
mismatch between the non-elastic graft and the viscoelastic blood vessel wall. Therefore, 
new tools (e.g. biomolecular cues, biomaterial scaffolds) must be developed to modulate 
cell responses to ensure faithful functional vascular tissue regeneration and ensure long-
term patency when used as small diameter vessel replacements. 
 
1.3 Project Rationale and Objectives 
 To overcome the poor vascular response to synthetic materials, recent studies 
have developed “natural or tissue-based” materials that could likely evoke more 
regenerative/ healing responses by the blood vessel. The extracellular matrix (ECM), 
once regarded simply as a structural scaffold, is now recognized as an important 
modulator of cell phenotype and function. From the tissue engineering perspective, it is 
increasingly apparent that ECM molecules provide the necessary biomechanical and 
biochemical stimulation of cells to create an environment similar to native tissues. A 
class of ECM molecules that are increasingly studied in the context of regenerative 
materials are glycosaminoglycans (GAGs). One such GAG, hyaluronic acid (HA), occurs 
naturally in connective tissues (e.g. skin) as a simple linear molecule consisting of 
repeating dissacharide units of N-acetyl-D-glucosamine and D-glucuronic acid 17. Most 
cells have the ability to synthesize HA at some point during their cell cycle, implicating 
its function in several fundamental biological processes 18.  
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 In recent years, HA has been recognized as a potential biomaterial for effective 
tissue regeneration. It is now known that HA, when degraded into small fragment sizes, 
plays a role in wound healing by promoting angiogenesis 19. HA fragments can, under 
specific circumstances, also promote early inflammation, which is critical to initiate 
wound healing, and then modulate later stages of the process, allowing for matrix 
stabilization and reduction of long term inflammation 18. HA is also highly biocompatible 
and does not elicit a foreign-body response upon cross-transplantation due to the 
homology of the HA structure across species 18. Although the mechanism of interaction 
between HA and the human body is still incompletely elucidated, its promising 
characteristics have assured its extensive use as a tissue engineering biomaterial, most 
recently for cartilage 20 and skin repair 21. Our lab is currently investigating the potential 
use of HA as a regenerative vascular implant material. Since HA forms a significant (4-
7% w/w) component of vascular ECM 22, we hypothesize that HA modified biomaterials 
will provide healthy biomechanical and biochemical signals to blood vessels. 
 HA has been shown to exhibit a size-specificity in modulating EC proliferation, 
essential to repopulating the luminal EC monolayer, and SMC elastin production. 
Exogenous HA oligomers (<20 kDa) have been shown to stimulate angiogenesis 23,24 and 
proliferation 23 of vascular ECs, while high molecular weight (HMW) HA (MW > 
1000 kDa) is generally bioinert 25. Recent studies have shown HA oligomers upregulate 
the activity of the EC receptor for vascular endothelial cell growth factor (VEGF) and 
induce VEGF release to stimulate EC proliferation and promote tube formation 26. In the 
context of influencing SMC behavior, independent studies have suggested critical roles 
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for HA and other GAGs in elastin matrix synthesis and organization by SMCs during 
development 27-29 and particular disease pathologies 30. Our laboratory, for the first time, 
has shown certain sized HA oligomers to stimulate inherently poor elastogenic adult 
SMCs to produce elastin matrix structures vital to maintenance of tissue homeostasis. We 
found that healthy SMCs, in the presence of exogenously supplemented HA oligomers, 
increased production of tropoelastin, desmosine and crosslinked elastin 31,32. In addition, 
the elastin fibers were laterally aggregated and thicker than those produced by SMCs 
cultured with HA of higher MW. Overall, these findings encourage the utility of 
exogenous HA cues and HA biomaterials to promote vascular endothelialization and 
elastogenesis. To date, the size-specific effects of HA on EC phenotype and long-term 
function, and the use of HA oligomers as biomaterials for enabling EC and SMC 
mediated vascular tissue regeneration/ remodeling have not been thoroughly investigated. 
Also, the effects of HA derivatization and/or crosslinking, necessary to obtain HA 
scaffolds with good handling properties, and the densities at which bioactive HA 
fragments should be presented within such scaffolds are unknown. Such information 
would also be vital in designing strategies to incorporate/ present these HA cues within 
existing synthetic or biologic scaffolding materials which may be more appropriate from 
a mechanical standpoint. We hope of fill this void. 
Our objective is to investigate the potential use of HA as a regenerative vascular 
material. Specifically, we aim to examine the size-specific ability of HA to promote 
vascular endothelialization and elastogenesis, as an exogenous supplement, a surface 
coating and a hydrogel. The results of this study will allow us to determine the optimal 
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fragment size (i.e. HMWHA, HA fragments, HA oligomers) and presentation modality 
(i.e. exogenous, surface coating, hydrogel) of HA for the regeneration of the vascular 
endothelium and production of an elastin rich matrix by SMCs. To investigate these 
issues, we propose four specific aims: 
 
1.4 Specific Aims and Hypotheses 
Aim 1: Investigate the impact of exogenously supplemented HMW HA, HA fragments, 
and HA oligomers on the phenotype and function of vascular ECs. 
Hypothesis: It is now known that HA, when degraded into small fragment sizes, plays a 
vital role in wound healing by promoting angiogenesis 19. In this regard, the exogenous 
supplementation of HA fragments and oligomers are more likely to stimulate EC 
proliferation and migration than HMW HA. However, under specific circumstances, 
these fragments may also incite early inflammation. Therefore, HA fragments and 
oligomers may also adversely affect ECs by inciting CAM expression and the release of 
cytokine/ chemokines resulting in enhanced platelet deposition. 
Approach: To generate HA oligomers, HMW HA (1500 kDa) will be enzymatically 
digested under iteratively defined conditions, until a mixture containing a maximal yield 
of HA oligomers is obtained. Initially, an EC proliferation study will be conducted by 
exogenous supplementation of HA oligomer digests, and commercially available HMW 
HA and HA fragments (200 kDa, 20 KDa) to determine the most angiogenic fragment 
size of HA. Then the effects of HMW HA and this angiogenic HA fragment on ECs will 
be compared by investigating angiogenesis potential, CAM and functionality marker 
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expression, cytokine release, thrombomodulin expression, and platelet deposition. From 
this study we will determine the HA fragment capable of stimulating endothelialization 
and identify its potential adverse effects, if any, on ECs. 
 
 
Aim 2: Prepare a surface tethered model for investigating the size specific effects of 
HMW HA, HA fragments, and HA oligomers on EC functionality and SMC elastin 
production. 
Hypothesis:  The biologically active group of HA (acetyl) is not used in the 
immobilization process. Therefore, surface tethered HA should function in the same 
manner as exogenously supplemented HA. However, the high negative charge of long-
chain HA due to the abundance hydroxyl and carboxyl groups will deter cellular 
attachment to its surface. This may only allow cell adherence to surfaces composed on 
HA fragments and oligomers. 
Approach: HA (1500 kDa, 200 kDa, 20 kDa) and oligomer mixtures (based on digests 
prepared in Aim 1) will be tethered onto an aminosilane (APTMS)-treated glass surfaces 
using a carbodiimide reaction. Immunofluorescence, SEM, AFM and XPS analysis will 
be used to determine the success of our immobilization technique by comparing the glass, 
APTMS and HA surfaces. The density of APTMS and HA will also be quantified using 
an amine s-SDTB assay and HA Fluorophore-Assisted Carbohydrate Electrophoresis 
(FACE), respectively. The stability of surface-bound HA over 21 days will be analyzed 
with toluidine blue. ECs and SMCs will then be cultured on these surfaces. The 
endothelialization potential of the surface will be based on EC morphology (Calcein AM 
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uptake), proliferation (MTT assay) and CAM expression (Immunofluorescence). Elastin 
production of SMC will be determined by an elastin assay (quantification), 
immunofluorescence (macro-structure), and TEM (micro-structure). From this study we 
will determine whether HA surfaces stimulate ECs and SMCs similarly to exogenous HA 
and identify surface bound HA fragments that benefit functional endothelialization and 
elastogenesis. 
 
Aim 3: Investigate the impact DVS crosslinked HMW HA hydrogels containing varying 
concentrations (w/w) of crosslinker and bioactive HA fragments on its physical, biologic 
and mechanical properties and utility for achieving functional endothelialization.  
Hypotheses: The incorporation of HA fragments into a HMW HA hydrogel reduces the 
overall bonding within the construct. Therefore, the presence of HA fragments 
diminishes the strength of the hydrogel and its resistance to enzymatic degradation. 
However, HA fragments potentially stimulate EC proliferation resulting in a surface more 
conducible to endothelialization. HA fragments also have the potential to elicit 
inflammatory CAM expression by vascular ECs but when incorporated within a bioinert 
HMW construct, these effects might be suppressed. Also, the use of a crosslinker may 
alter HA’s interaction with ECs. However, we aim to use a low concentration of DVS to 
minimize its affect. 
Approach: HMW HA and bioactive fragments (aim 1; 0, 5, 10, 20% w/w) will be 
incorporated into a crosslinked construct using two concentrations of DVS (1:1, 2:1 w/w 
HA:DVS) and the formation of crosslinks verified by FTIR. The mechanical properties of 
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these hydrogels will be determined by frequency sweep rheology, uniaxial compression 
testing, and swelling ratio. The stability of the gels will be analyzed by in vitro and in 
vivo degradation, and the gels will be subcutaneously implanted in a rat model to test 
their biocompatibility. Finally, ECs will be culture on the surface of these gels and their 
morphology, proliferation and CAM expression will be tested. In the event that the high 
concentration of HMW HA deters cell attachment, the gels will be soaked in a matrigel 
solution of low concentration to adsorb a minimum amount of laminin and collagen IV 
on the surface of the gels prior to seeding the ECs. This will force the ECs to interact 
with the HMW HA and bioactive fragments. The results will determine the 
endothelialization potential of bioactive fragments with a HMW HA construct and allow 
us to compare these results to pure HA surfaces and exogenously supplemented HA. 
 
Aim 4: Investigate the impact GM crosslinked HMW HA hydrogels containing varying 
concentrations of HA oligomers on its physical, biologic, and mechanical properties and 
use as a 3D elastogenic scaffold for SMCs.  
Hypotheses: The incorporation of bioactive HA fragments into a HMW HA hydrogel 
will reduce its strength and resistance to enzymatic degradation by lowering the overall 
bonding within the construct. However, HA fragments are capable of stimulating SMCs 
to produce elastin when supplemented exogenously and this should be replicated when 
the HA oligomers reside within a 3D scaffold. Also, the use of a crosslinker may alter 
HA’s interaction with SMCs but we aim to use a low concentration of GM to minimize 
its affect. 
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Approach: Prior to crosslinking, HMW HA and oligomers will be modified with 
glycidyl methacrylate (GM). Then GM modified HMW HA and HA oligomers (aim 1; 0, 
5, 10, 20% w/w) will be combined and treated with UV to form crosslinks; the presence 
of which will be verified by FTIR. The mechanical properties of these hydrogels will be 
determined by frequency sweep rheology, uniaxial compression testing, and swelling 
ratio. The stability of the gels will be analyzed by in vitro and in vivo enzymatic 
degradation, and the gels will be subcutaneously implanted in a rat model to test their 
biocompatibility. Finally, SMCs will be encapsulated within these gels and their 
morphology (calcein AM) and elastin production (immunolabelling) will be tested. In the 
event that the high concentration of HMW HA deters cell attachment, matrigel (laminin, 
collagen IV) will be added into the hydrogel construct prior to crosslinking. This will 
result in a 3D network of cell adhesion molecules (matrigel) and HA forcing the SMCs to 
interact with the HMW HA and HA oligomers. The results will determine the SMC 
elastogenic potential of HA oligomers within a 3D HMW HA construct and allow us to 
compare these results to pure HA surfaces and exogenously supplemented HA. 
 
1.5 Organization of Dissertation 
 This dissertation was arranged into seven chapters to most effectively convey the 
scope, analytical progression, eventual conclusions of this project. Chapter two 
introduces luminal ECs and medial matrix elastin as essential components of the 
vasculature and also presents a comprehensive review vascular disease, the deficiencies 
of the current treatment options including vascular grafting materials, current tissue 
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engineering strategies under development, and the attractive properties of HA that make 
it a suitable biomaterial for the regeneration of ECs and vascular elastin when lost due to 
disease or injury. Chapter three examines the effects of exogenous HA and HA fragments 
on EC phenotype and functionality. The surface immobilization of different sized HA 
and their ability to provide a microenvironment conducive to ECs growth and SMC 
elastogenesis are presented in chapter four. Chapter five is devoted to discussion of 
divinyl sulfone (DVS) crosslinked HA hydrogels and the effects of crosslinker and HA 
bioactive fragment concentration on EC function. Chapter six includes an analysis of the 
incorporation of HA bioactive fragments into glycidyl methacrylate (GM) crosslinked 
HMW HA hydrogels and its ability to stimulate elastin production by encapsulated SMCs.  
Finally, chapter seven will draw overall conclusions from all the studies conducted, 
identify inadequacies of the present work, and suggest future directions for the continued 
progress of this project. 
 
 12
CHAPTER 2 
 
LITERATURE REVIEW 
 
 
 
2.1 Vascular Structure and Function 
 Blood vessels contain three layers, each one containing a complex bundle of cells 
and extracellular matrix (ECM) distinctly organized to serve specific functions. In 
addition, many different types of blood vessels exist in the body and the structural 
components of each are adjusted to efficiently distribute nutrients and collect waste from 
the tissues via the blood. 
 
2.1.1 Components of the Blood Vessel and Their Function 
Vascular walls consist of three layers, the tunica intima, tunica media and tunica 
adventitia, as displayed in Figure 2.1. The tunica intima is comprised of endothelial cells 
(ECs) resting on a basement membrane, a meshwork comprised of ECM components, 
mainly collagen type IV, laminin and heparin sulfate proteoglycans, and an internal 
elastic lamina (IEL) composed of elastin sheets and fibers. The ECs form a continuous 
single layer boundary along the lumen and act as a barrier that regulates the coagulation 
of plasma proteins on its surface and the entry of blood elements into the vessel wall. The 
tissue between the EC layer and the IEL, or sub-intima, may house non-striated smooth 
muscle cells (SMCs) and macrophages 33.  
The tunica media extends from the IEL to the external elastic lamina (EEL). It 
consists of SMCs and elastin arranged into concentric alternating bundles. The SMCs 
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regulate blood flow by constricting and dilating the blood vessel. By contracting, the 
SMCs collectively decrease the diameter of the blood vessel inhibiting blood flow 
(vasoconstriction). In contrast, SMC relaxation increases blood flow by enlarging the 
diameter of the blood vessel (vasodilatation) 33.  
The tunica adventitia lies beyond the EEL as the outer most layer of blood vessels 
and is predominantly composed of fibroblasts and collagen-rich ECM 34. This densely 
fibrous layer prevents vessel over-expansion and rupture due to luminal blood pressure, 
and anchors the blood vessel to the surrounding tissue. The thickness of each layer is 
dependant on the type of blood vessel 33. 
 
 
Figure 2.1 Anatomy of blood vessels 35. 
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2.1.2 Types of Blood Vessels 
Blood leaving the heart is distributed to the tissue by the conducting arteries, 
distributing arteries, arterioles and finally capillaries. The conducting arteries (elastic 
arteries) contain a large amount of elastin, allowing them to expand and accommodate 
large volumes of blood flow. Distributing arteries (muscular arteries) are comprised of 
large numbers of medial SMCs that help control the amount of distributed blood by 
contracting or relaxing in response to sympathetic nerve stimulation. Arterioles have thin 
wall layers and regulate blood flow to specific capillary beds by the contraction and 
relaxation of SMCs. They are controlled by both nerve and hormonal stimulation. 
Capillaries possess very thin walls that provide permeability and allow the diffusion of 
nutrients, gases, hormones, etc. into the tissues. The blood within the capillaries also 
collects metabolic waste products and gases from adjacent cells 34. The relative 
characteristics of these vessels are shown in Figure 2.2. 
 
Figure 2.2 Characteristics of blood vessels 35. 
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Blood returns to the heart through the venules, medium veins and finally, the 
large veins. The venous wall is thinner than the arterial wall. The prominent layer in 
veins is the adventitia. Veins are much less muscular than arteries due to the lower blood 
pressures encountered within. For the same reason larger veins have valves that prevent 
backflow of blood, especially when propelled against gravity. Due to the greater 
pressures and hence stresses encountered in arteries then in veins, the former are more 
susceptible to injury or disease and even more so due to aberrations in the function of 
vascular SMCs that play key roles in the biochemical and biomechanical homeostasis of 
the vessel wall 34. 
 
2.2 Vascular Disease: Atherosclerosis 
 Cardiovascular disease, an extremely prevalent disorder in the United States, is 
frequently characterized by the development of atherosclerotic plaques.  The initiation of 
atherosclerosis is still debatable since the theories procured through the study of 
developmental animal models and advanced human atherosclerotic tissue do not coincide. 
But the most popular theory involves the development of a fatty streak and its 
transformation into a fibrous plaque. 
 
2.2.1 Cardiovascular Disease 
Cardiovascular disease (CVD) accounts for more deaths than any other disease in 
the United States 2. As per the 2008 estimates of the American Heart Association, the US 
health care system will incur over $448.5 billion in costs for treatment and management 
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of CVD 11. Research is working toward reducing this cost and saving lives by treating 
atherosclerosis, the causative factor in nearly three-fourths of the fatalities from 
cardiovascular disease 36. Atherosclerosis, an occlusive vascular disease, is characterized 
by the accumulation of low density lipoprotein (LDL) cholesterol, cell debris, calcium, 
and extra cellular matrix to form a plaque within the vessel wall, narrowing the lumen 
cross-sectional area and inhibiting blood flow. 
Atherosclerosis is likely triggered by damage to the endothelium. In an effort to 
develop therapies to limit destructive effects of the disease, physicians have identified 
several risk factors that can adversely impact endothelial health and viability through 
physical and chemical attacks. These factors include vessel morphology, hypertension, 
hyperlipidemia, diabetes mellitus, and free radicals caused by cigarette smoking 37. 
Endothelial dysfunction as a result of aging is an additional risk factor for atherosclerosis 
38-40. The early but reversible sign of atherosclerosis is the development of fatty streaks 
along the lumenal wall of blood vessels. 
 
2.2.2 Development of a Fatty Streak 
Atherosclerosis has been suggested to be initiated by an increase in the content of 
low-density lipoprotein (LDL) or bad cholesterol in the blood. LDLs gradually deposit in 
the vascular wall, especially at low flow sites within the arteries, and accumulate to create 
an initial lesion. The amassed LDLs within the lesion may undergo modifications, 
including slight oxidation by exposure to oxidative vascular waste. The endothelium 
responds to these minimally oxidized LDLs by attracting monocytes and T-lymphocytes 
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with chemotactic proteins and adhesion molecules, known as vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). The monocytes 
and T-lymphocytes migrate between the tight junctions of the ECs into the intima where 
the monocytes differentiate into macrophages and consume the minimally oxidized LDL, 
forming foam cells 41. The accumulation of foam cells within the sub-intima results in the 
formation of fatty streaks, which appear as yellow strips along the vascular wall. These 
fatty streaks appear in children as young as 10 – 14 years old and are completely 
reversible by reducing or eliminating the LDL content within the blood. 
 
2.2.3 Development of a Fibrous Plaque 
The continued accumulation of LDL within the sub-intima eventually triggers 
ECs, foam cells, and T-lymphocytes to produce pro-inflammatory growth factors, such as 
platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
transforming growth factor α (TGF-α), transforming growth factor β (TGF-β) and 
endothelial growth factor (EGF), resulting in exuberant intimal SMC proliferation and the 
migration of medial SMCs towards the intima, seen in Figure 2.3, a phenomenon termed 
hyperplasia. Hyperplasic SMCs, which now exhibit an unnatural synthetic phenotype, 
produce a hefty matrix comprised of collagen, elastin and proteoglycans. Extracellular 
lipids and debris accumulate as the foam cells die and release oxidized LDL and cellular 
structures into the subendothelium. The accumulation of all these products within the 
intima results in the formation of an uncomplicated fibrous plaque which has the 
potential to transform to a complicated fibrous plaque and become life threatening, as 
 18
shown in Figure 2.4 42. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Cascade of events during atherosclerosis 43. 
.2.4 Complicated Fibrous Plaques 
Complicated fibrous plaques are generated through two mechanisms, fibrous 
laque calcification and thrombus/ emboli production.  The deposition of calcium 
hosphate from the blood results in calcification of the fibrous plaque and degradation of 
e vascular elastic matrix causing reduced vascular elasticity. These brittle segments are 
rone to rupture, possibly resulting in an aneurysm.  
Plaques enclosed by a thin fibrous cap are considered vulnerable and at risk for 
pture, which commonly occurs at the edges of the plaque, a foam cell rich region 43. 
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The growing fibrous use the EC layer to 
enude resulting in platelet adherence to the exposed subendothelial matrix.  These 
-β, EGF and platelet-derived EC growth factor (PD-
ECGF)
atal complications that can be 
 plaque may occlude the blood vessel or ca
d
platelets release PDGF, TGF-α, TGF
 to further stimulate SMC proliferation and migration. If a sufficient number of 
platelets deposit, a thrombus or embolus may form, which can occlude blood flow 42. The 
blockage of coronary arteries, peripheral arteries and cerebrovascular arteries can result 
in myocardial infarction (heart attack), peripheral tissue necrosis and a stroke, 
respectively. These are very serious and potentially f
prevented through clinical treatment. 
 
Figure 2.4 Etiology of atherosclerotic plaque development 44. 
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2.3 Treatment of Atherosclerosis 
 To determine the mode of vascular treatment a patient requires, a physician must 
compare the risk of occlusion and amount/ type of tissue the occlusion would affect. If 
the diseased blood vessels exhibit a low risk of occlusion and the affected tissue is 
insignificant, noninvasive treatment is pursued. Surgical treatment is necessary when the 
vessel has a high risk of occlusion and a large portion of a vital organ is in danger. In 
most other situations, minimally invasive treatment is used. 
 
2.3.1 Non-Invasive Treatment Modalities 
Treatment of atherosclerosis can begin before manifestation of the symptoms, 
usually through lifestyle management to restrict risk factors and behaviors. These include 
cessation of smoking, diet alterations, exercise enhancement, and drug therapies (e.g. to 
decrease serum cholesterol levels, or control hypertension). When atherosclerosis 
ficant occlusion of the vessels is caused, physicians 
tion), the surgeon makes an 
cision down the center of the sternum. The ribcage is spread open using a retractor to 
heart is stopped for 90 minutes of the 5 hour 
progresses to a state wherein signi
must use more invasive treatments to correct these complications. 
 
2.3.2 Surgical Treatment 
Currently, the prevalent surgical method for treating vascular occlusions is bypass 
surgery, shown in Figure 2.5. During this procedure, the patient is completely sedated. In 
coronary bypass surgery (the most common bypass opera
in
expose the heart. In most instances, the 
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bypass 
 
down stream of the blockage  45. 
 
Coronary bypass surgery is capable of treating multiple coronary vessels with 
little increase in risk of complication. Most complications that arise from coronary bypass 
surgery are short-term including difficulty breathing, bleeding, infection, hypertension 
and arrhythmias. More serious complications, such as myocardial infarction, stroke and 
death, are usually the result of stopping the heart and using the heart-lung machine. Graft 
occlusion may also occur resulting in the need for a second bypass surgery; a procedure 
that presents a greater risk. Other risk factors include diabetes and age, though patients 
procedure using a cardioplegic solution while a heart-lung machine takes over the 
blood circulation and breathing functions of the body. The surgeon uses a graft to re-
route the blood passed the plaque occluded segment of the coronary vessel 12. Peripheral 
bypass surgery is also available for arterial blockages within the arms and legs. 
 
 
Figure 2.5 Bypass surgery. Occluded coronary arteries require a bypass graft to re-rout the blood passed 
the blockage and supply oxygen to the cardiac tissue dependant on these arteries for blood. The proximal 
end of the graft is attached to a major artery (aorta) and the distal end is fastened to the occluded artery 
 
Occluded Arteries Bypass Grafts 
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older than 80 years of age have benefited from coronary bypass surgery 12. In addition, 
bypass procedures are extremely expensive (~$10,000 for coronary bypass surgery) and 
highly invasive, often causing a great deal of trauma and requiring lengthy hospital stays 
with plenty of pain medication 46. Moreover, calcium channel blockers frequently need to 
be administered during the procedure to reduce vasospasms of denervated vessels, which 
can by themselves induce further complications 47. Nevertheless, bypass surgery may be 
the only option in cases of severe and almost total occlusions, especially if blood supply 
 a vital organ is directly and immediately threatened. 
.3.3 Minimally-Invasive Treatment 
utaneous vascular intervention (PI) 
procedures, depicted in Figure 2.6. PI patient
remain conscious throughout the procedure. Initially, a guide wire is inserted into the 
the region of occlusion. Guide wires are shaped and designed to percutaneously navigate 
traverse and hence provide a path enabling the catheter to reach the site of occlusion. The 
(usually an iodine derivative). 
deflated balloon-tipped catheter is inserted into the luminal space of the occluding plaque, 
to
 
2
Alternative to bypass techniques are perc
s are only administered a mild sedative and 
vasculature, usually through the femoral artery, and directed through the vasculature to 
through complicated vascular paths that a catheter would not otherwise be able to 
guide wire and catheter are visualized traversing the vasculature on an x-ray imager by 
radio-opaque markings on the tips and the injection of a radio-opaque contrast medium 
Through a procedure called percutaneous transluminal angioplasty (PTA), a 
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as seen in Figure 2.6. The balloon is then inflated with saline or contrast media at 
pressures averaging 5-17 atm, to enlarge the vessel diameter and compress the plaque 
against the blood vessel wall increasing blood flow capacity 48. The balloon is also radio-
paque and its expansion is seen on the x-ray imager. The balloon is then deflated, and 
provided with variable expanded balloon diameters. 
The ap
 
 
 
 
 
 
 
 
 
 
Figure 2.6 PI Treatments: (A) Balloon angioplasty , (B) rotational atherectomy , (C) transluminal 
 
o
the catheter removed. Catheters are 
propriate expanded balloon diameter must be chosen to prevent over dilation and 
rupture of the vessel. 
 
 
 
 
 
 
 
 
(A)                         (B) 
Rotating Blade Severs 
Plaque into Fine Debris 
Expanding Balloon compresses 
plaque into vessel wall 
 
49 50
extraction atherectomy 51, (D) laser angioplasty 52. 
 
 
 
PTA procedures are much less expensive than bypass surgery (~$6,000 for 
percutaneous transluminal coronary angioplasty; PTCA) and far less invasive 46. Patients 
usually spend one night in the hospital and return home the following day. They are 
    (C)             (D) 
Laser Evaporates Plaque Plaque is severed and extracted 
by a vacuum within the catheter 
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typically able to walk within 2 – 6 hours and return to their normal routine within a week. 
However, balloon catheters are incapable of re-vascularizing chronic total occlusions or 
ighly calcified occlusions due to their inability to penetrate into such plaques. Highly 
rom
alloon may dislodge a piece of the thrombus ridden plaque (embolus) allowing it to flow 
ownstream causing distal vascular occlusion (embolism). Atherectomy has been 
eveloped to address some of these concerns.  
Atherectomy is another PI procedure capable of removing highly calcified or 
rombotic plaque and chronic total occlusions. Atherectomy catheters exist in two 
ifferent forms (e.g. rotational, transluminal extraction) and incorporate a catheter tip 
tted with rotating blades that sever the plaque into small debris, depicted in Figure 2.6. 
otational atherectomy generates extremely fine debris, while transluminal extraction 
ted vacuum to remove the large particles that 
ave the potential to occlude a smaller blood vessel downstream 53. An additional method 
to re-va
h
th botic occlusions are also a concern for PTA operations because the expanding 
b
d
d
 
th
d
fi
R
requires the incorporation of a catheter fit
h
scularize a completely occluded vessel is laser angioplasty, seen in Figure 2.6, in 
which a laser catheter emits pulsating beams of light from its tip that vaporize the plaque 
54. Yet, advances in PI treatment have not completely eliminated bypass surgery as a re-
vascularization technique. PI operations presently have a high risk of re-occlusion and the 
need for repeat procedures. Therefore, they are not recommended for patients with more 
than two occluded vessels, or occlusions that surpass the collateral blood supply in 
vessels that act as the major blood supply to a vital organ. In order to prevent re-
occlusion, a metal mesh tube graft called a stent (further discussed in Section 2.4.4) may 
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be deployed after PI treatment. 
 
2.4 Vascular Grafting 
 Vascular grafts are blood vessel substitutes or implants that maintain the 
structural integrity of blood vessels. Many graft designs are currently under development, 
but only four are commonly used clinically: tissue autografts, synthetic grafts (Dacron; 
Teflon), and stents. 
 
2.4.1 Autografts 
Autografts (i.e. greater saphenous vein, internal mammary artery) are considered 
the gold standard for vascular grafting due to their long-term patency relative to synthetic 
grafts (discussed in Sections 2.4.2 and 2.4.3). This stems from its inherent antigenic 
nature and favorable mechanical properties. Studies indicate that the saphenous vein is 
capable of remodeling in the arterial environment, transforming into a more artery-like 
structure 55. Therefore, autografts are the most viable clinical option but they are limited 
by a lack of quality and availability. Many patients simply do not have enough 
appropriate blood vessels for use as grafts; either the blood vessels are systemically 
diseased or the blood vessels are unavailable due to prior explantation for use as bypass 
rafts 56,57. In such cases, readily available synthetic conduits made of Dacron 
te, PET) or Teflon (expanded Polytetrafluoroethylene, ePTFE) 
g
(polyethylene terepthala
are used. 
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2.4.2 Dacron Grafts 
 Dacron is a robust material with a tensile strength of 170-180 MPa and tensile 
odulus of 1.4×104 MPa 58. These properties contribute to its resistance to mechanical 
reduce its compliance relative to native tissue. Dacron is produced in 
either w
ars in large diameter vessels, studies have also shown that they tend to dilate in 
e arterial environment increasing their susceptibility to mechanical failure 59.  
m
failure, but also 
oven or knitted forms. Woven Dacron grafts are stronger, while knitted grafts are 
more compliant and have larger pores that promote greater tissue in-growth. The high 
porosity of knitted Dacron necessitates the use of a biological sealant such as gelatin, 
collagen, or albumin to plug the pores and prevent the leakage of blood. The porous 
nature of knitted Dacron grafts also increases their susceptibility to infiltration of 
hyperplasic medial SMCs. This is initiated by abnormal mechanical signals sourced from 
a compliance mismatch between the graft and blood vessel. Upon implantation into the 
body, proteins immediately adsorb to the luminal surface followed by platelets, 
macrophages, ECs and SMCs. Over the course of 18 months, this cellular mixture forms 
a three layer neointima consisting of a fibrin luminal layer, macrophage middle layer and 
connective tissue outer layer. Although Dacron has been shown to remain intact for more 
than 10 ye
th
 
2.4.3 Expanded Polytetrofluoroethylene Grafts 
ePTFE is a highly crystalline material. The material exhibits a stiffness of 0.5 GPa 
and tensile strengths on the order of 14 MPa 58. It has an electronegative surface that 
inhibits protein adsorption and thrombus formation improving its biostability. The pore 
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size of ePTFE can range from 20 – 90 µm but the most common pore size in ePTFE 
vascular grafts is 35 µm. A pore size of approximately 60 µm would enhance the tissue 
interaction with the graft. Upon implantation, ePTFE elicits a mild inflammatory 
response that results in the formation of a neointima, over the course of 18 months, 
similar to Dacron, and is a viable option for large diameter vessels. 
 
2.4.4 Stents 
Autografts, Dacron grafts and ePTFE grafts are commonly used to bypass 
occluded blood vessel segments. However when the occlusive plaque is subtotal and not 
diffuse, PI techniques are performed.  In such cases, stents are deployed at the site of 
occlusion in order to maintain the luminal diameter of the revascularized blood vessel 
and prevent reocclusion, a stent may be positioned at the PI-operated pl qua e site, as 
hown in Figure 2.7. A stent is a metal mesh tube that maintains the structural integrity 
 Angioplasty with stenting involves the 
deploy
res and expand when 
s
and dimensions of the re-vascularized vessel.
ment of a self-expanding or balloon expandable metal stent at the re-vascularized 
site of vessel constriction in an effort to prevent vessel collapse and to ensure its patency. 
Balloon expandable stents consist of collapsed stents placed over angioplasty balloon 
catheters. After balloon angioplasty, the stent is expanded to the appropriate diameter and 
provides a firm support to the vessel wall, ensuring that it remains patent. Self-expanding 
stents are delivered in the collapsed form and when released from the catheter expand to 
a pre-determined diameter. Memory alloy stents such as nickel or nickel-cadmium plated 
stents are processed to be in a collapsed state under cool temperatu
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exposed to heat. Immediately following balloon angioplasty, the memory alloy stents are 
th hot saline. Matching the expanded stent and blood vessel diameters is 
importa
expanded wi
nt when choosing an appropriate stent. Expansion and pressure profiles, stent 
strut design, and material all influence the success of stented PI treatments. 
 
Figure 2.7 Percutaneous stenting of a blood vessel . 
 
 
 
Stenting is now commonly adopted, comprising 70-90% of re-vascularization 
procedures . Stent use is determined by parameters such as location and size of the 
vessel, blood flow patterns and the disease state. Although advances in device technology 
have been significant, the utility of interventional strategies such as stents is still 
compromised by re-occlusion. 
 
2.5 Restenosis 
60
61
 To date, a vascular graft capable of long-term patency, especially in small-
diameter vessels, is not available due to re-occlusion, or restenosis. The mechanism of 
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restenosis of vascular substitute grafts and PI treated vessels with and without stent 
deployment are similar but differ slightly. Therefore, they are discussed separately in this 
section. 
 
2.5.1 Restenosis of Dacron and ePTFE Grafts 
Endovascular grafts must mediate a two-front attack involving the graft-tissue and 
graft-blood interfaces. The interaction of all three species involves highly complex 
microenvironments that are ultimately responsible for the graft patency. Immediately 
pon implantation, serum
rface and eventually re-distribute according to the Vroman effect. The Vroman effect 
predicts small proteins adsorb f
a rearrangement that depends on the concentration of proteins within the blood. 
attract the cellular components of the blood (platelets, neutrophils, monocytes) through 
tor mediated interactions. Adherent platelets eventually degrade, releasing bioactive 
al platelets, recruit monocytes, and stimulate SMCs 
protein layer and activated/ damaged ECs surrounding the graft. The monocytes 
radicals) and bioactive molecules (PDGF, FGF, TGF-β). These bioactive molecules 
u  proteins (albumin, fibrinogen, IgG) adsorb onto the graft 
su
irst followed by less mobile larger proteins. The larger 
proteins are more strongly bound to surfaces and displace the smaller proteins resulting in 
Depending on the type and concentration of protein adsorbed, these protein constructs 
recep
molecules that activate addition
within the vascular wall. These receptors also govern neutrophil (acute inflammatory 
response) and monocyte (chronic inflammatory response) adherence to the adsorbed 
differentiate into macrophages and release degradative agents (proteases, oxygen free 
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released by platelets, macrophages and damaged/ activated ECs trigger medial SMCs to 
become
t and vessel, and (4) exaggerated cell responses and healing 
due to 
 hyperplasic and migrate toward the lumen, and deposit an exuberant and 
unnaturally fibrous matrix. 
Early graft failure can occur due to a compliance mismatch between the non-
elastic graft and the viscoelastic blood vessel wall, and the development of SMC 
hyperplasia at the anastomosis site due to EC damage caused by sutures that tether the 
graft to adjoining healthy vessel segments. These events incite proliferation and 
migration of medial SMCs towards the intima and onto the lumenal surface of the graft, 
with subsequent synthesis of matrix proteins and other extracellular material. Direct 
exposure of these matrix components to blood, in the absence of a complete endothelium, 
initiates platelet adhesion followed by the infiltration of inflammatory cells and the 
eventual formation of an occlusive plaque 62. Even though extensive research has been 
carried out on intimal hyperplasia, its causes are still poorly understood; however, the 
development of atherosclerosis is known to be very strongly associated with disturbed 
flow and injury to the vessel wall. A majority of prosthetic vascular grafts fail within five 
years due to severe occlusion of the vessel immediately distal to the graft caused by 
intimal hyperplasia 63. Grafts can be limited by one or more parameters including (1) 
large pore size/high porosity as with Dacron grafts that permit lumenal infiltration by 
hyperplasic SMCs, (2) thrombogenicity, mediated by a surface conducive to deposition 
of adhesive proteins and platelets, (3) mechanical failure induced by a poor compliance 
mismatch between the graf
unnatural stimuli imparted by synthetic graft materials to contacting vascular cells 
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64. A successful graft must thus optimize tissue-biomaterial interactions to elicit non-
hyperplasic responses, exhibit inherent mechanical properties similar to that of host 
vascular tissues and be intrinsically non-thrombogenic at the lumenal surface. 
 
2.5.2 Restenosis of PI-Treated Vessels 
The rate of restenosis, or re-occlusion, within PI treated vessels is 30% – 40% 
after 6 months 8. Restenosis may occur through elastic recoil, negative remodeling or 
neointimal hyperplasia. Elastic recoil is almost immediate, resulting within 1 hour of PI. 
Balloon angioplasty stretches the elastic fibers within the vessel wall. The stretched 
elastic fibers respond by recoiling back to their original size resulting in a loss of luminal 
diameter 65. Negative remodeling occurs within 1 to 6 months. Balloon angioplasty often 
damages the vessel adventitia. This activates fibroblasts causing them to begin fibrotic 
remodeling. Such remodeling ultimately results in adventitial thickening and a reduction 
of luminal diameter 66. Neointimal hyperplasia, which is exuberant proliferation of 
medial SMCs towards the vessel lumen, is a common response to vascular injury and 
inflammation and also results in the reduction of luminal diameter 67,68. The expanding 
balloon can cause damage to the intima resulting in the accumulation of inflammatory 
cells, remodeling and cellular proliferation. As in atherosclerosis, this may result in 
repeated plaque-induced occlusion of the vessel. 
 
2.5.3 Restenosis in Stented Vessels 
A bare metal stent is also prone to restenosis since it is a foreign material and may 
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cause mechanical damage to the intima, which will incite an inflammation response. 
While 
 charge, hemodynamics, and vessel type 
.e. artery, vein), location (i.e. coronary, peripheral), and size are strong determinants of 
ls 70. 
 
it does inhibit elastic recoil and negative remodeling, a stent is also capable of 
promoting neointimal hyperplasia and thrombosis 69. Stent struts often protrude into the 
lumen altering the natural hemodynamics, and thus promote thrombosis 70. Since stenting 
also damages or denudes lumenal ECs, platelets bind to the sub-endothelial matrix and 
degranulate, to release bioactive molecules that can stimulate underlying SMCs to 
become hyperplasic and move towards the vessel lumen through gaps between the stent 
struts, to form an occlusive plaque.  
Studies suggest that the mechanisms leading to in-stent restenosis differ from 
those associated with restenosis caused by balloon-induced injury. Stent injury-induced 
restenosis shows a higher degree of neointimal growth and higher levels of neutrophil 
recruitment. Anatomical and pathological investigations show that coronary stenting 
associated with medial damage or penetration of the stent into a lipid core induces 
increased arterial inflammation accompanied by increased neointimal growth 71. Device 
design, material, pore size, surface roughness and
(i
restenosis in stented or grafted vesse
2.6 Blood Vessel Size as a Risk Factor for Restenosis 
The conventional techniques of revascularization described above for large 
vessels, are not as effective in small diameter vessels (< 5 mm), due to their particular 
pre-disposition to re-occlusion after intervention 14-16. One major problem with the 
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treatment of small vessels is the fact that the area decreases in proportion to the radius 
squared. Hence, the plaque required to occlude smaller diameter vessels is drastically 
decreased in comparison to larger vessels. Small vessels also have lower shear rates than 
larger vessels due to sluggish flow, which favor platelet deposition and plaque 
accumu
he high flow and low resistance conditions of 
rge peripheral arteries, they are not quite suitable for deployment in small diameter 
atency rate of 93% for aortic 
bifurca
lation. The development of long, diffuse plaque accumulations increases the 
difficulty of treating small vessels 72. These factors make small-diameter vessels prone to 
occlusion and difficult to treat.  
 
2.6.1 Dacron and ePTFE Grafts in Small-Diameter Vessels 
In large conduits where high pressures are encountered, such as in the aorta, 
stiffer and stronger polymeric grafts are desireable. However, in smaller grafts, 
compliance is more important than strength. While inert polymer grafts such as Dacron 
and ePTFE perform reasonably well in t
la
vessels 58,73. To illustrate, Dacron has a five-year p
tion grafting 74, but only 43% for above-knee femoropopliteal bypass grafts 17. 
One of the major flaws is their compliance mismatch with vascular tissues in small 
diameter vessels limit their applicability to such vessels 74. Furthermore, when exposed to 
relatively sluggish blood flow in small-diameter vessel, coagulation and platelet 
deposition is much enhanced on Dacron grafts. The addition of heparin has somewhat 
reduced coagulation in femoropopileteal bypass grafts, as shown by a three year study 75, 
but the duration of the heparin is yet to be determined 76. ePTFE similarly has a reported 
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5-year patency of 91% and 95% 74,77 when used as an aortic graft but exhibits much lower 
patencies (61% and 45%) when deployed as femoropopliteal bypass grafts 17.  
 
2.6.2 Stents in Small-Diameter Vessels 
ssels presents a number of 
technic
t 80.  
Performing interventional procedures on small ve
al challenges for the interventional cardiologist. Negotiating a stent to a given 
lesion in a small vessel may be hampered by distal location, vessel tortuosity and intra-
vascular calcification. An additional technical problem is that distal lesions are more 
frequently diffuse, thus requiring longer, less flexible stents to fully cover the diseased 
segment. There are also fewer stenting options (i.e. type, diameter, length) available for 
vessels < 3 mm 78. Another important issue is that the small vessel lumen leaves little 
room for error in sizing and stent expansion. 
The average extent of in-stent late lumen loss (radial lumen reduction; LLL) after 
implantation of a bare metal stent is 0.8 - 1 mm, regardless of vessel size. This has vital 
implications for small diameter vessels. To illustrate, a 4 mm diameter vessel with 1 mm 
of LLL experiences a 44% reduction in lumen area, while a 2 mm diameter vessel with 
the same LLL, suffers a 75% lumen area loss. Therefore, the impact of 1 mm LLL is far 
greater in small diameter vessels than large diameter vessels 79. Bare metal stents (BMS) 
have reduced the rate of restenosis to 19.9% in large arteries (≥ 3 mm diameter) but only 
32.6% in small arteries (< 3 mm) after 6 months which is drastically insufficien
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2.7 Vas
metabolism, cytotoxicity and pathogenicity. 
The di
gulatory-biomolecules. 
Tissue engineered vascular biomaterials have specific advantages over traditional 
nts) since they are designed to be biologically active 
d m
cular Tissue Engineering 
 Despite the progress in vascular engineering, scientists have still not created a 
viable vascular substitute that possesses the necessary complex mechanical properties and 
mimics the biological function of a native artery. A recent approach called tissue 
engineering, appears to have the most promise in developing a suitable blood vessel 
replacement. The field of tissue engineering encompasses both therapeutic and diagnostic 
applications. Diagnostic tissue engineering uses tissues or cells excised from the body 
and grown in vitro to test their drug uptake, 
agnostic form of tissue engineering also serves as an easily accessible and 
characterizable model to understand combinational interactions between cells, their ECM 
and exogenous or endogenous bio-signaling molecules. Therapeutic tissue engineering 
involves manufacturing a tissue and transplanting it into the body. Therefore, tissue 
engineering is defined as, ‘the use of a combination of cells, engineering materials or 
scaffolds, and suitable biochemical factors to improve or replace biological functions in 
an effort to effect the advancement of medicine’ 1. This definition clearly highlights the 
three key ingredients to successfully engineer tissues: cells, a scaffold or matrix, and 
re
 
materials (i.e. Dacron, ePTFE, Ste
an echanically responsive. A tissue-engineered vascular construct may contain 
synthetic materials, biological materials, biomolecules and/or cells but must integrate 
with the target tissue and eventually function as a native blood vessel. However the 
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challenges facing tissue engineered biomaterials include sufficient strength and elasticity, 
matched compliance with native vessels, and immediate functionality on implantation 
[86-90]. 
 
2.7.1 Biodegradable Synthetic Materials 
Some designers are investigating the use of biodegradable synthetic polymer 
scaffolds, as vascular biomaterials. Since the conditions used to create these polymers are 
too harsh for the cells to survive, cells cannot be directly encapsulated into the polymer 
prior to implantation. Therefore, if cellularization is desired, it must be accomplished by 
pressure-driven cell infiltration or dynamic cell seeding techniques 81. The concept 
underlying this approach is to generate a scaffold that initially acts as a mechanical 
support until infiltrating cells, from the target tissue or seeded in vitro, are able to 
produce a significant amount of ECM to maintain mechanical stability. Once implanted, 
r degradable polymers such as poly-L-lactic acid 81, polyhydroxyalkanoate 82, 
oly-4-hydroxybutyrate 83, polycaprolactone-co-polylactic acid 84 and polyethylene 
the polymer will be re-absorbed at the same rate that tissue regenerates, ideally. A 
challenge however, is to tailor the degradation rate of these polymers so as to exhibit 
extended degradation times, since the failure of the cells to properly infiltrate and rapidly 
produce the requisite amount of ECM can result in implant failure. 
The most commonly used synthetic, bio-degradable polymer for tissue 
engineering is polyglycolic acid (PGA). When unmodified, PGA is rapidly resorbed by 
the body causing premature weakening of the material. Therefore, it is copolymerized 
with othe
p
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glycol 85 to improve its long-term mechanical stability. In addition, cell interaction with 
such co
sms or stenosis was 
eviden
 of the same species 
(alloge
nstructs can be enhanced by incorporating adhesion peptides (RGD 86), proteins 
(fibronectin) or growth factors (TGF-β 29) such as RGD peptides.  
One co-polymer tested as a vascular prosthesis was PGA-polyhydroxyalkanoate 
(PHA). The polymer conduit was seeded with autologous fibroblasts, SMCs and ECs, 
and implanted in the abdominal aortic segments of lambs for 5 months. All the implants 
remained patent and no aneurysms developed at the time of sacrifice 82. Co-polymeric 
scaffolds of PGA and polycaprolactone-co-polylactic acid have also been seeded with a 
mixed population of autologous ECs and SMCs derived from the canine femoral vein. In 
canines, this implant completely degraded after 3 months while the vessel remained 
patent for 13 months with no evidence of dilation or stenosis. The first successful clinical 
application of a tissue engineered vascular implant was accomplished using this material 
formulation in a 4-year -old. After 7 months, no sign of aneury
t 84. Subsequent clinical trials using this degradable polymer with bone marrow 
cells resulted in 100% patency rate with no evidence of thrombotic or obstructive 
complications 87. Bio-degradable polymer have shown much promise in animals as 
vascular implant materials but these results must be replicated in the more complex 
human anatomy to establish these biomaterials as a viable option. 
 
2.7.2 Biological Tissues 
In the past, vascular tissues explanted from a member
nic) or another species (xenogenic), and then decellularized to yield non-cellular 
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matrix scaffolds, have shown little success due to the generation of an immune response 
in the host and a loss of mechanical properties after processing in vitro 88-90. 
Decellularization is usually accomplished by treating tissues with a combination of 
detergents, enzyme inhibitors and buffers that ideally remove the cells and epitopes from 
the vascular tissue 91. This process typically results in shrinkage due to the removal of 
proteoglycans 92. The lack of cells and proteoglycans can adversely impact the vessel, 
reducing the ultimate tensile strength and compliance 93. Yet, recent studies suggest that 
decellularized xenogenic vascular tissues are less susceptible to thromboembolism 94 and 
cryopreserved allogenic vascular tissues reduce aneurysm formation 95. An in vitro 
investigation also found decellularized human saphenous veins contain an intact ECM 
and exhibit mechanical properties adequate for implanting within small vessels 96. Small 
intestinal submucosa (SIS) has also been decellularized to create matrix conduits 
composed of primarily collagen with additional fibronectin, growth factors, 
glycosaminoglycans, proteoglycans, and glycoproteins 97. The patency rates for these 
decellularized autogenic and xenogenic vascular implants were comparable to that 
nous vein, in canines 98. Therefore, in the near future such 
method
obtained with the saphe
s may prove to be clinically applicable. 
 
2.7.3 Cell-Based Vascular Constructs 
 Some researchers also attempted to create a completely cell based vascular 
constructs. The most impressive to date has been designed by Auger et al. 72. His 
approach involved culturing sheets of SMC layers in the presence of ascorbic acid to 
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induce sufficient collagen production and wrapping them around a porous mandrel to 
form a media. The porosity of the mandrel allows the transport of nutrients to the lumenal 
cells. Subsequently, fibroblast layers were produced in a similar fashion and wrapped 
around the media to create an adventitia. After several weeks in culture these layers fused 
into a single cohesive unit. During this incubation period, the constructs were removed 
from the mandrels, the ends were cannulated and the lumenal surface was endothelialized 
by filling the lumen with a solution of ECs. The resulting blood vessels had distinct 
multilayer organization, contained abundant ECM deposition and a normally functional 
endothelium. This structure sustained burst pressures greater than the saphenous vein and 
a compliance greater than ePTFE but far lower than the small diameter vessels it was 
designed to replace. It was hypothesized that the lack of compliance was due to 
insufficient elastic fiber deposition. Also, the manufacture of these vessels takes at least 
three weeks and longer if the patients own cells are used 72. A major difficulty with any 
rgan developed in an ex vivo culture is that, over time, the cells alter their phenotype as 
-101. 
o
well as their immunogenic responses 99
 
2.7.4 Biopolymers 
Some groups have attempted to tissue engineer a hybrid vascular constructs by 
combining biopolymers (i.e. collagen) with synthetic biomaterials. The first attempt at 
tissue engineering a hybrid vascular biomaterial involved Dacron impregnated with 
collagen but was unable to withstand physiologic pressure conditions 102. Since then, 
blood vessel engineering has been successful at developing biomaterials that can 
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withstand arterial pressure for up to 6 weeks 103,104. Such hybrid vascular prostheses were 
developed using SMCs and collagen reinforced with a knitted, segmented polyester mesh 
to create compliance similar to the native tissue. The mechanical properties of these 
materials were improved by using SMCs and/ or fibroblasts with ascorbic acid to produce 
a three dimensional ECM similar to that observed in vivo, but requires 56 days of culture 
72. The biomaterial was successfully seeded with ECs and examined under pulsatile flow 
105. 
More recently, scaffolds comprised exclusively of biopolymer were constructed. 
The most popular biopolymer in vascular engineering is collagen I since it is the most 
abundant protein in the human body and a major component in the ECM wall, making it 
a natural cell substrate. Bovine collagen I has also been approved by the Food and Drug 
dministration for clinical 106. Fibrin is another commonly used biopolymer, which is the 
terial in blood clots and plays a major role in wound healing by being 
remode
A
major structural ma
led by cells into ECM post-injury. Clinically, it is used as common wound sealant. 
Both collagen and fibrin scaffolds are constructed in the form of a hydrogel within a 
hollow cylindrical mold and the mild fabrication conditions allow direct cellularization 
by cell entrapment during gelation. Collagen monomers spontaneously polymerize at 
body temperature while fibrin monomers require thrombin for polymerization 107,108. The 
mechanical properties of these gels are improved by cross-linking using ribose 109, lysyl 
oxidase 110 and Factor XIII 111. Yet, when fabricated into a tubular form, it was found that 
collagen fibers do not organize properly and its mechanical properties do not match that 
of native vessels. The strength of these collagen conduits and fiber organization within 
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were improved by subjecting them to dynamic contraction around a mandrel. However, 
the mechanics of the construct still fell short of the native vessel 104,112-115. It was 
reasoned that entrapped cells must be stimulated to produce their own ECM, align the 
fibers, 
ut cells cannot be entrapped during the 
and compact the fiber bundles by traction. 
 Continued study of SMCs and fibroblasts entrapped within collagen gels found 
ECM production to be suppressed relative to monolayer cultures 116. Conversely, 
fibroblasts entrapped in a fibrin gel were stimulated to produce ECM in comparison to 
collagen-entrapped fibroblasts 117. Neonatal rat aortic SMCs cultured within fibrin gels 
were shown to compact and align the gel fibers and deposit collagen fibers in the same 
circumferential direction potentially improving the mechanical properties 118.  
In order to promote desirable cellular activities, growth factors can be provided to 
cells within the tissue-engineered constructs. Incorporation of TGF-β1 and insulin were 
shown to increase SMC collagen production by 20-fold within fibrin gels, as compared to 
collagen gels. These constructs also exhibited uniaxial tensile strengths similar to rat 
abdominal aorta. Also, a significant amount of elastin production was observed when 
SMCs were cultured on fibrin gels, which does not occur on collagen gels 114. When 
implanted into a canine vasculature, endothelialized fibrin-based vascular constructs 
remained patent for up to 15 weeks 119. 
A new generation of biomimetic materials is being developed in terms of fibrillar 
structure. The electrospinning technique is capable of producing fibers with diameters 
similar to those found in natural ECM from collagen 120 and fibrinogen 121. It is capable 
of aligning the fibers in a pre-described pattern b
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electros
itioning to 
influen
n construct altered the SMCs to a more contractile 
henotype 132 and increased both the ultimate tensile strength and tensile tangent modulus 
pinning process and must be seeded post-fabrication. Other potential approaches 
to create small diameter fibers are based on self-assembly techniques 122 although to date 
it has not been truly successful.  
 
2.7.5 Role of Mechanical Transduction in Tissue-Engineering Vascular Constructs 
Recently, several groups have attempted to use mechanical cond
ce vascular cell behavior, and thus improve the structure and mechanics of tissue-
engineered vascular constructs. Blood vessels experience four hemodynamic forces 
including: (1) shear stress, (2) luminal pressure, (3) radial stretch and (4) longitudinal 
stretch. These mechano-transduction forces act independently and synergistically to 
control the behavior of vascular cells 123-125. Thus, subjecting cells in culture to these 
forces can induce more native cell responses, such as cell-matrix interactions.  
 
2.7.6 Pulsatile Distention Conditioning 
SMCs are primarily affected by the pulsatile distention forces mentioned above. 
The mechanical stretching of SMCs cultured on substrates or with a collagen gel has 
shown to extensively affect SMC behavior in terms of phenotype 126, orientation 127, 
ECM deposition 128, growth factor production 129, proliferation 130 and vascular tone 131. 
As a result, investigators utilize the application of these mechanical forces to enhance the 
development of cell-embedded tissue engineered vascular biomaterials. Cyclically 
loading SMCs within a collage
p
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of the construct by approximately three fold 113. In another study, blood vessels were 
created
 
ing 
 using biodegradable scaffolds made of PGA with embedded SMCs for 8 weeks 
under pulsatile conditions then seeded with ECs. These pulsed constructs proved to have 
a thicker vascular wall, better suture retention, greater SMC and collagen densities, and 
be patent longer than similar non-pulsed constructs. Average burst pressures of 2150 mm 
Hg were observed with these constructs but the compliance was low resulting in possible 
creep and aneurysm formation. These cultured vessels also showed contractile responses 
to pharmacological agents 133. 
2.7.7 Shear Stress Mechanical Condition
Shear stress directly affects the function of lumenal endothelial cells and can also 
indirectly modulate behavior of underlying SMCs through secondary signals released by 
the ECs. In this manner, the entire vessel can respond to changes in shear stress. Normal 
levels of shear stress reduce thrombogenicity, maintain proper vascular tone and inhibit 
SMC proliferation. Low levels of shear stress increase thrombus formation on the luminal 
surface and induce SMC proliferation and intimal thickening 123. The function, 
orientation and morphology of ECs are considerably affected by laminar flow while 
turbulent flow is incapable of inducing such changes 134. This process of 
mechanotransduction is not well understood but evidence suggests that the actin 
filaments of the cytoskeleton play a central role 135. Shear stress has shown to align ECs 
in the direction of flow with significant changes in cytoskeletal and subendothelial matrix 
formation altering the ability of ECs to transmit mechanical stresses 136. In addition, shear 
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stress regulates the transport of fluid and biomolecules across the vessel wall by affecting 
EC permeability in a time dependant manner 137. 
 
2.8 Vascular Endothelial Cells 
 ascular ECs are one of the most complex and sensitive components of the blood 
l signaling. They act as a wall between the 
blood a
d. The apical surface interacts directly 
ith the blood, the basal surface contains adhesion junctions that attach the EC to the 
aces are comprised of junctions responsible for joining 
V
vessel in terms of physical structure and cel
nd vascular tissue and therefore, are capable of communicating with both blood 
and tissue -based elements. Under healthy non-activated conditions these cells regulate 
numerous processes to maintain homeostasis but if damaged or diseased, ECs initiate 
restorative signaling pathways that can lead to further tissue impairment if prolonged. As 
a result, the ability to populate vascular biomaterials with functional cells is an important 
facet of its design. 
 
2.8.1 Endothelial Cell Structure 
A monolayer of ECs lines the lumen of all blood and lymph vessels. They have a 
simple squamous morphology with a central nucleus and are arranged either in a cobble 
stone pattern or aligned depending on the species and vessel type. On average, ECs are 1-
2 µm thick and 10-20 µm in diameter. In vivo, vascular ECs act as a semi-permeable 
layer that controls the transfer of cellular and fluid blood elements into the vessel wall. 
The surfaces of these cells are highly specialize
w
basal lamina and the lateral surf
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ECs together and allowing communication between ECs, as portrayed in Figure 2.8. The 
basal and lateral surfaces are referred to as a single unit; the basolateral surface. ECs are 
in close apposition and use these specialized junctions to create sheets that act as barriers. 
Adjacent ECs connect and communicate with each other via three types of cell 
junctions: tight junctions, anchoring junctions and gap junctions, depicted in Figure 2.8. 
Tight junctions form a seal between ECs to prevent apical proteins and cells from moving 
to the basolateral surface and vice versa 138. Gap junctions are composed of connexons or 
hemichannels which connect the cytoplasm of one cell to another across the intracellular 
ace. They allow rapid communication between cells by permitting small molecules to 
9. Anchoring junctions enable groups of cells to function 
as robu
and ag
sp
pass from one cell to another 23,13
st structural units by connecting the cytoskeletal elements of a cell either to those 
of another cell or to the ECM. Anchoring junctions occur in three structurally and 
functionally different forms.  Adheren junctions attach the actin filaments of ECs to each 
other or the subendothelial matrix in a Ca+ dependant manner and are involved in 
contractile mediated permeability functions 140,141. Desmosomes are specialized for cell-
cell adhesion linking the cytoskeleton and distributing tensile or shearing forces through 
the endothelium and underlying connective tissue 142. Hemidesmosomes anchor ECs to 
the underlying basal lamina 143. In all anchoring junctions, the specialized proteins 
involved in cell-cell and cell-subendothelial matrix interactions are cadherin and integrin, 
respectively 144. ECs also act as a selectively permeable and thromboresistent barrier, 
regulate vasodilatory response and blood flow and control platelet activation, adhesion 
gregation, leukocyte adhesion and SMC migration and proliferation as one 
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component of Virchow’s triad 145. Virchow’s triad describes the factors involved in the 
pathogenesis of thrombosis: alterations in blood flow (haemostasis), injury to the vascular 
endothelium, and alterations in blood constitution (hyper-coagulability).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Endothelial cell structure. (A) Position of ECs on the basement membrane, (B) EC junctions. 
 
2.8.2 Anti-Thrombotic Properties of Endothelial Cells  
ECs are essential to maintaining haemostasis by inhibiting the activation platelets. 
On the lumenal surface of ECs lies the glycocalyx, a negatively charged 0.5 µm-thick 
hydrated mesh of proteoglycns, GAGs and glycoproteins, bound directly or indirectly to 
the endothelial plasma membrane. Since most of these molecules are negatively charged, 
the glycocalyx prevents thrombogenic proteins from depositing on the lumenal vessel 
surfaces. This relatively thick layer also physically masks cellular adhesion molecules 
Connective tissue
Basement membrane
Apical pole
Basal pole
A B
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(CAM) on the EC surface from signaling leukocytes under healthy, non-inflammatory 
onditions 146. 
Nitric oxide (NO, previously called endothelial-derived relaxing factor or EDRF) 
 produced by ECs and is a very potent inhibitor of platelet adhesion to ECs 147,148 and 
latelet aggregation 149,150. Prostacyclin (PGI2), also produced by ECs, inhibits platelet 
cruitment and activation 151,152 by raising cAMP levels in the plasma 153. Endothelial 
cto-ADPase destroys ADP released upon platelet activation and degranulation 154.  
.8.3 Endothelial Cells Regulate Coagulation of Blood 
ECs regulate haemostasis and thrombosis through anti- and pro-thrombotic 
echanisms that involve coagulation factors and fibrinolysis, as shown in Figure 2.9. The 
intact endothelium inhibits the coagulation of blood through control of circulating levels 
of thrombin, a product involved in the last step of the coagulation process. Antithrombin 
III slowly inactivates thrombin by forming a covalent thrombin-antithromin complex that 
is cleared by the liver 155. This process is accelerated in the presence of heparin and 
heparin sulfate found on the apical EC surface 156,157. Thrombomodulin, an integral 
surface membrane protein of ECs, binds thrombin and activates protein C in the plasma. 
Protein C in conjunction with protein S, produced by endothelial  cells, inhibits the 
activation of factor V and VIII preventing thrombin formation 158,159. ECs also secrete 
protease nexin I which inhibits thrombin formation by forming a covalent complex with 
thrombin. This complex then binds to ECs, is internalized and degraded by lysosomes 160. 
Continued inhibition of thrombus formation occurs through fibrinonolysis by 
c
is
p
re
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2
m
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activation of soluble plasma plasminogen to a serine protease called plasmin. Local 
endothelial secretion of tissue plasminogen activator (t-PA) and subsequent endothelial 
assembly of fibrinolytic factors (plasminogen, t-PA) leads to plasmin generation and 
ccelerated fibrinolysis 161. Plasmin also inactivates clotting factors involved in thrombin 
 
a
generation. 
 
A. EC regulation of the coagulation cascade. 
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 Hepatic Clearance
Endothelium
 
B. EC regulation of fibrin content within the blood 
Figure 2.9 Endothelial cell regulation of coagulation. EC produce regulatory molecules that influence the 
coagulation cascade (A) or the concentration of fibrin (B) 162. 
 
 
2.8.4 Blood Vessel Repair 
Minor injuries of the EC layer heal by initial migration of ECs into the wound and 
eration to replace s require the additional 
proliferation and migration of medial SMCs and adventitial fibroblasts for remodeling. 
ECs produce many b tive gulate this remodeling activity:  
 
a. Basic fibroblast growth factor (bFGF) stimulates the proliferation and 
m tion of ECs, SMCs and fibroblasts 164. 
b. Platelet derived growth factor (PDGF) is mitogenic and chemotactic 
for SMCs, fibroblasts and microvascular ECs 165,166. 
c. ing growth factor β ates angiogenesis but 
the damaged cells 163. Major injurieprolif
molecules that reioac
grai
Transform  (TGF-β) stimul
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inhib
 
mation, macrophages and damaged/ diseased ECs produce 
cytokin
leukocyte 
adhesion molecule-1 (ELAM-1), intracellular adhesion molecule-1 (ICAM-1) and 
vascula ll adhe
and neutrophils 16
serine protease co Willebrand factor 
found i e basem
absence of ECs, a actor (TF) is expressed by sub-endothelial 
cells (i.e. SMCs) t acts as a necessary 
cofactor in the activation of Factor VII and fibrin formation (Figure 2.9) 174. Additionally, 
perturb
its EC proliferation 167. 
d. Heparin like inhibitor prevents SMC growth 168.  
In areas of inflam
es (interleukin-1, interleukin -6, interleukin -8, tissue necrosis factor-α) that 
stimulate leukocyte chemotaxis toward the endothelium and vascular ECs to express 
binding sites for leukocytes, depicted in Figure 2.10. E-selectin and L-selectin attract 
leukocytes to the endothelium through weak binding, while endothelial 
r ce sion molecule-1 (VCAM-1) mediate the strong adhesion of monocytes 
9-171. 
Phospholipids on activated EC membrane bind factors IX, X and V to create 
mplexes that facilitate thrombin synthesis 172. Von 
n th ent membrane also binds to platelets promoting clot formation in the 
s in vessel injury 173. Tissue f
and upon injury is exposed to the blood where i
ed ECs secrete plasminogen activator-inhibitor (PAI-1) that inhibits t-PA and thus 
promote clot formation, displayed in Figure 2.9 175. 
 
2.8.5 Vasodilatory Properties of Endothelial Cells 
Vascular ECs modulate SMCs by producing vasodilators. Rapid blood flow 
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causes a shear stress on ECs because of viscous drag. This causes the ECs to contort in 
the direction of flow stimulating them to release NO, which stimulates the production of 
cGMP in SMCs resulting in SMC relaxation and vasodilatation 176. PGI2 also has 
vasodil
 
Figure 2.10 The endothelial cell inflammatory response. 
 
atory functions 177. Endothelin is a powerful vasoconstrictor produced when ECs 
are damaged by force or by toxins and prevents loss of blood from severe blood vessel 
damage 178. 
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2.9 Engineering Vascular Biomaterials to Promote Endothelialization 
Most conventional vascular biomaterials (i.e. ePTFE, Dacron) are incapable of 
meeting the requirements for endothelialization. Therefore, surface modification of these 
biomaterials has been attempted to stimulate endothelial growth and maintain their 
normal functionality 84. 
 
2.9.1 Plasma Treatment of Surfaces 
One approach to altering the surface properties of biomaterials to improve their 
ability to recruit, adhere, and retain functional ECs, is by plasma treatment. In this 
process, a biomaterial is placed in a chamber under high vacuum. A gas is then 
introduced into the chamber and ionized by radio waves or microwaves to create plasma 
that reacts with the biomaterial creating surface functional groups that are dependant on 
the substrate and gas used. The most common surface functional groups created by this 
process are hydroxyl, carboxyl, carbonyl, ketone, carbonate and amine. Plasma treatment 
is used to create a ch  immobilization 
patibility or enhance cell attachment, with the added benefit 
of material sterilization. A concern with this process is material degradation due to the 
generation of free radicals, t
limiting the damage to only extremely susceptible materials. This procedure was 
successfully accomplished on the clinically available biomaterials (Dacron , ePTFE , 
prove cell attachment. Plasma treatment 
was also used to functionalize ePTFE prior to chemically adhering biomolecules onto the 
emically more reactive surface for secondary
procedures, increase biocom
hough the treatment is fairly rapid (on the order of seconds) 
179 179
stainless steel 180) for vascular intervention to im
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surface
 membrane. When these proteins adsorb onto a 
iomaterial surface, conformational changes may be induced depending on the 
tein and material surface 184. In body fluids (i.e. plasma) proteins 
are ma
 that promoted EC attachment 181. 
 
2.9.2 Antibody Coating 
Monoclonal antibodies directed against integrins of the endothelial cell membrane 
and ECM can also improve cellular attachment. Adsorbed monoclonal antibodies against 
EC membrane proteins, fibronectin or von Willebrand factor improved cell adhesion and 
proliferation 182. A similar avdin-biotin system was also created to enhance EC 
attachment and spreading 183. 
 
2.9.3 Protein Coating 
Protein coatings on biomaterial surfaces can provide additional binding sites for 
cell adhesion receptors, and is frequently used to improve the attachment and spreading 
of ECs on vascular biomaterials. Many proteins have been deposited onto the surface of 
vascular biomaterials to enhance EC attachment (laminin, poly-l-lysine, gelatin, fibrin) 
but the most common protein coatings are collagen and fibronectin particularly due to 
their presence in the endothelial basement
b
characteristics of the pro
de up of a hydrophobic core surrounded by a hydrophilic surface that permits 
solubilization in aqueous media. Upon interaction with hydrophobic materials, these 
proteins undergo conformational changes to expose their hydrophobic domains and 
strongly adsorb onto the material surface. Hydrophilic materials do not induce a 
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conformational change of adsorbed proteins, but bind more weakly with hydrophobic 
surface groups on the protein surface 185,186. Structural changes to proteins can drastically 
ty of protein binding sites for cells. In one study, the effectiveness 
of EC 
influence the availabili
binding to fibronectin adsorbed onto hydrophilic glass and hydrophobic silanized 
glass was compared. It was found that the fibronectin coated onto the non-functionalized 
glass enhanced the spreading, adhesion and development of focal contact points of ECs 
187. It was also shown that the conformation of fibronectin is dependent on the surface to 
which it is absorbed 180. 
Implantation studies were performed to test fibronectin functionalized vascular 
biomaterials seeded with ECs in the dynamic body environment. Fibronectin-coated 
ePTFE and PU of 4 mm in diameter were seeded with ECs and implanted in sheep 
carotid arteries. EC coverage was 80-90% at week 3 while the thrombus free surface area 
remained low until 3 – 6 weeks suggesting a lag phase in the recovery of EC function 188. 
The increase in thrombus free surface area of endothelialized biomaterials was confirmed 
by another study using a 6 mm diameter Dacron conduits implanted in dogs 189. Gelatin 
coated Dacron conduits with ECs seeded onto its lumen were implanted in dogs. 
Scanning electron microscopy revealed a confluent EC covering 5 mm from the edge of 
the implant and isolated EC in the center 190. 
Vascular biomaterials endothelialized in the above manner have also been 
clinically investigated. ePTFE conduits pretreated with fibronectin were endothelialized 
in vitro with autologous cells and implanted into patients. After 7 years of implantation, 
the endothelialized fibronectin coated biomaterials performed significantly superior to 
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endothelialized ePTFE without the fibronectin coating and ePTFE without ECs or 
fibrone
collagen IV (RGDX, X is a variant), 
thromb
 Mixtures 
 he ECM is composed of many biomolecules that surround and support cells. The 
olecules are: structural proteins (i.e. collagen, elastin), specialized 
link-pr
ctin treatment 191. The same procedure was used in other experiments and the 
results provide strong evidence that an endothelial lining improves the patency and 
facilitates healing of the biomaterial 192. 
 
2.9.4 Peptide Coating 
A novel approach for enhancing EC attachment on vascular constructs is through 
immobilization of specific protein peptide sequences involved in cell attachment. The 
most common integrin binding site is the RGD (arginine, glycine, aspartic acid) sequence 
found on many proteins including fibronectin (RGDS), von Willebrand factor (RGDS), 
vitronectin (RGDV), collagen I (RGDT), 
ospondin (RGDA) and laminin (RGDN). Other integrin binding sites include 
REDV and LDV on fibronectin 193 and YIGSR on laminin 194. In one study, RGD and 
YIGSR peptides were covalently bound to Dacron and ePTFE and found to significantly 
enhance EC attachment and spreading 195. Also, RGD containing peptides coated onto 
ePTFE improved the attachment and retention of EC after shear stress as compared to 
fibronectin coated ePTFE 196. 
 
2.9.5 Coating composed of ECM Protein
T
four classes of EMC m
oteins (i.e. fibronectin, laminin), proteoglycans (i.e. versican, fibromodulin), and 
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glycosaminoglycans (i.e. hyaluronic acid, heparan sulfate). The combination of these 
components as in the basement membrane appears to support EC attachment in a more 
superior manner to single protein coatings. Completely de-endothelializing a human 
artery and re-seeding the cells under flow conditions resulted in 94% EC attachment 197. 
Another group stimulated ECs to produce an ECM with β-FGF; then removed the cells 
and found the surface to enhance EC growth better than laminin, poly-L-lysine and 
fibronectin coated surfaces 198. 
 The ECM, predominantly composed of collagen, glycoproteins, proteoglycans 
and elastic fibers, is responsible for the passive biomechanical properties of blood vessels, 
providing mechanical strength, resilience, and compressibility. In addition to providing 
ECs with an adhesive surface (e.g. collagen I, IV, elastin), vascular ECM molecules are 
s and the structural integrity of blood 
ounded by an ECM that provides and modulates a variety 
an integral part of maintaining vascular homeostasi
vessels. Hence, alterations in composition or spatial arrangement of its elements affect 
vessel performance. Vascular SMCs routinely reproduce certain components of the ECM 
(i.e. collagen) throughout adulthood in response to its degradation but their capacity to 
synthesize elastin greatly decreases with age, compromising the integrity of blood vessels 
when they are degraded due to disease or injury. Therefore, as with the luminal EC 
monolayer, the regeneration of vascular elastin is vital to the viability of a vascular 
implant material for the treatment of vascular disease. 
 
2.10 Vascular Elastin  
 Vascular SMCs are surr
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of biochemical and mechanical cues that guide cell function. Within blood vessels, elastic 
fibers constitute a major part of the ECM, especially within large elastic vessels (30-57% 
w/w in the aorta) 199. Elastin is a structural protein that is predominantly distributed in the 
tunica media (Figure 2.2) layer of arteries where stretching and elasticity is required 200. 
 
2.10.1 Vascular Extracellular Matrix 
 The ECM is a major component of the normal blood vessel wall, accounting for 
up to 60% of the intimal volume. The ECM is not only a scaffold for cells, but is also 
central to controlling vascular remodeling. It is a dynamic structure that can control cell 
behavior by storage of growth factors, and as a site for arterial lipoprotein binding 201. 
Given this diversity, ECM can serve many functions, such as providing support and 
anchorage for cells, and regulating intercellular communication via specific cell surface 
ellular adhesion molecules (CAM), also known as integrins 200.  The ECM consists of 
ein components, including proteoglycans, collagen 
nd mu
f 
e vascular ECM. 
ines the physical elastic properties of 
c
elastic lamellae and three major prot
a lti adhesive matrix proteins. The highly viscous proteoglycans cushion cells are 
largely responsible for the volume of the ECM, insoluble collagen fibers provide strength 
and resilience, and soluble multi-adhesive matrix proteins bind components to receptors 
on the cell surface. SMCs are linked to the elastic lamellae by fibrillin-1 and type VI 
collagen-containing bundles of microfibrils 201. Table 2.1 lists the major components o
th
 The composition of the ECM largely determ
the vessel wall and is maintained and remodeled in the face of continual mechanical 
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stresses. SMCs have the capacity to produce most elements of the ECM as well as 
proteolytic enzymes (i.e. matrix metalloproteinase, MMP; serine proteases, SPs; cysteine 
proteases, CP) capable of degrading its components. Naturally occurring inhibitors of 
MMP activity in the vessel wall, known as tissue inhibitors of metalloproteinases 
(TIMPs), are also produced by SMCs preventing ECM degradation 202. In this manner 
SMCs regulate the composition and structure of the ECM. However, certain components 
of the ECM, such as elastin, are irreplaceable under normal conditions due to a lost 
ability of SMCs to produce elastin during adulthood 203. Elastin is an extremely important 
component of the blood vessel providing both biochemical signaling pathways and 
mechanical support, that if disrupted can initiate and progressively lead to the pathology 
of life threatening complications such as atherosclerosis, aneurysm and vasospasms 9,10. 
 
Collagens Glycoproteins Proteoglycans 
Family Type Family Type Family Type 
Fibr
Elastin Fecorin 
Decorin 
il-Forming I, II 
III, V 
XI 
Connective 
Tissue 
Fibronectins 
Tenascins 
Fibrillins 
Small  
Leucine 
Rich 
Fibromodulin 
Lumican 
Epiphycan 
Biglycan 
Basement  
Membrane 
IV Microfibril-
Associated  
Proteins 
Matrilins 
Thrombospondins 
Modular Perlecan 
Agrin 
Testican 
Aggrican 
Versican 
FACIT IX, XII 
XIV, XVI 
XIX 
Basement 
Membrane 
Laminins 
Nidogen/ entacin 
Fibulin 
  
Multiplexins XV, XVIII     
Orphans VI, VII 
VIII, X 
    
XIII, XVII 
 
Table 2.1 Structural Components of the ECM 204. 
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2.10.2 Chemical composition of Elastin 
 Elastin contains a high concentration of non-polar amino acids (alanine, glycine, 
valine, praline), as shown in Table 2.2, resulting in a hydrophobic protein. The 
polypeptide chains in elastin are cross-linked by unique polyfunctional heterocyclic acids 
alled desmosine and isodesmosine, as opposed to typical disulfide bridges. These 
distinctive internal linkages and inherent hydrophobicity make elastin a stable protein, 
resistant to the normal breakdown ch 3
 
Amino Acid Aorta 
c
aracteristic of most proteins . 
Proline 11.27 
G 33.24 lycine 
Alanine 22.39 
Valine 13.13 
Leuci e 5.82 n
Phenylalanine 2.97 
Isodesmosine1 0.55 
Desmosine1 0.96 
T .2. Amino acid composition of elastin derived from bovine aorta. Values are expressed as a 
p ge of the total amino acid residues. 
able 2
ercenta
role in organizing 
1Expressed as lysine equivalents 200. 
 
 
2.10.3 Elastin Fiber Assembly 
 Mature elastic fibers are composed of a central core of elastin surrounded by 
glycoprotein microfibrils (10-12 nm in diameter) 205. During the early stages of 
elastogenesis, these microfibrils are formed first and play a major 
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elastin into elastic fibers. The major microfibrillar components are fibrillin -1 and -2 that 
polymerize in a head-to-tail m eld the micr s. Calcium binding stabilizes 
the linear and rigid structure of fibrillin monomers, their interactions, the lateral packing 
of microfibrils, and thus the three ensional organization of their macroaggregates. 
Elastin is then deposited as small clumps of amorphous material within these bundles of 
fibrillin.  
   The soluble elastin poelastin, is secreted from cells and finds its 
way through the extracellula e it interacts with the microfibrils and becomes 
oriented within a growing e r for eventua sslinking 206. This assembly 
lex, which consists of 
ree proteins. Two among these are integral membrane proteins (55 and 61 kDa) that 
ween the extracellular compartment and the cytoskeleton. 
stin. Crosslinking of elastin is initiated by the action of lysyl oxidase (LOX), a 
u2+ de
anner to yi ofibril
-dim
precursor, tro
r space wher
lastic fibe l cro
process is mediated at the cell surface by an elastin-binding comp
th
form a transmembrane link bet
The third subunit is a 67 kDa bifunctional elastin binding protein (EBP) that also has 
galactolectin properties. It binds the hydrophobic VGVAPG sequence in elastin, the cell 
membrane, and galactosugars via three separate sites, as shown in Figure 2.11. The 
binding of galactosugars lowers its affinity for both tropoelastin and for the cell-binding 
site, resulting in the release of bound elastin and the dissociation of the 67-kDa subunit 
from the cell membrane. Galactosugar-containing microfibrillar glycoproteins may 
therefore be involved in the coordinated release of tropoelastin by the cell 207.  
 The tropoelastin deposited onto the microfibril matrix is then crosslinked into 
mature ela
C pendant endogenously produced enzyme that catalyses the oxidative deamination 
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of lysine residues into allysine 205. This is the only enzymatic step involved in elastin 
crosslinking. Subsequent formation of crosslinks between tropoelastin molecules by 
desmosine and isodesmosine occurs as a series of spontaneous condensation reactions, 
resulting in the production of a complete elastic fiber. The relative proportion of 
microfibrils to elastin declines with increasing age of the animal, adult elastic fibers 
having only a very sparse peripheral mantle of microfibrillar material. 
 
Figure 2.11. Schematic of possible mechanism of elastin fiber assembly 206. 
 
 
 
 Elastin fibers form random coiled structural networks that allow them to be 
stretched and then to recoil to their original state upon load-release (Figure 2.12). Elastic 
fibers formed by such aggregation vary in thickness, length and three-dimensional 
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architecture depending on the direction and magnitude of the forces exerted upon the 
tissue. This morphological diversification can be seen in different organ systems. In the 
aortic wall, elastic fibers form thick concentric lamellae in the tunica media with 
interlaminar connecting fibers scattered radially. Additionally, microfibrils are present as 
a complex meshwork throughout the aortic wall. It can be generalized that the elastic 
fibers are responsible for dilation and recoil, with the microfibrils acting as flexible links 
that make the aortic wall a working unit 205. 
 
 
Figure 2.12. Elastin molecule in relaxed and stretched conformations . 
 
 
205
 
2.10.4 Dynamics and mechanical properties of elastin 
 The mechanical properties of blood vessels influence a broad spectrum of 
physiologic phenomena, including blood pressure, flow rates, wall shear stress, 
relaxstretch
single elastin molecule
cross-link
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biomolecules, and mass cell transport that, in turn, critically impact cardiovascular 
omeostasis. As mentioned previously, the mechanical properties of blood vessels stem 
from microstructural wall components, such as collagen and elastin fibers, smooth 
muscle cells, and fibroblasts 205. Since these individual components take up loads at 
different stress levels, their source and location-specific differences, content and 
distribution within blood vessels, and their alteration in diseased states can render the 
mechanical properties of blood ves p ult to predict. Collagen and 
elastin affect the mechanical behavior of vessels i gure 2.13). Strain is 
initially accommodated by elastin allowing the vessel to expand with minimal resistance, 
and, eventually strain is strongly resisted by collagen preventing overexpansion. While 
collagen provides rigidity, elastin allows the connective tissues in blood vessels to stretch 
and then recoi s shown that 
xial elastin fibers in intimal and adventitial layers, and circumferential medial fibers 
ion and relaxation, conclusively 
h
els com lex and diffics
n different ways (Fi
l to their original positions 3. A study by Gundiah et al. 208 ha
a
help distribute tensile stresses during vessel inflat
providing evidence that emphasizes mechanical importance and indispensability of 
elastin fibers in the aortal anatomy.  
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 Figure 2.13. A typical stress-strain curve for a blood vessel. Shown are the respective regimes affected by 
physiologic state and organization of collagen and elastin. Reproduced with data from 209. 
 
 
 
2.10.5 Elastin in Vascular Disease 
 A common pathologic feature of vascular disease is the disruption of elastic fibers 
and the accumulation of SMCs within the intima between the endothelium and medial 
layer of the vessel wall resulting in the progressive occlusion of blood flow. Under 
normal conditions, vascular SMCs in the tunica media of blood vessels are quiescent and 
embedded in a network of elastin-rich ECM that acts as a barrier to SMC migration and 
proliferation 205. During atherosclerosis, different cell types, including ECs, platelets, and 
inflammatory cells release mediators, such as growth factors and cytokines that induce 
otype state to 
e active "synthetic" state, causing them to release matrix proteases degrading the ECM 
o aggressively migrate into the subendothelial space 
phenotype change of vascular SMC from the quiescent "contractile" phen
th
(including elastin) allowing them t
and contribute to neointima formation, as depicted in Figure 2.14 210. The degradation of 
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vascular elastin exposes other medial components (i.e. collagen, SMCs) to very high 
tensile stresses 208. The high plasticity of SMCs makes these cells susceptible to 
mechanically induced phenotypic changes that may result in continued aggravated 
protease secretion and ECM degradation.  
 
Figure 2.14. Model of elastin –SMC interactions in disease 211. 
 
 
 
 Since vascular SMCs modulate their phenotype readily, external factors in the 
arterial wall must instruct them to maintain a quiescent, contractile state if homeostasis is 
to be achieved. This regulation of vascular SMC activity occurs through defined receptor 
interactions and signaling pathways. In contrast to other matrix proteins, both in vitro and 
 66
in vivo studies implicate elastin matrix as a negative regulator of SMC activity within the 
arterial wall 211. Thus elastin regulates vascular homeostasis by signaling SMCs through 
defined pathways to localize around the elastic fibers in organized lamellar units and 
remain in a quiescent, contractile state. The disruption of elastin by vascular disease, or 
direct mechanical injury can interrupt cell-matrix signaling and directly up-regulate SMC 
hyper-proliferation 205. Thus, the disruption of elastin is not simply an end product of 
vascular disease, but an important contributor to the pathogenesis of occlusive vascular 
disease. Therefore, preventing elastin matrix degradation following vascular injury or 
restoring the lost/ degraded vascular elastin matrix is imperatative for vascular 
homeostasis restoration 211. 
 
2.11 Engineering Vascular Biomaterials to Promote Elastin Regeneration 
 Elastin is tion 128,212-214 and 
regulating the cell-signaling pathways 4-7 of blood vessels. Thus, the failure to reinstate a 
crucial to maintaining the native structural configura
healthy elastin matrix, when damaged by disease (e.g., inflammation-mediated elastin 
degradation in atherosclerosis) can severely compromise vessel homeostasis 81,215. 
Therefore, in addition to achieving functional and complete endothelialization, a major 
concern in the development of tissue-engineered vascular constructs is the ability of 
scaffolding materials to modulate SMC behavior and encourage the regeneration of 
elastin-rich matrix. 
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2.11.1 Synthetic Scaffolds 
 The most widely used synthetic scaffolds are poly-lactic (PLA), poly-glycolic 
acid (PGA), and poly-L-lactic acid (PLLA). Although these scaffolds are not ideal from 
the standpoint of eliciting poor cell attachment, PLLA has been shown to favor 
elastogenesis 216. SMCs seeded onto polyhydroxyalkanoates synthesize uniformly 
alligned elastin and collagen fibers in the direction of blood flow. Previous attempts by 
tock et al. 82 to regenerate elastin on laminin-coated PGA scaffolds in-vitro, did not 
 scaffolds 
ly ECM scaffolds, which theoretically would be expected to elicit 
ore closely native cell responses have gained much attention in the context of elastic 
ssue regeneration 216. 
S
replicate the amounts and ultrastructure of elastin, synthesized by the same
when implanted in-vivo 82. This underlies the absence of cell signals controlling elastin 
mRNA expression in vitro and also leads to the conclusion that biosynthesis and 
crosslinking of elastin appears to be one of the most complex and tightly regulated 
processes during blood vessel maturation. Application of mechanical stimuli (e.g., 
dynamic stimulation), growth factors (e.g., TGF-β), and of stem cells (e.g., endothelial 
progenitor cells) can upregulate amounts of elastin biosynthesis within synthetic scaffolds 
but not to the extent of mimicking native arterial elastin 216. Thus, biological scaffolds, 
and more important
m
ti
 
2.11.2 Biological Scaffolds 
 Biological scaffolds are normally fabricated from one or all the components such 
as elastin, collagen, glycosaminoglycans and more recently of fibrin, which has been 
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clinically approved for promotion of elastin biosynthesis when incorporated in a three 
dimensional (3D) arrangement within scaffolds. However, each of these components 
differs in the levels of elastin biosynthesis they elicit. Previously, Ramamurthi and 
Vesely showed enhanced elastin biosynthesis by rat neonatal SMCs cultured onto 
hyaluronic acid gel scaffolds as compared to controls (plastic) 216. Collagen scaffolds fail 
to regenerate elastin in vitro even in presence of seeded vascular SMCs. Long and 
Tranquilo showed higher levels of elastin biosynthesis by neonatal vascular SMCs seeded 
onto fibrin scaffolds and within fibrin-collagen constructs 114. Cells entrapped and 
cultured within 3D fibrin gels allowed formation of complex elastin geometries similar to 
that observed in native elastin. Although promising, above results were generated by 
neonatal SMCs and dermal fibroblasts; both cell types that retain high elastogenic 
potential, unlike adult SMCs 217. Also, the organization of elastin fibers into structural 
networks, and their mechanical properties were not characterized. Yet, this study 
validates previous claims as to the overall superiority of 3D, ECM-based cell scaffolds 
ver 3D synthetic scaffolds or two dimensional (2D) monolayer cell cultures to efforts to 
 physical environment of tissues 64,114,218. Cells with 3D 
affold
o
simulate the chemical and
sc s exist in a more natural environment in which they contact other cells and ECM 
in three dimensions and are therefore expected to more closely evoke native cell 
responses than 2D substrates. Lee et al. has demonstrated in a study involving SMCs 
seeded onto ECM scaffolds that the phenotype of SMCs in engineered tissues is strongly 
regulated by the chemistry of scaffold in vitro, as a result of which SMCs exhibited a 
differential cell growth and ECM production depending upon the scaffold to which they 
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adhered 219. More specifically elastin production was stimulated on PGA scaffolds, used 
as controls in comparison to enhanced collagen production onto collagen I scaffolds 219. 
So it was elucidated by this study that, 2D culture models still provide useful information 
since trends in scaffold chemistry- dependent variations of cell phenotype and matrix 
synthesis are maintained, but not necessarily to the same levels, when translated into a 3D 
culture system. The physical and mechanical characteristics of the scaffold are important 
only to exaggerate or dampen scaffold-chemistry-dependent cell responses or direct the 
structural organization of the synthesized matrix towards defined end goals 219. Since 
gene expression of cells cultured within 3D scaffolds, as within native tissues, can be 
regulated by various scaffold-derived cues including cell adhesion molecules, growth 
factors, and mechanical stimuli, ECM-based scaffolds are more likely to evoke native 
integrin-ECM interactions and preserve the native cell phenotype; similar variations in 
the type and extent of cell receptor-ECM ligand interactions with different ECM 
molecules can profoundly influence cell phenotype and matrix (e.g., elastin) synthesis 
64,114,218. Accordingly, successful up-regulation of elastin synthesis and it’s organization 
into mature elastic tissue is crucially contingent on the selection of an appropriate 
scaffold material from among a sub-set of ECM molecules shown to actively facilitate 
elastogenesis in vivo. One class of ECM molecules that may have great potential as 
elastogenic cell scaffolds are glycosaminoglycans (GAGs) 220. 
  
2.12 Hyaluronic Acid and its use as Vascular Regenerative Biomaterial 
 Over the years, the components of the ECM have proven to dynamically 
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contribute to tissue homeostasis. Hyaluronic acid, a GAG, in particular, appears to have 
three major characteristics resulting in an array of dynamic functions: unique 
hydrodynamic properties, interactions with extracellular hyaladherins and cell signaling 
capability. These properties of hyaluronic acid seem to be molecular weight dependant. 
Therefore, we seek to manipulate these characteristics by combining different molecular 
weights of hyaluronic acid into a vascular biomaterial capable of stimulating 
endothelialization and elastogenesis. 
 
2.12.1 Glycosaminoglycans 
The ECM, once regarded simply as a structural scaffold, is now recognized as an 
important modulator of cell phenotype and function. From the tissue engineering 
perspective, it is increasingly apparent that ECM molecules elicit cell responses that are 
less exaggerated and more representative of cell behavior in native tissues. This is largely 
due to the biomechanical and biochemical signaling provided by such substrates to 
cultured cells.  
A class of ECM molecules that are increasingly studied in the context of cell 
 unbranched culture scaffolds are glycosaminoglycans (GAGs). These molecules are long
polysaccharides that contain a repeating disaccharide unit. The disaccharide units are 
composed of at least one of two modified sugars (N-acetylgalactosamine, GalNAc; N-
acetylglucosamine, GlcNAc) and a uronic acid such as glucuronate or iduronate. 
Although each of these GAGs has a predominant disaccharide component, heterogeneity 
does exist 199. GAGs have a high negative charge and extended conformation that imparts 
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a high viscosity to the solution. Along with the high viscosity of GAGs comes low 
compressibility, which makes these molecules ideal for a lubricating fluid in the joints. 
At the same time, their rigidity provides structural integrity to cells and maintains 
assageways between cells, allowing cell migration. GAGs are also capable of interacting 
eceptors and binding cell signaling molecules controlling 
cellular
nic acid is a large, linear, negatively charged GAG. First discovered in the 
vitreou
p
with cell through specific r
 events. The specific GAGs of physiological significance are hyaluronic acid, 
dermatan sulfate, chondroitin sulfate, heparin, heparan sulfate, and keratan sulfate 199. 
These GAGs are found in a multitude of tissues, as listed in Table 2.3. 
 
2.12.2 Hyaluronic Acid Structure and Properties 
Hyaluro
s humor by Meyer and Palmer in 1934 221, the GAG was named hyaluronic acid 
due to its naturally glassy state and its high uronic acid content. The term hyaluronan was 
later proposed by Endre Balazs in the 1980’s, to encompass the different forms the 
molecule can take such as the acid form (hyaluronic acid) and the salts (i.e. sodium 
hyaluronate), which form at physiological pH 30. 
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Type of GAG Localization Characteristics 
Hyaluronate Synovial fluid, vitreous humor, 
ECM of loose connective tissue 
Large polymers, shock absorbers 
Chondroitin sulfate Cartilage, bone, heart valves Most abundant GAG 
Heparan sulfate Basement membranes, components Contains higher acetylated 
han heparin of cell surfaces glucosamine t
Heparin Component of intracellular 
granules of mast cells lining the 
arteries of the lungs, liver and skin 
More sulfated than Heparan 
sulfates 
Dermatan sulfate Skin, Blood vessels, heart valves  
Keratan sulfate Cornea, bone, cartilage aggregated  
with Chondroitin sulfates 
 
lcNAc) and D-glucuronic acid (GlcUA) 
17 linked together by alternating b1,3 and b1,4 glycosidic bonds, as shown in Figure 2.15. 
Each repeating disaccharide unit has one carboxylate group, four hydroxyl groups and an 
acetam o group. The negative charge of the molecule is due to ionization of the carboxyl 
groups of the glucuronic acid constituents at physiological pH.  
A is unique among the GAGs in terms of its structure and cellular synthesis. 
Unlike other GAGs, HA is not sulfated or found covalently attached to proteins as a 
proteoglycan but it is a component of the proteoglycan complexes with in the ECM. HA 
polymers are very large (200 nded length of 2-25 µm allowing 
large volume th s and 
sorbers. Other GAG  on the A is 
Table 2.3 Characteristics of glycosaminoglycans 199. 
 
 
 
2.12.3 Structure of Hyaluronic Acid 
The hyaluronic acid (HA) molecule is a polymer chain consisting of repeating 
disaccharide units of N-acetyl-D-glucosamine (G
id
H
 – 10,000 kDa) with an exte
it to displace a of water. This property makes em excellent lubricator
shock ab s are relatively smaller, order of 15 – 20 kDa. H
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also synthesized on the inne brane, while other GAGs are 
es within the golgi apparatus of cells 128,222. 
 
 
 
 
 
 
 
 
 
 
Three transmembrane glycotransferase enzymes (HA synthases: HAS1, HAS2, 
HAS3) regulate the biosynthesis of HA. The amino acid sequences of these enzymes are 
similar but they are produced from genes located at three distinct locations of the 
chromosome. Each enzyme contains two components (or gylcosyltransferases), one adds 
GlcNAc and the other is responsible for GlcUA with each addition occurring at the 
reducing end of the growing chain. The HAS enzymes are trans-membrane proteins with 
an active site located on the inner surface of the plasma membrane where HA is 
polymerized from monomer units. As the HA chain is being synthesized, it is extruded 
through the plasma membrane via the HAS complex onto the cell surface or into the 
ECM. This unrestrained synthesis mechanism allows HA to amass into large chain 
lengths, exceeding four million daltons 223. 
r surface of the plasma mem
produced by enzym
 
2.12.4 Synthesis of Hyaluronic Acid 
Figure 2.15. Structure of HA [63]. 
N-acetyl-D-Glucosamine D-Glucuronic acid
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2.12.5 
a day ile collagens have half-lives of several weeks 30,224. Hi
HA (HMWHA) is degraded extracellularly through enzymatic and n
zymatic degradation occurs by the action of hyaluronid
xosaminidases. Non-enzymatic degradation of HA occurs duri
 and involves reactive oxygen species, hydrogen pero
als 225,226. This partially fragmented HA is then engulfed a
f tissue cells and macrophages or transferred to the lym
.12.6 The Biological Functions of Hyaluronic Acid 
HA is present in almost every tissue of vertebrates but is most abundant in the 
CM of soft connective tissue. Therefore, it is a very important physiologic molecule and 
as three known molecular functions: (1) It encompasses a large hydrodynamic domain 
y binding large quantities of salts, metal ions and water molecules; this allows HA to act 
as a physical barrier preventing disturbances to developing cells or create an uninhibited 
pathway for migrating cells. (2) HA interacts with HA binding proteins and 
roteoglycans to form composite ECM which t to the assembly and 
The Catabolism of Hyaluronic Acid 
 The turnover of HA within the body is relatively rapid compared to other ECM 
e skin epidermous is 
half , wh gh molecular weight 
on-enzymatic 
processes. En ases, chondroitinases 
and he ng inflammation and 
tissue injury xide and hydroxide 
radic nd degraded in the 
lysosomes o ph nodes where it is 
ingested and through an unknown mechanism. The highly degraded product is then 
transported by the blood to the liver where it is hydrolyzed to single sugars and 
metabolized 
molecules. The half-life of HA in the blood is 5 minutes and in th
30. 
 
2
 
E
h
b
p is vitally importan
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structure of several tissues. (3) HA binds to cell surface receptors that mediate important 
signaling pathways. All of these molecular interactions with HA involve binding proteins, 
termed hyaladherins. 
 
2.12.7 Hyaladherins 
 Hyaladherin is a term given to a diverse group of proteins capable of binding to 
HA. Many of the known hyaladherins bind to HA through a 100 amino acid sequence 
called a link module, which contains an immunoglobulin domain and two adjacent link 
modules. It is thought that the link modules mediate protein-HA binding and the 
immunoglobulin controls protein-proteoglycan interactions. Hyaladherins are classified 
as either extracellular or cellular . 
 
2.12.8 Extracellular Hyaladherins 
 The interaction between hyaladherins and HA has been implicated in the 
development and stabilization of the ECM. Aggrecan, a major proteoglycan found within 
cartilage, strongly interacts with HA through the HA binding domain and stabilizes the 
ECM. Other major extracellular hyaladherins include vesrican, neurocan, and brevican. 
The interaction of these molecules with HA is responsible for retaining these 
proteoglycans within the ECM . 
 
2.12.9 Cellular Hyaladherins 
 The most well known and characterized cellular hyaladherin is the CD44 receptor 
227-229
228,230,231
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232. CD44 is produced from a single gene but several exon splicing combinations result in 
different isoforms of the receptor. All isoforms are single-pass transmembrane 
glycoproteins consisting of four functional domains, though a link sequence within the 
istal extracellular domain is primarily responsible for HA binding. HA-CD44 binding is 
ycosylation, alternative splicing, 
imeriz
ghly enriched with HA. This is accomplished by cell surface 
ceptors and HA bound to HAS in addition to HA interactions with extracellular 
a complex, hydrated microenvironment that supports and promotes 
d
subject to numerous influences, including gl
d ation, receptor clustering, and integrity of the cytoplasmic domain 233. Depending 
on the cellular context, the binding of HA results in intracellular CD44 interactions with 
certain regulatory and adapter molecules including SRC kinases, RHO GTPases, VAV2, 
GAB1, ankyrin and ezrin 234-236. Transcription of CD44 is also upregulated in response to 
proinflammatory cytokines (IL-1) and growth factors (EGF, TGF-b, BMP-7). IL-1 
induced elevation of CD44 enhances the ability of SMCs to bind HA, which may be 
responsible for the increased levels of SMC CD44 expression and HA in atherosclerotic 
lesions 237,238. Studies of embryonic development, regeneration and healing, cancer and 
vascular disease reported that the pericellular matrix surrounding proliferating and 
migrating cells is hi
re
hyaladerins to create 
the behavior of mitotic cells 239,240. HAS activity also fluctuates with the cell cycle and is 
maximum during mitosis 241. Other cellular functions known to be influenced by the HA-
CD44 interaction includes cell aggregation, cell-matrix signaling, and receptor-mediated 
HA internalization and degradation 3,239,242. 
 The receptor for HA mediated motility (RHAMM) is available in several isoforms 
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depending on the various splicing combinations and can be present on the cell surface, 
ithin the cell cytoplasm or in the nucleus. Surface RHAMM has been implicated in 
 c-src, focal adhesion kinase and MAP kinases 122,243. 
sensitive. Therefore, the function of TSG-6 is 
kely to be tissue specific with a dependence on pH and GAG content 244. In addition, the 
ble to stabilize the ECM by cross-linking the HA chains 244. 
w
intracellular pathways that activate
Intracellular RHAMM interacts with the actin cytoskeleton and microtubules. Both 
surface and intracellular RHAMM regulate Ras 227. 
 TSG-6 is a multifunctional protein and its actions include neutrophil migration 
and protease network modulation. It interacts with HA among other ligands, including 
heparin, chondroitin 4-sulfate, aggrecan, versican, IαI, pentraxin-3 and thrombospondin-
1, and its interactions appear to be pH 
li
TGS-6/ IαI complex may be a
 Other more recently discovered hyaladherins include the hepatic HA clearance 
receptor, LYVE-1 and layilin. The hepatic HA clearance receptor is present on the 
surface of endothelial cells and activated macrophages in the liver, spleen and lymph 
nodes. It is thought to remove HA from the blood during steady-state tissue remodeling 
245. LYVE-1 expression is limited to the lymph vessel endothelium and interacts with HA 
through a tightly regulated mechanism 246. Layilin contains a membrane-binding site for 
talin, an ECM linker between the cytoskeleton and the cell membrane, and is thought to 
mediate cell migration and morphology 247. 
 
2.12.10 Molecular Weight-Specific Biologic Effects of Hyaluronic Acid 
 HA is known to be involved in many fundamental physiological and pathological 
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processes such as cell development, migration, adhesion, proliferation and differentiation, 
immunogenicity, inflammation, wound healing, multi-drug resistance, angiogenesis, 
malignant transformation, and ECM stability and integrity. Some of the functions of HA 
appear to be molecular weight dependant. High molecular weight HA (HMWHA) binds 
cells and extracellular hyaladherins to maintain the structural stability and integrity of 
tissues with few stimulatory effects on cells. In contrast, low molecular weight HA 
(LMWHA) interacts with cellular receptors resulting in a multitude of cell signaling 
cascades. In addition, the large strands of HMWHA is capable of blocking biomolecules 
from stimulating the cell while LMWHA allows these biomolecules to influence cell 
behavior, as illustrated in Figure 2.16. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16. Molecular-weight dependent HA-cell interactions. 
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B. HA Oligomers
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2.12.11 High Molecular Weight Hyaluronic Acid 
 HMWHA (> 1000 kDa) is considered to be a space-filling molecule primarily 
impacting cells through physical interactions. HMWHA binds to cells in a polyvalent 
manner and surrounds them creating a dynamic protective coating through additional 
interactions with extracellular hyaladherins (Figure 2.16). During embryonic 
development, HMWHA surrounds migrating and proliferating cells 229. This coating 
isolates proliferating cells, allowing them to develop without being disturbed from the 
extracellular environment, and also provides hydrated migration pathways for cells. In 
the same manner, HMWHA surrounds proliferative tumor cells and acts as the interface 
t the site of tumor invasion into the host tissue 241. Additionally, HMWHA is inherently 
ls and infectious 
stimulation of specific cell signaling cascades, 
a
anti-inflammatory and immunosuppressive by preventing free radica
organisms from migrating into the tissue 218. Therefore, HMWHA allows tissues to heal 
by inhibiting the entry of damaging molecules and organisms, and thus reduces scar 
formation. This may be significant in the fetal circulation where HMWHA is found in 
high concentrations. HMWHA also appears during the early stages of wound healing by 
creating spaces through which leukocytes can infiltrate the wound area and binding 
fibrinogen to induce clot formation. However, HMWHA must be fragmented in order 
stimulate-receptor mediated cellular responses. 
 
2.12.12 Hyaluronic Acid Oligomers 
 HA oligomers (0.75–10 kDa) are capable of binding to cell surface receptors in a 
monovalent manner resulting in the 
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possibly by allowing HA–bound receptors to cluster and/or multiple HA molecules to 
bind to a single receptor, as depicted in Figure 2.16. Therefore, this form of HA 
communicates directly with th
 matic digestion of 
promote angiogenesis 
in vitro 23,229 tors and signaling 
rs enhances EC 
production of vascular endotheli F) and therefore promotes 
endothelial cell proliferation ers 
stimulate endothelial cells to  and enhance the synthesis of 
collagen type the angiogenic phenotype. This 
liferation, migration and adhesion by 
e cells influencing their metabolic functions. 
Based on previous studies, HA oligomers, formed by enzy
larger HMWHA, are thought to play a role in wound healing due to their ability to 
in vivo and the proliferation of vascular endothelial cells cultured 
. The reason for this occurrence may involve specific recep
pathways of these endothelial cells. The stimulation of the CD44 recepto
al cell growth factor (VEG
26.  In addition, it has been shown that HA oligom
 produce angiogenic proteins 248
s I and VIII which are produced by ECs of 
angiogenic HA oligomers also stimulate EC pro
activating focal adhesion kinase and mitogen activated protein kinase pathways 249,250. 
HA oligomers have been discovered within proliferating ECs and SMCs possibly 
interacting with intracellular receptors. 
 HA oligomers can, under specific circumstances, promote early inflammation, 
which is critical for initiating wound healing, but then can moderate later stages of the 
process, allowing matrix stabilization and reduction of long term inflammation 18. Studies 
have shown that HA fragments induce the expression of cytokine gene expression in 
macrophages, which is crucial for initiating and maintaining the inflammatory response. 
HA oligomers are potent activators of dentric cells, an antigen presenting cell of the 
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immune system, and most pro-inflammatory HA fragments can signal dendric cells and 
ECs through TLR-4 251,252.  
 The production of ECM, specifically elastin, is highly upregulated in SMCs 
cultured in the presence of HA oligomers 220. Recent studies by our group found SMCs, 
in the presence of exogenously supplemented HA oligomers, increased production of 
tropoelastin, desmosine and crosslinked elastin 31,32. In addition, the elastin fibers were 
laterally aggregated and thicker than those produced by SMCs cultured with HA of 
higher MW. These findings encourage further study into the utility of HA biomaterials as 
caffolds for elastic tissue regeneration. 
ed as a biomaterial. But 
s
 These studies provide a general idea of how HA can be us
in order to create a long-term HA implant, it must be converted into a stable, insoluble 
biomaterial. HA is amenable to chemical derivatization and cross-linking, and can yield a 
variety of biomaterials that exhibit a wide range of biologic, chemical, and mechanical 
characteristics 253-255. 
 
2.12.13 Hyaluronic Acid Derivitization and Cross-linking Strategies 
Chemical modification of HA has been well recognized as a means to enhance the 
biostability and mechanical properties of the material. Two possible methods to modify 
HA are through derivatization and cross-linking. Both derivitization and cross-linking 
can be achieved through reactions between the available functional groups of HA (COOH, 
OH). Derivitization of the hydroxyl groups include carbodiimide-mediated reactions, 
especially with adipic dihydrazides (ADA), and esterification 256,257. ADA modified HA 
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can be loaded with drug molecules and highly esterified HA (HYAFF) is temporarily 
insoluble is water and can be fabricated into a degradable biomaterial. Carboxyl group 
derivitization strategies consist of sulfation, esterification, isourea coupling and periodate 
oxidation 258. Sufation was used to increase the blood compatibility of HA, and 
esterification and isourea coupling processes were used to bind therapeutic agents to HA. 
Periodate oxidation may damage the HA molecule but is used to create reactive 
combines the carboxyl groups of HA generating two N-
y of hylans to be close to that of uncross-linked 
A 262
bisaldehyde on HA. Reductive amination of the reducing end of HA is used to 
fluorescently label HA molecules and quantify them through electrophoresis. Some of 
these derivitization techniques are also used as cross-linking strategies. 
A number of cross-linking mechanisms involving carbodiimides 259, hydrazides 
260, bisepoxides 259 and esters 261 have been documented, as seen in Figure 2.17. These 
cross-linking mechanisms do not involve the biologically active acetyl groups and hence 
retain the highly biocompatibility and non-antigenicity of the native HA molecule 262. 
Carbodiimide cross-linking 
acylurea linkages in a by product free environment 259. An interesting HA derivative 
involves cross-linking HA with small amounts of an aldehyde, such as formaldehyde to 
produce a unique soluble polymer fluid with very high viscoelasticity 200. Similar 
materials can be obtained by cross-linking of HA with divinyl sulfone (DVS). Both of 
these cross-linkers preferentially react with the hydroxyl groups of the HA molecule. 
Balazs first coined the term hylans to describe these cross-linked HA gels. Limited 
testing has suggested the biocompatibilit
H ,263. The nondestructive environment involved in photo-cross-linking has the 
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advantage of allowing cellular incorporation within the gel as it forms. In this process, the 
HA hydroxyl groups were derivatized with glycidyl methacrylate and in the presence of a 
photoinitiator were irradiated at 365 nm resulting in stable cross-links 264. With the 
advent of such cross-linked HA gels and films, there are now a number of biomedical 
roducts on the market aimed towards the prevention of post-surgical tissue adhesions 263 
ifecore Corporation. 
The bio
p
(i.e. Seprafilm® and Sepracoat® from Genzyme, Lubricoat® from L
medical applicability of these biomaterials is based on their non-interactivity with 
these cells rather than ability to evoke healthy cell responses 263. 
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Figure 2.17 Chemical cross-linking rategies for HA. (A) bisepoxide cross-linking, (B) divinylsulfone 
cross-linking, (C) biscarbodiimide cross-linking, (D) ADH cross-linking with a homobifunctional linker, 
(E) ADH cross-linking with a macromolecular linker, (F) HA cross-linking using four-component 
 est
 
 st
condensation with formaldehyde, cyclohexyl isocyanide, and lysine ethyl er 258. 
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2.12.14 Hyaluronic Acid Biomaterials 
A occurs naturally in connective tissues. Most cells have the ability to 
synthesize HA at some point during their cell cycle, implicating its function in several 
fundam ntal biological processes 18. HA is also highly biocompatible and does not elicit a 
foreign-body response upon cross-transplantation due to the homology of the HA 
structure across species 18 and its dissolution into simple sugars. In addition, its physical 
properties (viscoelasticity, hydration) make it suitable for various medical applications. 
Commercially, HA is isolated from tissue sources including the umbilical cord, synovial 
fluid, skin and rooster comb, or produced through bacterial fermentation. Therefore, HA 
has been used as a biomaterial for various medical and pharmaceutical applications. 
In recent years, HA has been recognized for its excellent potential as a biomaterial 
for effective tissue regeneration. Although the mechanism interaction between HA and 
the human body is still incompletely elucidated but its promising characteristics have 
assured its extensive use as a tissue engineering scaffold, most recently for cartilage 20 
and skin repair 21. It is also used as a viscoelastic, ophthalmic filler material to support the 
implantation of intraocular lenses in cataract patients 265. HA and its derivative 
formulations have been developed as topical, injectable and implantable vehicles for the 
controlled and localized delivery of biologically active molecules for the treatment of 
bone and skin disease 266,267.  In recent years, HA has found applicability abroad as a joint 
lubricant in arthritic joints, owing to its favorable rheological properties 268. Recently, 
Anika, Biomatrix, and Fidia obtained FDA approval for the use of HA as an injectable in 
the USA 269. Since the molecule is highly anionic, hydrophilic and not conducive to 
H
e
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protein deposition, HA or its derivatives (i.e. sulfated HA) have been explored as 
hydrophilic coatings for catheters, guidewires, and sensors, to improve their 
biocompatibility 270. In addition, HA has been used as an implant fluid /film to improve 
lubricity, and reduce fouling and tissue abrasion 218. In these applications, the long-term 
success of the product is significantly facilitated by the inherently non-antigenic and non-
immunogenic properties of HA, a result of their strong homology of structure across 
species 263. 
 
generative vascular 
aterial. Specifically, we aim to examine the size-specific ability of HA to promote 
ascular endothelialization and elastogenesis, as an exogenous supplement, a surface 
oating and a chemically-crosslinked hydrogel. The results of this study will allow us to 
.e. HMWHA, HA fragments, HA oligomers) and 
present
2.13 Project Scope 
Our objective is to investigate the potential use of HA as a re
m
v
c
determine the optimal fragment size (i
ation modality (i.e. exogenous, surface coating, hydrogel) of HA for the 
regeneration of the endothelium and production of an elastin rich matrix by SMCs. 
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CHAPTER 3 
EXOGENOUS HYALURONIC ACID CUES TO PROMOTE FUNCTIONAL 
ENDOTHELIALIZATION OF VASCULAR CONSTRUCTS 
 
 
3.1 Introduction 
 With the evolution of tissue engineering, the choice of scaffolding materials for 
vascular regeneration has shifted from purely synthetic biomaterials to biological 
polymers, such as extracellular matrix (ECM) proteins (i.e. collagen, fibrin), that could 
hypothetically more faithfully elicit native cell responses and likewise regenerate 
damaged tissue 208,271. However, the necessity to chemically stabilize such biopolymers, 
and process them to remove immunogenic donor epitopes can compromise their native 
biological/ mechanical characteristics. Thus, recent studies have focused on other ECM 
molecules such as certain glycosaminoglycans (GAGs), which are non-immunogenic 272, 
and do not induce chronic inflammation 273 likely due to the preserved structural 
homology across species 18. One such GAG is hyaluronan (HA), whose content and form 
in vessels varies with their state of development and health 274,275. In vivo, HA vitally 
regulates embryonic development, tissue organization 276, wound healing, and 
angiogenesis 21. In a biomaterials context, long-chain or high molecular weight HA 
( HMW >1000 kDa) is non-cytotoxic 264, non-thrombogenic 277, and can endure chemical 
stabilizion with little biologic alteration. Since various functional groups (hydroxyl, 
carboxyl) are present on the HA chains, HA can be variably derivatized and crosslinked 
to generate biomaterials with diverse physical and mechanical properties 278, and also 
bound to peptides, matrix proteins, and growth factors to help modulate cell responses. 
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However, due to the vast excess of HA over incorporated crosslinker amounts and the 
fact that biologically active functional groups (e.g., acetyl) are not involved in 
crosslinking, favorable biologic properties of the parent HA chains can be retained. These 
properties in addition to the presence of HA in the vascular intima and media, and its 
mechanical versatility render it an attractive biomaterial for effective cardiovascular 
tissue regeneration. 
 Prior studies have suggested that biologic effects of HA are highly specific to HA 
molecular weight (i.e. fragment size) and the cell type they interact with 
18,19,23,26,229,234,241,249-252. HMWHA typically stabilizes tissues and impacts cell behavior 
through physical, rather than via biologic interactions. It aids embryonic development by 
surrounding cells with a fluid environment that permits their migration, and under 
specific circumstances, creates pericellular sheaths that prevent cell-cell communication 
and cell response to extracellular cues 229. Additionally, HMWHA is inherently anti-
inflammatory and immunosuppressive by preventing free radical-generating microbes 
from migrating into tissues 18. In contrast, oligomers of HA (0.75–10 kDa) interact 
dynamically and differently with cellular HA receptors (e.g., CD44, Receptor for HA-
Mediated Motility or RHAMM, Toll-Like Receptors or TLRs) to induce a multitude of 
cell signaling cascades. 
 A key challenge to reinstating vascular homeostasis is the restoration of an intact, 
complete, normally functional, and non-activated EC lining along the luminal vessel/ 
graft surface 279, by EC recruitment from the surrounding tissue. Since synthetic materials 
poorly evoke such a response, other, more readily endothelializable materials must be 
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explored. In this context, HA oligomers cues have been shown to promote angiogenesis 
in vivo and proliferation of ECs derived from various tissue sources (e.g. vascular, 
pulmonary) when cultured in vitro 19,23 by stimulating EC receptors that trigger their 
migration 280,281 and enhance the production of vascular endothelial cell growth factor 
(VEGF), an angiogenic stimulator 26. However, to date, there has been no systematic and 
comprehensive study that has simultaneously investigated the size-specific effects of HA 
on all aspects of EC behavior, including their proliferation, angiogenic potential, 
functionality, and activation. 
 Previous studies concentrate only on HMWHA and HA oligomers, therefore, in 
elucidating the effects of HA on EC behavior, we have presently chosen to initially 
investigate a wide range of HA molecular weights to determine the fragment size that 
most ardently stimulates HA proliferation. Continued study was then focused on 
HMWHA and the most proliferative fragment. Since pure HA oligomers (6mers, 
MW=1156 Da), which we previously showed to usefully promote EC proliferation, are 
prohibitively expensive to procure and can be arduous to prepare, we sought to determine 
if rough enzymatic digests of high MW HA would elicit identical EC responses, and thus 
be used instead. 
 
3.2 Materials and Methods 
3.2.1 Preparation of HA Oligomer Mixtures 
 Closely-defined mixtures of oligomers were generated by enzymatic digestion of 
streptococcus equi - produced HA sodium salt (5 mg/ml) of MW = 1500 kDa (HA 1500; 
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Sigma, St Louis, MO) in digest buffer (150 mM NaCl, 100 mM CH3COONa, 1 mM Na2-
EDTA, pH 5.0). HA was digested with 0.45, 1.8, 4.5 and 9 mg/ ml of testicular 
hyaluronidase (Sigma, St Louis, MO; 439 U/mg) for 3 - 60 h at 37 °C. The enzyme was 
then precipitated and its activity terminated by boiling (2 min), and then cooled on ice. 
Following centrifugation (2800 rpm, 10 min), to separate the enzyme from the mixture, 
the supernatant was dialyzed in water (12 h) using Tube-O-DialyzerTM tubes (Millipore, 
Billerica, MA) with a MW cut-off of 1 kDa, and then freeze-dried overnight to generate 
HA oligomers. Aliquots of the mixture were then analyzed by fluorophore assisted 
carbohydrate electrophoresis (FACE) for size-characterization of HA fragments. 
 
3.2.2 Size - Characterization of HA Fragments in Oligomer Mixtures 
 For FACE analysis, a 50-µg sample of the digest was dissolved in 40 µl of a 
0.0125 M solution of the fluorescent dye 2-aminoacridone (AMAC, Sigma) prepared in 
acetic acid/ DMSO (3:17 v/v), and incubated for 15 min in the dark. A 40-µl aliquot of an 
aqueous solution of 1.25 M sodium cyanoborohydride (Sigma) was then added to each 
sample and incubated (37 °C, 16 h, dark). Following this, 20 µl of glycerol was added to 
each sample. The standards (oligomer ladder, 2mer, 6mer; Associates of Cape Cod, East 
Falmouth, MA) were prepared in the same manner. 
 For electrophoresis, all 8 lanes of a polyacrylamide MONO® gel (Glyko, San 
Leandro, CA) were loaded simultaneously with 4 µl of sample/ standard and run with 
MONO® gel running buffer (Glyko) at < 10 °C, as described previously 282. Samples 
were electrophoresed at a constant 500 V with a starting current of 25 mA/ gel and a final 
 91
current of 10 mA/ gel for 80 min. After electrophoresis, the gels were illuminated with 
UV-B light (λ = 365 nm) in a FluorChem 8900 (Alpha Innotech, San Leandro, CA) and 
band intensities quantified and compared to an HA oligomer ladder (10-20mer; 1915-
3811 Da) and commercially procured HA 2mer (397 Da) and HA 6mer (1156 Da; 
Associates of Cape Cod, East Falmouth, MA) to determine the size range of HA 
fragments within the digest. 
 
3.2.3 Model to Predict Oligomer Content within Enzymatic Digests of HMWHA 
 To limit the necessity for iterative changes in digestion parameters towards 
obtaining specific HA fragment-size distributions, a mathematical model was developed 
based on the observed digestion outcomes. The effects of hyaluronidase enzyme 
concentration and digestion time on the amount of HA oligomers (HA 6mer and HA 
12mer) produced, was fit using a hierarchial regression analysis (HRA), wherein a new 
predictor was added to or dropped from that used in the previous analysis based on the 
statistical significance of a particular model 283.  The quadratic regression model used 
accommodated linear, curvature and interdependence of digestion time (x) and enzyme 
concentration (y) and was described as: 
R = a + b*x + c*y + d*x*y + e*x2 + f*y2    (Eq 3.1) 
where R is the dependent variable (amount of HA oligomer), a, b, c, d, e, and f are the 
estimated regression coefficients.  After initialization with the full quadratic regression 
model given in Equation 1, the backward elimination procedure 284,285 was used to reduce 
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the number of terms in the model until all the remaining terms were statistically 
significant (p < 0.05). We chose to utilize two digest mixtures in further experiments: D1 
(0.45 mg/ ml, 18 h) and D2 (4.5 mg/ ml, 48 h). 
 
3.2.4 Cell Culture 
 To prepare the HA stock solutions used for exogenous supplementation of HA 
into the culture media, all forms of HA were dissolved in water (24 h, 4 °C).  The HA 
solutions were then filter-sterilized by passage through a low-protein binding 0.22 µm 
syringe filter (Millipore).  All HA boluses were prepared fresh prior to addition to cell 
cultures.  
 Low passage (6-8) adult rat aortic ECs (Cell Applications, San Diego, CA) were 
selected for this study to be consistent with our intention to conduct future in vivo studies 
in a rat model. Stock cells were trypsinized (0.25% trypsin/ 0.1% v/v EDTA; Invitrogen, 
Carlsbad CA), pelletted by centrifugation (500g, 7 min), resuspended in MCDB-131 
supplemented with 10% v/v FBS (Invitrogen), 1% v/v penicillin–streptomycin 
(Invitrogen), 50 µg/ ml EC growth supplement (Becton Dickinson, Franklin Lakes, NJ), 4 
mmol/L L-glutamine (Invitrogen), and 30 U/ml heparin (Sigma). Spent medium was 
replaced thrice weekly over the 14 days of culture. 
 
3.2.5 DNA Assay for Cell Proliferation 
 The DNA content of EC monolayers was used to compare the number of cells 
present at days 1 and 14, and hence quantify the proliferation of ECs in culture. ECs were 
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seeded at 1 × 104 cells/ well in 6-well plates (A = 9.6 cm2) with exogenous HA of 1500, 
200, 20 kDa (HA 1500; HA 200, Genzyme, Cambridge MA; HA 20, Lifecore 
Biomedical, Chaska MN), HA 6mer and enzymatic digests of HA oligomers (D1, D2) at 
doses of 0 (negative control), 0.2, 2, and 20 µg/ ml to assess the size- and dose- specific 
affects of HA on EC proliferation. To measure their DNA content, briefly, cell layers 
were rinsed with 1% v/v PBS, free of Ca2+ and Mg2+, incubated with 1 ml of 0.25% v/v 
trypsin/ 0.1% v/v EDTA per well (37 °C, 5 min). The adherent cells were scraped off the 
substrate, pelletted by centrifugation (500g, 7 min) and resuspended in 1 ml of NaCl/ Pi 
buffer (4 M NaCl, 50 mM Na2HPO4, 2 mM EDTA, 0.02% w/v Na Azide, pH 7.4).  
Aliquots (495 µl) of this cell suspension were sonicated over ice, and the DNA in the 
homogenate measured using the fluorometric method described by Labarca and Paigen 
286 (n = 3). Actual cell counts were then calculated based on the average DNA content of  
a diploid cell in G1 phase (6 pg), assuming this amount remained unchanged through the 
period of culture 287. Results are reported as the ratio of cells at day 14 to day 1 
(proliferation ratio).  
 
3.2.6 Tube Formation (Angiogenesis) Assay 
 The ability of ECs to form tubes (a measure of angiogenic potential) when 
cultured with exogenous HA, was measured. MatrigelTM, a matrix that promotes EC tube 
formation in vitro, was cast in 24-well culture plates (Beckton-Dickson; 100 µl/ well), 
heat-treated for 30 min at 37 °C to stimulate crosslinking, seeded with ECs (7.5 × 104 
cells/ well) and incubated with exogenous HA (HA 1500, D2, HA 6mer; 0 and 2 µg/ ml) 
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for 48 h at 37 °C. Suramine (40 µM, Calbiochem, San Diego, CA) was used as a negative 
control; TNF-α (10 ng/ ml) was added as an additional positive controls. After incubation, 
the media was aspirated and the cells were washed twice with Hank’s Balanced Salt 
Solution (HBSS) and stained with Calcein AM (8 µg/ ml, Invitrogen) for 30 min at 37 °C. 
The cells were washed with HBSS to remove excess dye and imaged on an inverted 
florescent microscope (Eclipse TE2000-S, Nikon, Melville, NY) and the number and 
length of tubes formed quantified using Image Pro Plus software (n = 10 regions/ culture; 
n = 3 cultures/condition). 
 
3.2.7 Flow Cytometry 
 Expression levels of functionality marker proteins and cell adhesion molecules 
(CAMs) by ECs, in presence or absence of added HA/ oligomer cues, were compared by 
flow cytometry. Monolayers of ECs (n = 3/ marker) were grown to semi-confluence 
(~80%) in 6-well plates (3 cultures/ maker; 2-3 × 106 cells/ culture) over 3 - 4 days, and 
were then supplemented with HA (HA 1500, D2, HA 6mer; 0 and 2 µg/ ml) for 48 h, 
rinsed with PBS containing 0.1% w/v sodium azide (PBS-azide) and finally incubated 
(10 min, 37 °C) with 1 ml of cell dissociation solution (Sigma) to gently release the cells 
into solution. The suspended cells were washed once with PBS-azide and then labeled for 
the expression of von Willebrand factor (vWF; for EC identity), low density lipoprotein 
receptor (LDLR; for EC identity), endothelial nitric oxide synthase (eNOS; for EC anti-
platelet activity) and vascular endothelial cell receptor 2 (VEGFR2; for EC function). EC 
activation was gauged from the extent of expression of CAMs involved in attracting 
 95
leukocytes and platelets to the EC surface. These included platelet-endothelial cell 
adhesion molecule 1 (PECAM-1), intracellular adhesion molecule 1 (ICAM-1), and 
vascular cell adhesion molecule 1 (VCAM-1). 
 For direct immunolabeling, cell suspensions were incubated at 4 °C for 1 h with 
fluorescein isothiocyanate (FITC)-conjugated mouse anti-rat CD54 (ICAM-1; Abcam, 
Cambridge, MA) and Alexa 488-conjugated mouse anti-rat CD106 (VCAM-1; Biolegend, 
San Diego, CA) diluted 1:100 v/v in PBS-azide. For indirect immunolabeling, cell 
suspensions were incubated under the same conditions with the following anti-rat 
antibodies diluted 1:100 v/v in PBS-azide: rabbit anti- vWF, rabbit anti- eNOS, rabbit 
anti- LDLR, rabbit anti-VEGFR2 and mouse anti-CD31 (PECAM-1) (all from Abcam). 
The cells were subsequently washed once with PBS-azide and immunolabeled with a 
secondary antibody (1:1000 v/v in PBS-azide) of donkey anti-rabbit IgG coupled with 
phycoerythrin (PE) or donkey anti-mouse IgG coupled with PE (Abcam) for 1 h at 4 °C. 
For immunolabeling of vWF and eNOS, cells were permeablized with methanol for 1 
min prior to incubation with the antibodies. ECs incubated with the secondary antibodies 
processed under PE conditions and untreated EC processed under FITC/ Alexa 488 
conditions were used as additional negative controls to confirm indiscriminate binding/ 
fluorescence did not occur. The CAM samples were also compared to cultures 
supplemented with TNF-α (10 ng/ ml, positive control). The shifts of the peak intensities 
are reported normalized to the no HA condition. 
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3.2.8 Thrombomodulin Assay 
 Endothelial cell surface expression of thrombomodulin, a potent inhibitor of 
coagulation, was measured as described previously 288. Briefly, ECs grown to semi-
confluence in 24-well plates (A = 1 cm2), were incubated with HA (HA 1500, D2, HA 
6mer; 0 and 2 µg/ ml) for 48 h, washed twice with phenol red-free DMEM: F12 media 
(Invitrogen) and incubated (1 h) with 250 µl of medium containing human α-thrombin 
(0.1 NIH U/ ml; Haematologic Technologies, Essex Junction, VT) and human protein C 
(12 µg/ ml; Haematologic Technologies). The α-thrombin was subsequently inactivated 
with the addition of access hirudin (4 ATU/ ml; American Diagnostica, Stamford, CT). 
Aliquots (70 µl) of this solution was combined with 30 µl of S-2366 (450 mM; 
Chromogenix, Milano, Italy) and incubated at room temperature for 5 min before 
measuring the absorbance at λ = 410 nm using a spectrophotometer (Molecular Devices, 
Sunnyvale, CA) (n = 3). The samples were compared to cultures supplemented with 
TNF-α (10 ng/ ml), a second positive control. 
 
3.2.9 Platelet Adhesion 
 The thrombo-protective properties of ECs cultured with exogenous HA/oligomers 
were quantitatively estimated by the lack of platelet attachment onto their surface. ECs 
were grown to confluence in 4-chamber polystyrene chamber slides, then cultured with 
exogenous HA (HA 1500, D2, HA 6mer; 0 and 2 µg/ ml) for 48 h. These samples were 
compared to cultures supplemented with TNF-α (10 ng/ ml, positive control). Following 
removal of the culture medium, and a gentle rinse with phosphate-buffered saline (PBS, 
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1X), aliquots (150 µl) of rat plasma (Innovative Research, Southfield, MI) were overlaid 
atop each of the the EC monolayers and incubated (15, 45 min) at 37 °C (n = 3 
/substrate). Aliquots of this overlaid suspension were then recovered and counted for 
platelets in a coulter counter (Beckman-Coulter, Fullerton, CA) (n = 6). The stock plasma 
platelets were also counted. Platelet deposition on the EC monolayers was estimated by 
quantifying the number of platelets removed from the stock suspension. 
 
3.2.10 Electron Microscopy of Adherent Platelets 
 SEM was used to confirm the degree of platelet adhesion onto EC layers, as 
quantitatively measured (see section 3.2.9) and their activation, when exposed to 
HA/oligomer. Activation of adhered platelets was assessed from EC-induction of platelet 
aggregation/focal clumping. In preparation for SEM, following a gentle rise with 1X PBS, 
the adhered platelets were fixed with 2% w/v glutaraldehyde in 0.1 M Na-cacodylate 
buffer with 0.1 M sucrose (1 h, room temperature), treated with filtered 1% tannic acid in 
sodium cacodylate buffer (1 h, room temperature), and incubated with 1% w/v osmium 
tetroxide in 0.1 M Na-cacodylate buffer (1 h, room temperature). The samples were then 
dehydrated in a graded series of ethanol (70-100% v/v), and dried by incubation with 
HMDS (hexamethyldisilazane, Electron Microscopy Sciences, Fort Washington, PA) for 
3 min. The HDMS was aspirated and the samples were allowed to air-dry in a desiccator 
(25 min), sputter-coated with gold over 60 seconds in a sputter-coater (VG Microtech) 
and visualized by SEM. 
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3.2.11 Cytokine Array 
 The type and amount of cytokines produced by ECs in response to the presence or 
absence of exogenous HA/oligomers was determined using an ELISA-based cytokine 
array to deduce the inflammatory potential of ECs deduced in each case. ECs were 
cultured in 6-well plates to semi-confluence, and then subjected to exogenous HA (HA 
1500, D2, HA 6mer; 0 and 2 µg/ ml) for 48 h. These samples were compared to cultures 
supplemented with TNF-α (10 ng/ ml, positive control). The release of 19 different 
cytokines, chemokines and growth factors from cultured ECs into the media were 
detected by a ChemiArrayTM rat cytokine array I (Millipore) consisting of the 
corresponding antibodies spotted in duplicate onto a membrane. The membranes were 
processed in accordance with the manufacturer’s protocol and the imaged under 
chemiluminescence (20 min exposure time) in a FluorChem 8900 gel imaging station 
(Alpha Innotech), to quantify relative spot intensities. The intensities due to each 
cytokine were normalized according to the positive signal of each membrane, and the 
corresponding intensity under conditions of no HA. Results were averaged from 
outcomes of three replicate experiments. 
 
3.2.12 Statistical Analysis 
 As appropriate, statistical significance between and within groups ( n ≥ 3/group) 
as determined using Microsoft Excel’s statistical function for t-tests, assuming unequal 
variance and two-tailed distribution. Differences were considered statistically significant 
at p < 0.05. Quantitative results are reported as mean standard deviation. 
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3.3 Results 
3.3.1 Composition of HA Oligomer Mixtures 
 The amounts of enzyme and the digestion periods were varied methodically until 
a minimal number of different sized HA fragments, lying within a narrow size range were 
produced (primarily HA 6mer and HA 12mer). Low enzyme concentrations (0.45 µg/ ml, 
1.8 µg/ ml) produced broad ranges of oligomers even over long periods of digestion (60 h 
and 24 h, respectively). However, higher enzyme concentrations (4.5 µg/ ml, 9 µg/ ml) 
degraded HA 1500 to predominantly generate two fragment sizes HA 6mer and HA 
12mer in 24 h and 6 h, respectively. From this matrix of digestions (Table 3.1, Figure 
3.1) we chose two sets of conditions to incorporate into our further experiments. Previous 
work in our lab showed HA digests generated with 0.45 mg/ ml of enzyme for 18 h were 
bioactive and stimulated SMCs to produce an enhanced amount of matrix. Therefore, this 
formulation (D1) was used on ECs as well and FACE analysis found these digests to 
contain 13.9 ± 3.6% HA 6mers and 8.0 ± 1.6% HA 12mers. Previous studies suggest the 
most angiogenic HA oligomers are 6 – 12mers. As a result, a much more concentrated 
digest was also used in this study involving ECs. Digestion of HA 1500 with 4.5 mg/ ml 
of enzyme over 48 h generated an oligomer mixture (D2) that was shown to contain 33.3 
± 2.44% w/w of HA 6mers and 39.2 ± 2.68% w/w of HA 12mers by FACE, with other 
oligomers forming the balance. 
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  Hours of Digestion
 
Enzyme 
(mg/ ml) 
% 3 6 9 12 15 18 21 36 48 60 
% 6mer 7.5 7.9 9.5 10.2 11.1 13.9 14.8 24.3 27.1 30.20.45 
% 12mer 4.9 5.4 6.2 6.7 6.9 8.0 8.9 15.3 16.3 16.7
% 6mer 10.1 12.9 16.6 18.8 22.1 24.1 27.4 - - - 1.8 
% 12mer 6.8 7.3 9.8 11.1 15.0 17.9 22.0 - - - 
% 6mer 15.7 22.1 22.9 23.2 23.4 23.5 23.9 - 33.3 - 4.5 
% 12mer 10.5 12.4 16.7 18.1 21.3 23.4 31.4 - 39.2 - 
% 6mer 24.7 27.2 23.6 22.6 21.0 19.9 17.3 - - - 9 
% 12mer 18.9 27.2 31.4 37.6 40.9 44.7 48.4 - - - 
Table 3.1 Quantification of HA digestions based on the concentration of HA 6mer and HA 12mer. The 
concentration of HA 6mer and HA 12mer gradually increased over time for enzyme concentrations below 9 
mg/ ml. The digest containing 9 mg/ ml dramatically increased HA 12mer concentration but slowly 
decreased the concentration of HA 6mer over time.  
 
 
 
 Control 2Control 1 D1D2
HA 2mer
HA 6mer
HA 20mer
HA 18mer
HA 16mer
HA 14mer
HA 12mer
HA 10mer
 
 
 
 
 
 
Figure 3.1 FACE analysis of the enzymatic digest of HA. The sample bands were obtained by digesting 
HA 1500 with0.45 mg/ ml enzyme for 8 h (D1) and 4.5 mg/ ml enzyme for 48 h (D2). The two primary 
bands correspond to HA 6mer and HA 12mer, the predominant fragment sizes in the digest. 
 
 
3.3.2 Mathematical Model to Predict Digestion Outcomes 
 The mathematical model designed as a fit to digestion outcomes is a three-level 
full factorial with no repetitions of the digest preparations, which leaves 24 degrees of 
freedom for regression analysis in each case.  In this fashion, we can report with good 
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certainty on linear and curvature trends of enzyme concentration and digest time, without 
repetitions. The parameters for the non-linear regression models and their significance 
values are given in Table 3.2.  It is observed that in the case of HA 6mers, the 
experimental observations were handled in terms of only 1st-order (trend) terms 
significant at the 95% confidence level and an interdependence term (x*y), while a 
significant 2nd-order dependence on enzyme concentration was apparent for HA 12mer 
production.  As shown in Figure 3.2, each of the non-linear regression models adequately 
fits the respective experimental data for 6-mer and 12-mers observed in this study.  In 
both cases, residual analyses and ANOVA indicated that the residuals had a normal 
distribution, constant variance and average equal to zero, confirming that the proposed 
models (data not shown) represented good fits.  According to Montgomery and Peck 285, 
all the above criteria should be fulfilled in order to conclude that a statistical model has 
been successfully adjusted to the experimental data. 
 
 
HA 
oligomer 
(%) 
Non-linear 
regression model 
Regression 
coefficients 
Statistical 
significance of 
coefficients (p)
Statistical 
significance of the
non-linear 
regression fit 
a = 4.8529 0.052 
b = 0.7426 0.0002 
c = 2.6109 0.0001 6-mer R = a + b*x + c*y + d*x*y
d = -0.1199 0.0013 
P = 0.001 
a = 4.2122 0.0008 
b = 0.282 0.0061 
d = 0.1399 0.0001 12-mer R = a + b*x + d*x*y + f*y
2
f = 0.153 0.0001 
P = 0.001 
 
Table 3.2 Model of HA digestions. Results obtained from non-linear regression analysis of the HA 
oligomer production by time-dependent enzymatic digests. In these models, R represents the amount of HA 
oligomer produced (%), while x and y represent the digest time and enzyme concentration, respectively. 
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Figure 3.2 Plot predicting yield of HA 6mers and HA 12mers within t. hyaluronidase digests of long-chain 
HA, under different conditions of digestion. The concentration of HA 12mer (B) within all digests 
increased with time and the amount of enzyme utilized. The concentration of HA 6mer (A) followed a 
similar trend until higher enzyme concentrations and longer digestion periods were used, at which point it 
began to decrease. 
 
 
3.3.3 Cell Proliferation  
 Towards compositional optimization of HA biomaterials capable of 
endothelialization, we sought to assess the size- and dose- specific effects of exogenous 
HA fragments on the proliferation of cultured adult rat aortic ECs. In general, ECs 
cultured with HA cues (HA 1500, HA 200, HA 20 D1, D2, HA 6 mer) proliferated much 
more rapidly than those cultured without. Cell proliferation ratios (i.e., ratio of cell 
numbers at day 14 to day 1) appeared dependent on provided dose of HA/oligomers; 
higher doses stimulated more rapid EC proliferation (Figure 3.3). Identical doses of D1, 
D2 and pure HA 6 mers induced similar levels of EC proliferation and greater levels of 
EC proliferation than did HA 1500. However, in all cases D1 and HA 6mer stimulated a 
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slightly greater amount of ECs proliferation than D2. Therefore, continued 
experimentation involved only HA 1500 and D2. 
 
 
 
 
 
 
 
 
 
Figure 3.3 Proliferation of HA-supplemented EC cultures. The proliferation ratios of ECs increased with 
HA concentration, independent of fragment size. At all tested doses, ECs treated with HA 6mer and D2 
proliferated to a greater degree than HA 1500. 
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3.3.4 Angiogenesis 
 ECs cultured on matrigel developed capillary projections that connected to form 
tubular networks (Figure 3.4). As expected, cultures that received suramin, an inhibitor of 
various growth factors (e.g., IGF, EGF, PDGF, TGF-β, VEGF, bFGF), and hence of EC 
proliferation and migration, did not exhibit any tube formation. HA 1500 induced 
formation of thicker, and longer individual tubes (Panel H), but showed few laterally 
branching tubes resulting in low tube numbers relative to that formed by control ECs (no 
HA addition; Panel F).  Lengths of individual tubes (Figure 3.5A) in TNF-α− (Ε), HA 
6mer- (G) and D2- (I) stimulated cultures were similar to that in the controls but the 
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numbers of tubes (Figure 3.5B) were significantly higher, resulting in a greater 
cumulative tube length (Figure 3.5C). These tube lengths were in the order TNF-a > HA-
6mer > D2 > HA 1500. In all cultures, except those that received suramin and TNF-α, 
tubes appeared fairly regular, and extended between clusters of cells. In general, tubes 
formed by TNF-α-supplemented ECs appeared incompletely formed and also appeared 
much thinner than in other cases. 
 
 
 
 
 
 
 
 
 
 
 
 
A
D E F
CB
300 µm 
Figure 3.4 Fluorescence images of EC tubes formed on matrigel. Suramin (A) drastically inhibited tube 
formation and tubes in TNF-α-supplemented cultures (B) seemed to be incomplete, with gaps between 
junctions. The number of tubes formed was enhanced by HA 6mer (D) and D2 (F), and inhibited by HA 
1500 (E), relative to HA-free controls (C).  ECs were labeled with Calcein AM (green). 
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Figure 3.5 Impact of HA and HA oligomers on EC tube formation on matrigel. HA 1500 increased 
individual tube lengths (A) but decreased tube densities (B) resulting in a cumulative tube length (C) 
similar to the non-HA control. Lengths of individual tubes in TNF-α−, HA 6mer- and D2- stimulated 
cultures were similar to that in the controls but the number of tubes were significantly higher, resulting in a 
greater cumulative tube length. [* denotes a p-value < 0.05 in comparison to the no HA control]. 
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3.3.5 Functionality Marker- and CAM- Expression 
 Irrespective of added HA fragment size, HA-supplemented EC cultures showed 
mild enhanced expression levels of LDLR, VEGFR2 markers and a moderate suppression 
of vWF and eNOS expression levels relative to HA-free control ECs, suggesting a 
possible alteration of the control phenotype (Figure 3.6A). D2 and HA 6mers similarly 
altered control expression levels of all tested EC functional markers. HA 1500 induced 
the same effects, although the magnitude of the increases or decreases in marker 
expression (relative to control) was less than that observed with the HA oligomers. HA 
1500 elicited expression levels of EC activation markers that were mostly attenuated and 
identical to non-HA control cultures (Figure 3.6B). HA 6mers enhanced expression levels 
of ICAM-1 and VCAM-1, but not PECAM-1, however these increases were limited 
relative to the increases in EC CAM expression induced by TNF-α; D2 CAM expression 
levels were higher than HA 6 mers in all cases, but again, lower than that in TNF-α-
supplemented cultures.  This suggests the combination of HA 6mer and HA 12mer is a 
somewhat more potent stimulus of EC CAM expression. 
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Figure 3.6 FACS analysis of EC protein expression. All fragment sizes of HA mildly enhanced expression 
levels of LDLR and VEGFR2, and suppressed expression levels of vWF and eNOS relative to non-HA 
control ECs (functionality markers; A). D2 elicited greater expression of EC cell adhesion molecules 
(PECAM-1, ICAM-1, VCAM-1; B) than did HA 1500 and in controls.  HA 6mer CAM expression levels 
were lower than D2. [* denotes a p-value < 0.05 in comparison to the no HA control] 
 
 
3.3.6 Coagulation and Thrombogenic Potential 
 ECs cultured with HA 6mer, D2, and HA 1500 exhibited thrombomodulin 
activity levels very similar to control ECs, and significantly greater than ECs stimulated 
with TNF-α, indicating the retention of a healthy phenotype capable of regulating blood 
coagulation (Figure 3.7). On the other hand, significant differences in platelet adhesion 
were observed (Figure 3.8); HA 1500 drastically inhibited platelet adherence to ECs, 
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while HA 6mer and D2 mildly enhanced platelet adhesion beyond that in non-additive 
control cells. This increase in platelet adhesion was, however, highly attenuated relative 
to that induced in EC cultures upon stimulation with TNF-α, or on cell-free glass 
substrates. The incubation time (15 min or 45 min) of the plasma with the cell 
layers/glass substrate did not impact platelet adhesion. There were no differences in 
platelet adhesion within cultures supplemented with D2 versus those that received HA 
6mers. 
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Figure 3.7 Thrombomodulin expression of ECs. ECs cultured with both D2 and HA 1500 exhibited 
thrombomodulin activity levels very similar to control ECs, and significantly greater than ECs stimulated 
with TNF-α. [* denotes a p-value < 0.05 in comparison to the no HA control] 
 
 
SEM micrographs of EC cultures are shown in Figure 3.8.  ECs that had been 
cultured on tissue culture plastic (plasma-treated polypropylene) without any additives 
(HA-free control; Panel B), and those stimulated with HA 1500, both elicited sparse 
attachment of discrete and rounded platelets when contacted with human plasma (Panels 
B, F respectively). However, the surface of the ECs in the latter cultures appeared 
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textured, likely due to deposition of the long-chain HA.  D2- and HA 6mer-stimulated 
ECs induced mildly greater platelet adherence (Panels D, E).  Though most of these 
platelets were discrete and rounded a few platelet aggregates were also seen; some ECs 
were completely void of platelets. TNF-α−stimulated ECs  induced severe platelet 
deposition and aggregation, with the aggregates covering the ECs completely (Panel C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
Glass No HA TNF-alpha HA 6mer HA 1500 Digest 2
A
dh
er
en
t P
la
te
le
ts
  
15 min 45 min
No HA TNF-α HA6  1500 D2lass
A
dh
er
en
t P
la
te
le
ts
15 in
* *
*
*
* *
Platelet 
Clusters
Platelet-
Free EC 30 µm
A B C
FED
Figure 3.8 Impact of HA and HA oligomers on platelet adhesion to cultured ECs. HA 1500 drastically 
inhibited platelet adherence to ECs, while HA 6mer and D2 mildly enhanced platelet adhesion beyond that 
in non-additive control cells, but to a far lesser extent than when TNF-α was added. The incubation time 
(15 min or 45 min) of the platelet solution did not alter their attachment levels or clumping. [* denotes a p-
value < 0.05 in comparison to the no HA control]. Scanning electron micrographs of platelets adhered on 
EC layers are also shown: (A) no platelets, (B) no HA, (C) TNF-α, (D) HA 6mer, (E) D2, (F) HA 1500. 
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3.3.7 Cytokine, Chemokine and Growth Factor Release 
 Cytokine arrays detected the presence of all 19 cytokines under each culture 
condition with their relative amounts shown in Figure 3.9. Here we focus on the 9 
cytokines, chemokines and growth factors that showed altered EC expression levels in 
response to HA/oligomers. Both HA 1500 and D2 up-regulated the EC expression of 
interferon γ (IFN-γ), tissue inhibitor of metalloprotease 1 (TIMP-1), and granulocyte 
macrophage colony stimulating factor (GM-CSF), and suppressed Fraktalkine (FKN) 
production, beyond that of no HA controls and tumor necrosis factor α (TNF-α) - added 
cultures. ECs cultured in presence of D2 showed a greater expression of vascular 
endothelial cell growth factor (VEGF) and TNF-α, relative to no HA controls. The EC 
production of macrophage inflammatory protein 3α (MIP-3α), monocyte chemotactic 
protein 1 (MCP-1), and leptin were modestly enhanced by both HA 1500 and D2; TNF-a 
supplemented cultures on the other hand dramatically increased MCP-1 expression, but 
did not alter control levels of MIP-3α expression. 
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Figure 3.9 Cytokine production by ECs. Of the 19 cytokines tested in each cytokine array, we reported 9 
that were significantly altered by HA fragment size and their corresponding spot intensities. In general, D2 
upregulated the production of angiogenic growth factors and hormones, but in addition mildly enhanced 
chronic inflammatory cytokines. HA 1500, in general, had a more mild effect on ECs. [* denotes a p-value 
< 0.05 in comparison to the no HA control] 
 
 
3.4 Discussion 
 On of the long-term goals of our research is to develop vascular biomaterials that 
recruit and sustain a complete normal functional luminal endothelium. A healthy and 
confluent EC lining is crucial to reinstate anti-thrombotic and anti-hyperplasic endothelial 
signaling pathways that are disrupted by vascular injury or disease. 
 The choice of hyaluronan (HA) as the basis for these vascular implant materials 
stems from it's biocompatibility and non-immunogenicity, outcomes of it’s highly 
conserved structure across species 18, and its potential, as a ECM component, to evoke 
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non-exaggerated, healthy responses from cultured vascular cells. HA has also been 
shown to elicit angiogenic responses, although these effects, as with other phenomena 
observed with other cell types, appear to be highly specific to HA of certain fragment 
sizes 19. In a previous study, we showed that cells, including ECs, respond to HA 
oligomers (< 10 kDa) more exuberantly than they do to larger-sized HA fragments and 
long-chain HA (> 1000 kDa) 289. Other studies collectively indicate that different aspects 
of cell behavior have unique dependencies on HA fragment size. However, it has also 
been shown that HA fragments and HA oligomers can induce inflammatory responses 
under specific conditions 18. Thus, the distribution of bioactive HA fragments and 
oligomers within mechanically stable implant materials based on biocompatible, long-
chain HA must be defined and optimized to elicit desired outcomes (i.e., functional 
endothelialization) and prevent unwanted ones (i.e., inflammation). Currently, we thus 
seek to investigate the effects of HA/oligomers on EC function and eventually use this 
information to tailor the oligomer content within these HA biomaterials so as to promote 
vascular endothelialization, while preventing untoward effects. 
 In order to limit potentially adverse inflammatory responses, we exposed ECs to a 
low concentration of HA digest (HA-o; 2 µg/ ml). This dose lies within a range of doses 
(0.2 – 200 µg/ ml) that we have shown to significantly impact SMC behavior 31,32. Also, 
we have shown that HA-o stimulates ECs to proliferate faster than when other, or no cues 
are provided. To account for this, expression levels of markers have been normalized to 
the number of cells present at the time of analysis, and are thus effectively reported on a 
per cell basis. 
 113
 HA oligomer mixtures (D2) were obtained by digesting HMWHA (HA 1500) 
with testicular hyaluronidase. Previous studies partially digested HA using relatively 
small quantities of this enzyme (~40 U enzyme/ mg HA) to generate a ladder of different 
sized HA fragments including small amounts of HA fragments of interest, which were 
then purified and supplemented to cells 23,171,290. Our approach bypasses the laborious and 
inefficient oligomer purification process, and highlights our eventual need to mass 
produce HA oligomers of sizes deemed useful, with consistency and good predictability 
for incorporation into vascular scaffold constructs. 
 The digestion time and enzyme concentrations were optimized to obtain the 
highest yield of HA 6mer and HA 12mer within the digest. As expected, a greater amount 
of enzyme and longer digestion periods resulted in narrower fragment size distributions 
of the oligomers. However, 9 mg/ ml of enzyme consistently reduced the amount of HA 
6mer over time with a concurrent increase in intensity of the HA 12mer band. These 
outcomes suggest that testicular hyaluronidase favors production of the HA 12mer; 
generation of the HA 6mer product is also favored but to a lesser extent. Other 
hyaluronidases have shown such specificity in HA oligomer production such as 
hyaluronidase Streptomyces hyalurolyticus, which gives mixtures of HA 6mer and HA 
4mer as final degradation products of HA 291. Also, it has been reported that testicular 
hyaluronidase is only active for 5 h in solution at 37 °C 292. Here we show that this 
enzyme retains its activity over periods longer than 5 h, though, this may decrease with 
time. The degradation products of HA 6mer and HA 12mer were modeled as a function 
of enzyme concentration and digestion time. These models can be used to generate HA 
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oligomers with a specific concentration of HA 6mer and HA 12mer without optimizing 
the digest conditions. As our results in section 3.3 confirm that both D2 (containing HA 6 
mers and 12 mers) and pure HA 6mers elicit almost identical EC responses, which 
justifies the use of these composition-defined mixtures in future applications. 
 The ability of D2 to promote EC proliferation (an important aspect of 
endothelialization and angiogenesis) was tested through exogenous supplementation. 
Previous studies on the influence of HA oligomers on EC proliferation were limited to a 
few hours and resulted in modest yet significant changes 23,290. Our prolonged culture 
study over 2 weeks showed similar results, and confirmed that HA (both HA 1500 and 
D2) is conducive to EC proliferation, in a dose dependant manner, and useful to achieve 
rapid endothelialization of vascular grafts. The angiogenic nature of D2 was confirmed 
by a tube formation (angiogenesis) assay. The large HA 1500 polymer strands reduced 
the cumulative capillary production but increased the length of each individual tube, 
likely due to physically limiting the EC migration pathways and inhibiting capillary 
branching. The small fragments of D2 did not influence EC migration physically but 
stimulated a greater extent of capillary production possibly through interactions with EC 
receptors.  
 CD44 is a trans-membrane receptor found in several cell types, including ECs, 
and is one of the most well characterized cell membrane receptors for HA, the others 
being Receptor for HA Mediated Motility (RHAMM), and Toll-Like Receptor 4 (TLR4) 
232. Studies have shown that HA oligomers can incite very different cell responses when 
bound to CD44 receptors, than when HMWHA interacts with them, because HA 
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oligomers can cause clustering of multiple receptors and thus alter intracellular responses 
293. Under inflamed conditions, ECs have been shown to enhance their expression of 
CD44 and TLRs 294. The stimulation of CD44 receptors by HA oligomers has been 
suggested to enhance the production of vascular EC growth factor (VEGF) and therefore 
promote EC proliferation 26. Our results show that VEGFR2 is also mildly up-regulated 
by D2. Additionally, cytokine-arrays showed D2 stimulate ECs to produce certain 
angiogenic factors (Leptin, VEGF, TNF-α) that could potentially further enhance their 
proliferation and angiogenic potential through autocrine effects 295,296. HA 1500 and D2 
also very marginally enhanced EC production of TIMP-1, an inhibitor of matrix 
metalloproteases (MMPs) which can in turn temper the ability of MMPs to degrade the 
ECM and thus facilitate endothelial migration and new blood vessel sprouting 297. 
Collectively, these results indicate that HA 6mer and HA 12mer mostly up-regulate 
angiogenesis, while HA 1500 provides some degree of protection against excessive 
MMP-mediated ECM degradation. Thus a key strategy to formulate HA gels capable of 
endothelialization, and yet prevent excessive vascularization is to combine both 
HMWHA and HA oligomers into a single material, and optimize the concentration of 
each. 
 Lower flow shear rates in small diameter vessels favor platelet deposition and 
thrombus formation, which can severely compromise the long-term patency of vascular 
implants 72. Under healthy conditions ECs in intact vessels express thrombomodulin and 
release nitric oxide (NO), which serves to regulate coagulation and attenuate thrombosis, 
respectively; thrombomodulin, an integral surface membrane protein of ECs, binds 
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thrombin and activates protein C in the plasma. Protein C in conjunction with protein S, 
produced by ECs, inhibits the activation of factor V and VIII preventing thrombin 
formation and hence clot formation 158,159. On the other hand, NO released by ECs is 
taken up by platelets where it binds to and activates guanylyl cyclase. This enzyme 
catalyzes the dephosphorylation of GTP to cGMP, which serves as a second messenger 
for many important cellular functions, particularly preventing platelets from adhering to 
the EC surface and aggregating with one another 298. The results show that HA 1500 and 
D2 do not alternated thrombomodulin expression, though D2 did mildly decrease eNOS 
expression, relative to controls, possibly marginally enhancing platelet deposition and 
aggregation on ECs. 
 The adhesion of platelets to injured endothelial layers is a coordinated multi-step 
process that involves platelet activation, subsequent firm adhesion to the vascular wall, 
and further strong activation and degranulation of platelets to cause their aggregation to 
form thrombi. The initial initial activation of platelets is mediated by cell adhesion 
molecules (CAMs) expressed on the surface of activated ECs in response to 
inflammatory stimuli, or injury 299. Our results show that EC expression of ICAM-1 and 
VCAM-1 is enhanced in the presence of D2, possibly contributing to the greater level of 
platelet deposition and aggregation relative to non-HA controls, and HA 1500-
supplemented cultures. However, as seen in the SEM micrographs, clearly, platelet 
adhesion and aggregation as induced by D2 is far less than that induced by inflammatory 
factors such as TNF-α. 
 Another very important determinent of vascular graft patency is the interaction 
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between ECs and leukocytes. Upon initial activation, due to injury or stimulation by 
inflammatory agents, ECs release CXC chemokines (interleukin 8, IL-8) and acute 
inflammatory cytokines (TNF-α; interleukin 1, IL-1) into the circulation to attract 
polymorphomuclear neutrophils (PMNs) and T-cells to the site of EC activation (acute 
inflammation) 300. If continuously agitated, they also summon monocytes/macrophages, 
activated T cells, B cells, eosinophils, basophils, and dendritic cells by releasing CC 
chemokines (MCP-1, MIP-3α) 301 to stimulate chronic inflammation and possible graft 
failure. In addition, the cytokine GM-CSF is known to prolong the circulating half-life of 
PMNs and induce a delay in PMN apoptosis and thus prolong inflammatory responses 302. 
HA fragments in the oligomeric size range are known to be produced in areas of 
inflammation by enzymatic degradation of long-chain HA, to trigger a healing response. 
However, continued degradation of HA has also been noted to induce prolonged 
inflammatory responses including the activation of leukocytes 303. Therefore, it is not 
surprising that D2 stimulated TNF-α production caused a modest increase in MCP-1, 
MIP-3α and GM-CSF release.  On the other hand, HA 1500 had no effect on TNF-α 
production and only very marginally enhanced MCP-1, MIP3α and GM-CSF. The EC 
expression of acute inflammatory chemokines/ cytokines, other than TNF-α was not 
affected by HA 1500 or D2 (data not shown). Other cytokines released in response to 
HA/oligomers were IFN-γ and FKN (mild increase relative to controls). IFN-γ appears to 
cause early suppression of IL-8 to inhibit PMN-EC interactions, but stimulates IL-1β and 
TNF-α production by neutrophils during a later inflammatory stage to promote these very 
interactions 304. FKN exists in two forms, one that is secreted as a potent chemoattractant, 
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and one that is membrane bound and supports adhesion of monocytes and T cells 305. 
These results suggest that D2 and HA 1500 have both leukocyte- agonist and antagonist 
capabilities. In general, it is important to note, any increase in release of pro-
inflammatory cytokines by D2, can be muted when presented to ECs in a biomaterial 
together with an abundance of HA 1500. 
 
3.5 Conclusions 
 In summary, our results show that both D2 and HA 1500 interact with ECs in a 
positive manner; D2 enhanced EC proliferation, and angiogenesis, while HA 1500 
significantly alternated platelet attachment to ECs and their aggregation and activation. In 
addition, D2 stimulated modest inflammatory cytokine production and CAM expression, 
while HA 1500, in general, had a more limited effect. Therefore, in the near future we 
seek to develop vascular scaffold materials composed of optimized ratios of D2 and HA 
1500 capable of stimulating ECs to grow on its surface regenerating a normally 
functional endothelium. 
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CHAPTER 4 
A SURFACE-TETHERED MODEL TO ASSESS THE SIZE-SPECIFIC EFFECTS 
OF HYALURONIC ACID ON VASCULAR ENDOTHELIAL CELL FUNCTION 
AND ELASTOGENESIS OF SMOOTH MUSCLE CELLS 
 
 
4.1 Introduction 
The extracellular matrix (ECM), once regarded simply as a structural scaffold, is 
now recognized as an important modulator of cell phenotype and function. From a tissue 
engineering perspective, it is increasingly apparent that ECM structures/ substrates 
provide the necessary biomechanical and biochemical stimulatory cues to cultured cells 
to create micro-environments similar to native tissues. A class of ECM molecules that are 
increasingly studied in the context of cell culture scaffolds are glycosaminoglycans 
(GAGs). One such GAG, hyaluronic acid (HA), occurs naturally in connective tissues 
(e.g. skin) as a simple linear molecule consisting of repeating dissacharide units of N-
acetyl-D-glucosamine and D-glucuronic acid 17. Most cells have the ability to synthesize 
HA at some point during their cell cycle, implicating its function in several fundamental 
biological processes 18. 
In recent years, HA has been recognized as a biomaterial for potentially effective 
tissue regeneration. It is now known that HA, when degraded into smaller-sized 
fragments, facilitate wound healing by promoting angiogenesis 19. HA fragments can, 
under specific circumstances, also promote early inflammation, which is critical to 
initiate wound healing, but can also modulate later stages of the process, allowing for 
matrix stabilization and reduction of long term inflammation 18. HA is also highly 
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biocompatible and does not elicit a foreign-body response upon cross-transplantation due 
to the high degree of structural homology of HA across species 18. Although mechanisms 
of interaction between HA and the human body are still incompletely elucidated, its 
promising characteristics have assured its extensive use as a tissue engineering scaffold, 
most recently for cartilage 20 and skin repair 21. 
Our lab is focuses on investigating the potential use of HA biomaterials for small 
vessel grafting or regeneration. It is generally understood that complete endothelialization 
of the graft lumen is essential to ensure long-term patency of vascular grafts and thus key 
to the long-term success of intravascular implants. In the previous section (chapter 3) we 
reported on the size-specific effects of exogenous HA/ fragments on ECs. Briefly, we 
found exogenous supplementation of a mixture (D2) of HA oligomers containing 
predominantly 6mers and 12mers, to stimulate EC proliferation, angiogenesis and the 
secretion of angiogenic growth factors reinforcing our conviction that HA fragments may 
be suitable as vascular biomaterials. In addition to achieving complete lumenal coverage 
with functional ECs, enabling regeneration of medial elastin is another crucial 
requirement critical to maintaining vascular homeostasis in part by native biomechanical-
transductive cues to cells. Vascular SMCs typically synthesize elastin as soluble 
tropoelastin, which is then post-translationally crosslinked by lysyl oxidase into a 
structural matrix. In a previous study, we showed the elastogenic effects of exogenous 
HA fragments on SMCs to also be size-specific 31,32. However, only exogenous 
supplements of broad HA oligomer mixtures (D1), containing a lower concentration of 
6mers and 12mers, up-regulated elastin synthesis by adult SMCs, and enhanced the 
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formation of an elastin fiber-rich matrix. It was clear from our previous studies 31,306 that 
while exogenous supplementation models broadly predict cell responses to substrate/ 
scaffold components, presentation of these very components to cells, immobilized on a 2-
D substrate, may more closely simulate cell responses within 3-D scaffolds. 
Studies such as that of Deed et al. 171, have suggested that since exogenous 
HA/fragments likely only transiently interact with cells, they may inadequately simulate 
cell response to HA substrates; thus, the true effects of HA size on cell response as a 
scaffolding material may more accurately be predicted by long-term cell contact with 
surface-immobilized HA/HA fragments. Therefore, investigation of the differential 
effects, if any, of exogenous vs. surface-tethered HA/fragments is important to determine 
the validity of use of an exogenous supplementation model in ascertaining the fragment-
size specific effects of HA on endothelialization and SMC elastognesis. The current study 
will also elucidate how chemical immobilization of HA on the surface of scaffolds will 
influence their ability to interact with cells, in the absence of other possible influencing 
parameters such as crosslinks, present within a 3-D scaffolding microenvironment 307. 
This study thus describes our attempts to immobilize native HA, in a wide range of 
fragment sizes, on 2-D glass surfaces and test EC angiogenic responses and SMC 
upregulation of elastin synthesis. 
 
4.2. Materials and Methods 
4.2.1 Preparation of HA Oligomer Mixtures 
As mentioned in section 3.2.1, HA 1500 was enzymatically digested to produce 
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two mixtures of HA oligomers: D1 and D2. Briefly, HA 1500 (5 mg/ ml) was digested 
with bovine testicular hyaluronidase, (439 U/mg) in a solution of digest buffer (37 °C). 
The different oligomer mixtures were produced by altering the enzyme concentration 
(D1: 0.45 mg/ ml; D2: 4.5 mg/ ml) and time of digestion (D1: 18 h; D2: 48 h). The 
enzyme was then precipitated, its activity terminated by boiling (2 min), and cooled on 
ice. Following centrifugation (2800 rpm, 10 min), to separate the enzyme from the 
mixture, the supernatant was dialyzed in water (12 h) and then freeze-dried overnight to 
generate lyophilized HA oligomers. Previously, these mixtures were analyzed by FACE 
and found to contain a broad (D1: 13.9 ± 3.6% HA 6mers and 8.0 ± 1.6% HA 12mers) 
and narrow (D2: 33.3 ± 2.44% w/w of HA 6mers and 39.2 ± 2.68% w/w of HA 12mers) 
range of oligomers. 
 
4.2.2 Immobilization of HA, HA Fragments, and Oligomers 
HMW HA, large HA fragments, and HA oligomers were tethered onto glass 
surfaces using a carbodiimide linking chemistry 308. HA 1500, HA 200, HA 20, and in-
house prepared oligomer mixtures (D1) were immobilized onto 4-well glass chamber 
slides (Nalge Nunc International, Napersville, IL). The chamber slides were incubated in 
1 M NaOH for 1 hour to de-protonate the exposed hydroxyl groups and render the glass 
surface uniformly reactive. The glass surface was rinsed with DI water and 95% v/v 
ethanol (Sigma, St Louis, MO), and then activated by incorporation of aminosilanes. A 
3% v/v solution of 3-aminopropyl-trimethoxysilane (APTMS; Fluka Chemical Corp., 
Milwaukee, WI) in 95% v/v ethanol was prepared and the silane was allowed to convert 
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into silanol over 5 minutes. A 1-ml aliquot of the solution was then reacted with the glass 
slide (30 min, 23 ºC) with shaking. The slides were then briefly rinsed in 100% v/v 
ethanol (Sigma), dried under a steady stream of argon gas, and finally heated in an oven 
(1 hr, 115 °C), rinsed three times with 95% v/v ethanol, and dried again under argon gas. 
Immobilized amines were covalently reacted with the carboxyl groups present on 
HA, using a carbodiimide reaction (Figure 4.1). Briefly, an aqueous HA solution (3 
mg/ml) was prepared with 200 mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC; Pierce Biotechnology Inc., Rockford, IL) and 100 mM N-
hydroxysuccinimide (NHS; Pierce Biotechnology Inc.). A 1-ml aliquot of this solution 
was applied to each well and allowed to react for 16 hours with continuous agitation on a 
shaker. The slides were then soaked in DI water for 2 hours to leachout unbound HA, and 
finally air-dried under inert argon gas. 
 
 
 
 
 
 
 
 
 
 
 
 
Glass APTMS
HA
+
NHS, EDC
pH 5
Heat
Figure 4.1 Schematic of the chemistry involved in the immobilization of HA. 
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4.2.3 s-SDTB Assay for Quantification of Tethered Amine Groups 
Aminosilanated surfaces were rinsed with 50 mM NaHCO3 buffer, pH 8.5. A 1-
ml aliquot of this buffer containing 2% v/v dimethyl formamine (DMF) and 0.1 mM 
sulfo-succinimidyl-4-O-(4,4’-dimethoxytrityl)-butyrate (s-SDTB) was incubated (30 min, 
23 ºC) with each well of the aminosilanated chamber slides to allow s-SDTB to bind to 
the exposed amine groups. The slides were then gently rinsed with methanol to remove 
unreacted s-SDTB, and then treated with a 50% v/v solution of 60% v/v perchloric acid 
in methanol (10 min, 23 ºC) to elute the 4, 4’-dimethoxytrityl cation from the bound s-
SDTB. The amount of cation was measured using a spectrophotometer (Molecular 
Devices, Sunnyvale, CA) at λ = 498 nm. The concentration of the cation, and hence 
surface amines, was determined by comparison of the unknowns with a calibration curve 
generated with known amounts of 4, 4’-dimethoxytrityl chloride prepared in perchloric 
acid/ methanol solution. 
 
4.2.4 Fluorescence Microscopy for Detection of Surface-Immobilized Molecules 
Successful surface-immobilization of amine groups was confirmed by 
fluorescence labeling with an Alexa-488-conjugated amine-reactive dye (Molecular 
Probes, Temecula, CA; 1:1000 v/v in NaHCO3 buffer, pH 8.5). The dye solution was 
allowed to react with the aminosilane surfaces (1 hour, dark), then removed and the 
surface was washed with NaHCO3 buffer and DI water. The slides were mounted with 
Vectashield (Vector Labs, Burlingame, CA). Negative controls were not treated with the 
amine reactive dye. The slides were visualized using a Ziess Axiovision-200 
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epifluorescence microscope fitted with a FITC filter. 
Surface-bound HA/ HA fragments were detected by immunofluorescence, either 
using a biotinylated HA binding protein (HABP) and rhodamine-conjugated streptavidin, 
or with FITC-pre-conjugated HA. A solution of biotinylated-HABP (b-HABP; 0.5 mg/ml, 
diluted 1:100 in PBS; Associates of Cape Cod, E. Falmouth, MA) was added to the slide 
chambers and allowed to react with the HA-tethered surfaces (1 hour). Excess 
biotinylated-HABP was removed by rinsing with PBS. A solution of bovine serum 
albumin (BSA; 5% v/v in PBS) was added to the slides as a blocking agent (20 minutes). 
The slides were then again washed with PBS to remove the blocker. Texas Red-
conjugated neutravidin (Molecular Probes; 1:500 v/v in PBS) was allowed to react with 
the b-HABP on HA (1 hour, dark). The solution was then aspirated, the surfaces washed 
with PBS and DI water, and the slides mounted with Vectashield. The negative control 
was not treated with HABP. The slides were imaged using a confocal microscope (Leica 
TCS SP2 AOBS, Allendale, NJ). 
 
4.2.5 Scanning Electron Microscopy 
Glass, aminosilanated glass, and HA-tethered glass surfaces were visualized using 
scanning electron microscopy (SEM) to assess the homogeneity of the coated layers. 
Argon-dried surfaces were coated with gold (60 s) in a sputter coater (VG-Microtech, 
Uckfield, UK) and visualized using a SEM 3500 (Hitachi Ltd, Tokyo, Japan) at 150× to 
1500× magnification. 
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4.2.6 Atomic Force Microscopy 
 Atomic force microscopy (AFM) was performed on glass, aminosilane and HA-
tethered substrates to determine the surface roughness and gauge the uniformity of the 
coatings at the cellular (micron) scale. Argon-dried surfaces were analyzed using a 
Digital Instruments CP-II (Veeco, Woodbury, NY) AFM equipped with an Utralever 
contact mode tip (Veeco, Woodbury, NY) and titanium cantilever. Three areas per 
sample were imaged under contact mode and analyzed with Proscan 1.9 and Image 
Analysis 2.1 to obtain a linescan section profile used to measure the peak heights. 
 
 4.2.7 X-ray Photoelectron Spectroscopy 
X-ray photoelectron spectroscopy (XPS) was used to compare the elemental 
composition and chemical structure characteristics of the glass, aminosilane and HA-
coated surfaces. Dried slides were stored in a desiccator prior to analysis using an Axis 
165 XPS system (Kratos, Chestnut Ridge, NY) with a monochromatic aluminum target x-
ray source (15 kV and 10 mA). Samples were analyzed at a pressure of 10-9 torr and 
temperature of 23 ºC with a takeoff angle close to 0º. Scans between 1200 eV and 0 eV 
were performed and the resulting spectra were referenced to the substrate C 1s peak. 
Higher resolution spectra were also generated to monitor the formation of functional 
groups upon HA immobilization. 
 
4.2.8 Assays for Quantification of HA Loss from the Surface 
Loss of surface-bound HA over 3 weeks of incubation was assessed in serum-free 
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culture medium using (a) colorometric toluidine blue assay and (b) Fluorophore Assisted 
Carbohydrate Electrophoresis (FACE). For both assays, HA-tethered surfaces were 
incubated in culture medium (MCDB-131, Invitrogen, Carlsbad, CA; 37 ºC) for 0, 1, 4, 7, 
14, and 21 days. On these respective days, the supernatant medium was aspirated and a 
500-µl aliquots of aqueous toludine blue solution (0.075 mg/ml) added to the HA 
surfaces, and agitated by shaking for 10 minutes. The absorbance of this solution, 
following removal toluidine blue by binding to surface-tethered HA, was measured 
spectrophorometrically at λ = 630 nm, and compared to it’s absorbance prior to 
incubation with the surfaces. The decrease in absorbance indicated the presence of HA. 
FACE analysis was used to quantify the amount of HA/ HA fragments remaining 
on the slide surface after 1, 14 and 21 days of incubation with culture medium. In 
preparation for FACE, 20 mU of hyaluronidase SD (Associates of Cape Cod, East 
Falmouth, MA) solubilized in 0.1 M ammonium acetate, pH 7.0, was added to each well 
of the chamber slide and incubated (37 ºC, 6 hrs) to digest HA off the surfaces. The 
resulting solution, containing HA disaccharides (∆DiHA), was freeze-dried and then re-
suspended in 40 µl of 0.0125 M solution of the fluorescent dye 2-aminoacridone (AMAC, 
Sigma) prepared in acetic acid/ DMSO (3:17 v/v) and incubated (23 ºC, 15 min, dark). A 
40 µl aliquot of an aqueous solution of 1.25 M sodium cyanoborohydride (Sigma) was 
then added to each sample and incubated (37 ºC, 16 hrs, dark). Following this, 20 µl of 
glycerol was added to each sample. Standards were also prepared using known amounts 
of commercially available HA disaccharides (V-Labs, Covington, LA). If necessary, 
samples were stored at -20 ºC, prior to use. 
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For electrophoresis, all 8 lanes of a polyacrylamide MONO® gel (Glyko, San 
Leandro, CA) were loaded simultaneously with 4 µl of sample/standard using an 8-
channel glass syringe (Hamilton, Reno, NV) and run with MONO® gel running buffer 
(Glyko), as adopted from a previously published method 282. Briefly, the electrophoresis 
apparatus (Glyko) was placed in a trough of ice to maintain the buffer temperature below 
10 ºC throughout the electrophoresis process. Samples were electrophoresed at a constant 
500 V with a starting current of 25 mA/gel and a final current of 10 mA/gel for 80 
minutes. After electrophoresis, the gels were illuminated with UV-B light (λ = 365 nm) in 
a FluorChem 8900 (Alpha Innotech, San Leandro, CA) and the band intensities were 
quantified and compared to the standard to quantify the amount of ∆DiHA present. 
 
4.2.9 Endothelial Cell Culture 
 As stated in section 3.2.4, rat aortic ECs (passage 6-8) were cultured in MCDB-
131 supplemented with FBS, pen/strep, ECGS, and L-glutamine. Spent medium was 
replaced thrice weekly. 
 
4.2.10 DNA Assay for Cell Proliferation 
 The DNA content of EC cultured on surface-tethered HA 1500, HA 200, HA 20, 
D1, and D2 was used to compare the number of cells present at days 1 and 14, and hence 
quantify the proliferation of ECs in culture. The protocol for this assay is outlined in 
section 3.2.5. 
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4.2.11 Calcein AM Labeling 
 Calcein acetoxymethyl ester (Calcein AM; VWR) was used to fluorescently 
detect live cells and assess their morphology when cultured on HA surfaces. 
Metabolically active (alive) cells take up non-fluorescent calcein AM where intracellular 
esterases cleave the AM moiety producing highly fluorescent calcein within the cell 
outlining its morphology. ECs were seeded onto the HA surfaces at a concentration of 2 × 
104 cells/ well of a 4-well culture slide and cultured for 1 week. Cells were then 
incubated with calcein AM (8 mg/ ml) in Hank’s Buffered Salt Solution (HBSS; VWR; 
45 min) and fixed in 4% w/v paraformaldehyde (Sigma). Surface adherent ECs were 
imaged on a TCS SP2 AOBS confocal microscope (Leica, Allendale, NJ). 
 
4.2.12 Immunolabeling for CAM Expression 
 Expression levels of cell adhesion molecules (CAMs) by ECs cultured on D2-
immobilized and fibronectin-coated (control; VWR) 4-well chamber slides, and with 
exogenously supplemented TNF-α (control; VWR) were compared by 
immunofluorescence and quantified by calculating the mean fluorescence intensity (MFI) 
on a per cell basis. EC activation was gauged from the extent of expression of 
intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1), previously shown to be elevated when EC cultured were exogenously 
supplemented with D2. ECs were seeded onto the HA surfaces at a concentration of 2 × 
104 cells/ well of a 4-well and cultured for 1 week. The cells were then fixed with 4% w/v 
paraformaldehyde and incubated at 4 °C for 1 h with fluorescein isothiocyanate (FITC)-
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conjugated mouse anti-rat CD54 (ICAM-1; Abcam, Cambridge, MA) and Alexa 488-
conjugated mouse anti-rat CD106 (VCAM-1; Biolegend, San Diego, CA) diluted 1:100 
v/v in PBS-azide. The slides were mounted with Vectashield containing 4,6-diamidino-2-
phenylindole (DAPI, Vector Labs, Burlingame, CA) to stain the nuclei and cells were 
imaged using a Ziess Axiovision-200 epifluorescence microscope fitted with a FITC 
filter. To quantify the CAM expression, the MFI and cell number (based on number of 
nuclei) was calculated with Image J (n = 9/ condition), and the quotient was computed to 
determine the MFI/ cell. All images of CAM expression were taken with an exposure 
time of 100 ms. 
 
4.2.13 SMC Cell Culture 
 Adult rat aortic smooth muscle cells were isolated by a method based on that 
described by Oakes et. al.[127]. Adult male Sprague-Dawley rats, each weighing 250-
300 grams, were sacrificed previously by CO2 asphyxiation as per protocols approved by 
the Animal Research Committee at the Medical University of South Carolina and at 
Clemson University. Aortal segments were removed from euthanized rats, from arch to 
the celiac axis, under sterile conditions, and spliced lengthwise in petri dishes containing 
cold phosphate-buffered saline (PBS) containing 2 mM Ca2+. These spliced sections were 
then transferred to a dish containing 1-2 ml of collagenase (2 mg/ml; Worthington, 
Lakewood, NJ) and incubated for 10 minutes at 37 °C. DMEM:F12 media was then 
added to these collagenase treated samples and mixed well with gentle pippetting. 
Isolated aortal segments were further chopped crosswise into 0.5-m long pieces and 
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transferred using fine needles onto sterile petri dishes, pre-scratched to facilitate cell 
attachment. The explants were incubated in limited volumes of the above medium at 
37 °C for a week, to establish primary culture. Cells were periodically observed 
microscopically in order to monitor attachment and proliferation. At the end of one week, 
the explants were removed carefully and sufficient DMEM:F12 added to the dish to 
promote cell proliferation. 
Low passage rat aortic smooth muscle cells (SMCs; P4-8) were obtained by 
passaging primary cells isolated from adult rat aortal explants. Stock cells were 
trypsinized (0.25% trypsin/ 0.1% v/v EDTA; Invitrogen), pelletted by centrifugation 
(500g, 7 min), re-suspended in DMEM: F12 containing 10% v/v FBS and 1% v/v 
penicillin-streptomycin and seeded onto D1-coated 1-well glass chamber slides (Nalge 
NUNC International, Naperville, IL; culture area = 8 cm2) at a density of 104 cells/ cm2. 
The SMCs were also cultured on unfunctionalized 1-well glass chamber slides with and 
without exogenously supplemented D2 at a concentration equivalent to the average 
surface-tethered density (4 µg/ well). In all cases, cells were harvested at 21 days of 
culture (n = 9 wells/case). Spent medium was replaced twice weekly during the duration 
of culture, and pooled at the end of the 21-day culture period, along with the harvested 
cell layers. 
 
4.2.14 Fastin Assay for Elastin 
A Fastin assay was used to quantify the total amount of elastin matrix within cell 
layers (matrix elastin), and that released into the culture medium as a soluble precursor 
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(tropoelastin).  Matrix elastin derived from the 21-day-old cell layers was digested with 
0.1 N NaOH (98 °C, 1 h), and centrifuged (10,000g, 10 min) to yield an insufficiently 
crosslinked, alkali soluble fraction (S1), and a mature, mostly highly crosslinked, 
insoluble pellet (P2). Since the Fastin assay (Accurate Scientific and Chemical 
Corporation, Westbury, NY), quantifies only soluble α-elastin, the insoluble elastin was 
first reduced to a soluble form before subjecting to the assay. To do this, the elastin pellet 
(P2) was dried to a constant weight, solubilized with three cycles of treatment with 0.25 
N oxalic acid (1 h/cycle, 95 ºC), and the pooled digests then filtered in microcentrifuge 
tubes fitted with low molecular weight (10,000 Da) cut-off membranes (Amicon, 
Houston, TX). The insufficiently crosslinked, soluble elastin fraction retained in the 
oxalic acid-free fraction (S3) and in the water-reconstituted hydrolysate (S2) were also 
quantified using the Fastin assay.  The weight of insoluble elastin using the Fastin assay 
was compared to that determined by weighing the dry elastin pellet (P2), to affirm low/ 
no loss of elastin material during matrix processing. In each case, the ratio of matrix 
elastin to total (tropo+ matrix) elastin was compared to gauge efficiency of crosslinking 
into a structural elastin matrix. 
 
4.2.15 Desmosine Assay 
 Desmosine content was assayed using an ELISA 221 to confirm the extent of 
crosslinking within the matrix elastin. Briefly, cell layers were scraped off, re-suspended 
in 1 ml of 5%v/v trichloroacetic acid, and centrifuged (3000g, 10 min, 4 °C). The pellet 
was digested with collagenase type VII (Sigma-Aldrich; 12 h, 37 °C) and re-centrifuged 
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(3000g, 10 min, 4 °C) to obtain a supernatant (D1) and a pellet. The pellet was digested 
with pancreatic porcine elastase type III (Sigma Aldrich; 12 h, 37 °C) to obtain soluble 
peptide fractions (D2). Fractions D1 and D2 were pooled together, hydrolyzed with 6 N 
HCl at 110 °C and dried to powder under inert nitrogen over 18–24 h. The dried samples 
were reconstituted in double deionized water and diluted for assay. The wells in micro-
titer plates to be used for assay were pre-blocked using desmosine-albumin conjugate 
(EPC, Owensville, MO) in 0.05M sodium carbonate buffer (pH 9.6, 4 °C), then washed 
with 0.05% v/v Tween-20 and phosphate-buffered saline (PBS) solution (1 h, 25 °C). 
Desmosine standards/samples were incubated (12 h, 25 °C) with rabbit antiserum to 
desmosine–hemocyanin conjugate (Elastin Products Company, Owensville, MO). After 
removal of primary antibody solution, the wells were successively incubated with 
peroxidase-conjugated anti-rabbit IgG 0.05% v/v Tween 20-PBS solution (2 h, 25 °C). 
Finally, 0.08mg of the colorimetric compound 2,2 (E-Azinobis (3-ethylbenzothiazoline-
6-sulfonic acid)) (Sigma), dissolved in 0.1M citrate phosphate buffer containing 0.003% 
v/v hydrogen peroxide (pH 4), was added to the wells and incubated (1 h, 25 °C). 
Absorbances were read in a UV spectrophotometer at λ = 405 nm. 
 
4.2.16 Analysis of Matrix Ultrastructure 
TEM was used to selectively compare the distribution and ultra-structure of 
matrix elastin between cell layers cultured with exogenous or surface-tethered HA 
oligomers, or in their absence (control). For TEM, the adhered cell layers (n = 3/ case) 
were fixed in 2.5% w/v glutaraldehyde, post-fixed in 1% w/v OsO4, dehydrated with 
 134
ethanol, then embedded in resin, cut into 70 nm thick sections and finally stained with 
uranyl acetate and lead citrate.  
 
4.2.17 Statistical Analysis 
All experiments were performed in triplicate, unless otherwise mentioned. 
Statistical significance between and within groups was determined using Microsoft 
Excel’s statistical function for t-tests, assuming unequal variance and two-tailed 
distribution.  Differences were considered statistically significant at p < 0.05.  
Quantitative results are reported as mean ± standard deviation. 
 
4.3 Results 
Surface Characterization 
4.3.1   Characterization of the Aminosilane Surface 
 An amine reactive dye was initially used to determine the presence of primary 
amines on the glass surface after treatment with the aminosilane (Figure 4.2). The 
silanated surface fluoresced brightly and uniformly indicating homogeneous tethering of 
amines. SEM and AFM micrographs (Figures 4.4B, 4.5B) and XPS spectra (Figure 4.6, 
Table 4.1) confirmed the presence of homogenous silane coatings, distinctly different 
from glass surfaces (Figures 4.4A, 4.5A). The s-SDTB amine assay indicated a surface 
amine density of 9 ± 3 amine groups/ nm2.   
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Figure 4.2 Amine reactive dye detection of APTMS. On non-functionalized glass (A) and absence of 
amines, the dye remained non-fluorescnece. However, upon interaction with amine groups on APTMS 
functionalized surfaces (B) the dye fluoresced green. 
 
 
4.3.2 Microscopic Visualization of HA-Coated Surfaces 
 The presence of HA (HA 1500), or its fragments (HA 200, HA 20) chemically 
bound to the surface-tethered amine groups was confirmed by red fluorescence (Figure 
4.3A-C). HA 1500 surfaces appeared somewhat less homogeneous with some gaps 
between areas of intense fluorescence while the HA 200 and HA 20 surfaces fluoresced 
more uniformly. Fluorescently-tagged HA 90 immobilized onto the chamber slides also 
appeared coated on the glass substrates (Figure 4.3D) similar to HA 20. Controls, HA 
surfaces not treated with biotinylated HABP (Figure 4.3E) or FITC-imaged 
aminosilanated glass (Figure 4.3F), did not fluoresce. 
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Figure 4.3 Immunofluorescence detection of surface-immoilized HA. HA 1500, HA 200, and HA 20 were 
tagged with b-HABP and a rhodamine-conjugated streptavidin and appear homogeneously coated (red) on 
the surface (A, B, C). FITC-conjugated HA (MW 90 kDa) was also uniformly bound (D; green). Controls, 
HA surfaces not treated with biotinylated HABP (E) or FITC-imaged aminosilanated glass (F), did not 
fluoresce. Magnification: 20×. 
 
 
 Scanning electron micrographs of the glass surfaces showed random circular 
patches, a likely attribute of commercial plasma treatment (Figure 4.4A). On silane-
treated surfaces, these speckled patches were not seen although other structures, 
assumably aminosilane molecules, were seen across all replicate samples indicating a 
successful silane coating (Figure 4.4B). HA-coated surfaces (Figures 4.4C-F) were void 
of these structures, but instead showed smooth (HA 1500) or more fenestrated (HA 200, 
HA 20, D1) sheets, not seen on untreated glass and aminosilanated glass. 
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Figure 4.4 Scanning electron micrographs of glass, APTMS, and HA-tethered surfaces. Glass surfaces 
appear smooth with spotted disfigurements attributed to the commercial plasma coating (A). Aminosilane-
treated glass shows the presence of APTMS molecules (B). HA 200, HA 20 and D1 appear as fibrous 
sheet-like networks (D, E, F) with some gaps within, while HA 1500 coated the surfaces as a smooth sheet 
without any detected morphology (C). Magnification: 150×. 
300 µm
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 AFM also conclusively demonstrated the presence of tethered aminosilane groups, 
HA and HA fragments and, for the most part, their formation of homogeneous layers. 
The increase in average peak height (roughness) of the aminosilane treated surfaces 
(0.1305 ± 0.0695 µm) in comparison to untreated glass (0.004 ± 0.001 µm), as indicated 
by AFM, confirmed the successful immobilization of the aminosilane. The roughness of 
the HA surfaces showed an inverse correlation to molecular weight of HA fragments 
(Figure 4.5). The average peak height atop surfaces coated with HA 1500, HA 200, HA 
20 and D1 were 0.09142 ± .06699 µm, 0.0.4934 ± 0.2002 µm, 0.8345 ± 0.3771 µm and 
0.8871 ± 0.3734 µm, respectively (n = 3/ surface). 
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Figure 4.5 Atomic force micrographs and the corresponding peak heights of glass, APTMS and HA-
tethered surfaces. Glass surfaces appear very smooth with a consistent atomic topography (A). The addition 
of aminosilane to the glass surface resulted in a much rougher surface (B). The peak heights indicate that 
the HA surface roughness are inversely proportional to MW of tethered HA chains. In accordance, HA 
1500 (C) and HA 200 (D) appear more smooth than HA 20 and D1. 
 
 
4.3.3 Elemental and Chemical Structure Analysis of Coated Surfaces 
 The results of elemental and chemical structure analysis of treated substrates, as 
determined by XPS, are shown in Table 4.1, Table 4.2 and Figure 4.6. XPS spectra 
generated on glass surfaces exhibited strong peaks for elemental silicon and oxygen, with 
carbon, calcium and sodium as minor contaminants. Tethering aminosilanes onto the 
surface reduced detection of silicon and oxygen while the elemental content of carbon 
and nitrogen was enhanced. The XPS elemental scan and high resolution spectra 
generated by the HA-coated surfaces varied as a function of their molecular weight, as 
will be discussed later. The high resolution spectra for HA 1500 and HA 200 were 
quantitatively similar, as were those for HA 20 and D1. Therefore, only one spectrum 
from each group was included. 
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Figure 4.6 XPS elemental scan and C1s high resolution spectra of glass, APTMS and HA/ fragments/ 
oligomer-tethered surfaces. The prominent peaks observed corresponded to oxygen, silicon, nitrogen, and 
carbon (A). High resolution spectra of the HA C1s peaks indicated that the relative amount of N-C=O 
functional groups was inversely proportional to MW of tethered HA chains (B). Presumably, this is due to 
the inefficient binding of HMW HA to the aminosilanes. 
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 XPS Atomic Composition (%) 
Surface Si O C N 
Glass  26.3 ± 0.2 66.5 ± 0.4 5.9 ± 0.4 — 
APTMS 11.0 ± 0.2 23.8 ± 1.4 53.0 ± 1.0 12.1 ± 0.4 
HA 1500 1.5 ± 1.7 29.7 ± 2.5 57.6 ±  1.7 11.2 ±  2.1 
HA 200 0.6 ±  0.4 28.8 ±  2.6 59.9 ± 1.0 10.7 ±  2.0 
HA 20 2.0 ± 0.7 24.4 ± 0.8 68.6 ± 1.8 5.0 ± 1.9 
D1 2.9 ± 0.3 23.0 ± 1.2 65.4 ± 0.6 8.3 ± 0.9 
         
Substance XPS Atomic Composition (%) 
Quartz 66.6 33.3 - - 
APTMS 9.1 27.3 54.5 9.1 
HA - 42.3 53.8 3.8 
     
 
Table 4.1 XPS analysis of glass, amine-bound and HA-bound surfaces and the corresponding theoretically 
predicted elemental profiles. Glass is composed primarily of oxygen and silicon. An increase in carbon and 
decrease in silicon is observed with the introduction of APTMS, a carbon based structure. Likely, the large 
chains of HA 1500 and HA 200 significantly block the detection silicon while a substantial spectral peak 
corresponding elemental nitrogen was still observed. The smaller chains of HA 20 and D1 allowed 
enhanced detection of elemental silicon but reduced the nitrogen peak. Results represent mean ± SD of 
readings obtained from n = 2 regions/ sample with a total of n = 4 samples/ substrate. 
 
         
 XPS C1s Composition (%) 
Surface CH C-N/ C-O   O-C-O/ N-C=O 
HA 1500 39.0 53.0  8.0 
HA 200 13.7 76.4  9.9 
HA 20 60.6 28.4  11.0 
D1 57.3 27.6   15.1 
     
 
Table 4.2 High resolution C1s composition of the HA surfaces. A greater amount of C-N and lower 
quantity of N-C=O was detected on surfaces with larger HA fragments (HA 1500, HA 200) indicating a 
higher binding efficiency of the smaller HA fragments (HA 20, D1) with the silane amines. 
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Quantification of HA Loss from the Surface 
4.3.4 Toluidine Blue Assay 
The amount of HA bound to the aminated glass surfaces was estimated from the 
decrease in absorbance due to loss of toluidine blue from a contacting solution, by 
reaction with surface-tethered HA (Figure 4.7). Absorbances of toluidine blue solution 
contacted with HA/ fragment-tethered surfaces were consistently much lower than glass 
and amine-tethered surfaces, indicating successful immobilization of HA. A high 
absorbance was generated on glass (3.07 ± 0.03) and APTMS-treated surfaces (2.89 ± 
0.05), similar to fresh toluidine blue solution (3.07 ± 0.19). Toluidine blue incubated with 
the HA 1500 surface exhibited absorbances (0.85 ± 0.20) much lower than that for both 
HA 200- and HA 20-tethered surfaces (1.60 ± 0.38, 1.76 ± 0.39) and remained 
unchanged over 21 days of incubation of the substrate with culture medium. Retention of 
D1 on surfaces was tested with toluidine blue only on 0 and 21 days of incubation with 
medium, and generated the highest absorbances of the HA surfaces (2.45 ± 0.12). 
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Figure 4.7 Toluidine blue assay of glass, APTMS and HA-tethered surfaces. Irrespective of fragment size, 
tethered HA appears to be stably retained over 21 days of incubation with serum-free medium as evidenced 
by a lack of absorbance change (i.e. increase) of the toluidine blue solution. Higher molecular weights of 
HA were able to bind more toluidine blue molecules from the solution due to a greater number and 
availability of unreacted carboxyl groups. [* denotes a p-value < 0.05 in comparison to day 0] 
 
 
4.3.5 FACE Analysis 
FACE analysis was used to quantify the amount of HA present on the surfaces. At 
day 0, HA 1500-tethered surfaces contained approximately 9 times the amount of HA 
dissacharide units (9.36 ± 1.68 µg) than the other fragment sizes (Figure 4.8). At day 0, 
HA 200, HA 20 and D1 surfaces contained approximately the same amount of HA 
dissaccharides (1.00 ± 0.48 µg, 1.31 ± 1.15 µg, 0.92 ± 0.56 µg, respectively). These 
coated amounts remained unchanged after 21 days of incubation with medium suggesting 
negligible loss from the surface irrespective of tested HA fragment size. 
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Figure 4.8 FACE analysis of HA surfaces. More HA 1500 was present on the surface than the other 
molecular weights. The amount of HA 200, HA 20 and D1 was similar. In all cases, the amount of HA was 
stable on the surfaces throughout the 21 days. [* denotes a p-value < 0.05 in comparison to day 1] 
 
 
Endothelial Cell Culture 
4.3.6 Endothelial Cell Proliferation 
 HA 1500, HA 200, HA 20 and D1-tethered surfaces did not incite significant 
proliferation of rat aortic ECs over 14 days of culture; the proliferation ratios were 
comparable to that obtained on the APTMS surfaces (negative controls; Figure 4.9). 
However, D2 provided the necessary stimulus for vascular EC proliferation; proliferation 
ratios were similar to that of the positive control cultures, i.e. cells cultured on glass and 
fibronectin. 
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Figure 4.9 Proliferation of rat aortic smooth muscle cells on glass, APTMS, HA/ fragment/ oligomers, and 
fibronectin surfaces. Most HA surfaces (HA 1500, HA 200, HA 20, D1) did not support cell proliferation 
and induced similar proliferation ratios as the APTMS substrate. However, D2 surfaces stimulated EC 
proliferation to levels similar to glass and fibronectin. [* denotes a p-value < 0.05 in comparison to the 
glass control] 
 
 
4.3.7 Endothelial Cell Morphology 
 HA 1500 (C) and large HA fragments (HA 200, D; HA 20, E) were unable to 
support EC adhesion, as seen in Figure 4.10. ECs attached to both D1 (F) and APTMS 
(negative control, B) but appeared rounded on D1 (F) surfaces and exhibited an abnormal 
morphology on APTMS surfaces. D2 (G) surfaces allowed ECs to attach and spread 
similarly to glass (A) and fibronectin (H) surfaces (positive controls). 
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Figure 4.10 Cell morphology of ECs cultured on HA surfaces. Most HA surfaces (HA 1500, HA 200, HA 
20) did not support EC attachment (C, D, E). ECs were able to attach to APTMS (B) and D1 (F) surfaces 
but retained a strange phenotype or remained rounded. D2 surfaces (G) supported EC attachment and 
spreading similar to glass (A) and fibronectin (H) surfaces. 
 
 
4.3.8 Expression of Cell Adhesion Molecules 
 D2 surfaces elicited expression levels of EC activation markers that were greater 
than fibronectin surfaces but more attenuated than TNF-α-stimulated ECs. D2-tethered 
surfaces enhanced cellular expression levels of ICAM-1 (Figure 4.11) and VCAM-
1(Figure 4.12) beyond that of fibronectin-coated surfaces (negative control), although 
these increases were significantly less relative to the increases in EC CAM expression 
induced by TNF-α (positive control). In addition, VCAM-1 expression levels were higher 
than ICAM-1 in all cases. 
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Figure 4.11 ICAM-1 expression of ECs cultured on fibronectin and D2 surfaces, and with TNF-α. D2 
stimulated an increased amount of ICAM expression relative to fibronectin surfaces, however, this 
expression level was attenuated compared to TNF-α stimulated ECs. [* denotes a p-value < 0.05] 
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Figure 4.12 VCAM-1 expression of ECs cultured on fibronectin and D2 surfaces, and with TNF-α. D2 
surfaces stimulated ECs to express a greater amount of VCAM then fibronectin surfaces, but these 
expression levels did not reach those of ECs cultured with TNF-. [* denotes a p-value < 0.05] 
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Smooth Muscle Cell Culture 
4.3.9 Tropoelastin Synthesis 
 Measured tropoelastin amounts (ng) were normalized to the average DNA content 
(ng). SMCs cultured on surface-presented and exogenous supplemented D1 showed 1.75 
± 0.001 and 1.74 ± 0.001 times the tropoelastin output, respectively, relative to the non-
HA control cultures (156,509 ± 151 ng/ ng, 155,590 ± 116 ng/ ng respectively). There 
were no statistical differences in tropoelastin synthesis between cultures supplemented 
and surface-tethered with D1 (Figure 4.13). 
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Figure 4.13 Effects of surface-tethered D1 oligomer mixtures on tropoelastin synthesis by adult RASMCs. 
Shown are the mean ± SD of average tropoelastin/ DNA (ng/ng) ratios normalized to corresponding 
measurements in control cell layers (no HAoligomers) plotted for surface-tethered and exogenous HA 
oligomers. The culture period was 21 days. Note that error bars are too small to be seen. 
 
 
 
4.3.10 Crosslinked Matrix Elastin Synthesis 
 Elastin incorporated into the extracellular matrix was measured as a sum of two 
fractions, namely, a highly crosslinked, alkali-insoluble elastin pellet, and a more weakly 
crosslinked, alkali-soluble fraction. In general, the total DNA-normalized output of 
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matrix elastin for HA-oligomer supplemented cell cultures was significantly higher than 
that of control (non HA) cultures. In the presence of surface-tethered D1, DNA 
normalized matrix elastin output was 2.6 ± 0.04 times that produced by controls (931 ± 
26 ng/ng). Similarly the DNA normalized matrix elastin output by cells cultured with the 
exogenous HA oligomer mixture was 2.7 ± 0.02 times that produced in controls (Figure 
4.14). Differences between the test cultures were deemed statistically insignificant. 
 
0
0.5
1
1.5
2
2.5
3
surface-tethered exogenous
Fo
ld
 In
cr
ea
se
 
 
 
 
 
 
Figure 4.14 Effects of surface-tethered D1 on crosslinked elastin matrix synthesis by SMCs. Shown are the 
mean ± SD of average matrix elastin/ DNA (ng/ng) ratios normalized to corresponding measurements in 
control cell layers (no HA-oligos) plotted as functions of HA-oligos (surface-tethered and exogenously 
supplemented). The elastin matrix amounts respresent the sum of alkali-soluble and alkali-insoluble 
fractions. 
 
 
4.3.11 Alkali-Insoluble Matrix Elastin Synthesis 
 In general, the total DNA-normalized output of alkali-insoluble matrix elastin for 
HA-oligomer supplemented/ tethered cell cultures was significantly higher than that of 
control (non HA) cultures cultured on glass substrates (Figure  4.15). In the presence of 
surface-tethered HA oligomers, DNA normalized matrix elastin output was 9.6 ± 0.6 
times that produced by controls (682 ± 41ng/ng). Similarly, the DNA-normalized matrix 
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elastin output by cells cultured with the HA oligo mixture exogenously supplemented 
was 10.9 ± 0.2 times that produced in their controls (777 ± 12 ng/ ng; Figure 4.15). 
However, differences in between the test cultures (surface-tethered and exogenous HA 
oligomer mixtures) were deemed statistically insignificant. 
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Figure 4.15 Comparison of amounts of alkali-insoluble pellet elastin synthesized by HA-oligomers 
(surface-tethered and exogenously supplemented) in comparison to their controls. Shown are mean ± SD of 
the measured amounts of pellet elastin/ DNA (ng/ ng) normalized to corresponding measurements in 
control cell layers (no HA), plotted as functions of HA oligomer mixtures either surface-tethered or 
exogenously supplemented. 
 
 
4.3.12 Desmosine Assay for Matrix Elastin 
 Cells cultured with D1 showed greater amounts of desmosine synthesis respective 
controls. In addition, SMCs cultured on surface-tethered D1 further enhanced desmosine 
production beyond exogenous D1 indicating a benefit of surface immobilization (Figure 
4.16). 
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Figure 4.16 Comparison of desmosine synthesis by cells cultured with HA-oligomers (surface-tethered and 
exogenously supplemented) versus their controls. Shown are mean ± SD of the measured amounts of 
desmosine/ DNA (ng/ ng) and matrix elastin/ DNA (ng/ ng) normalized to corresponding measurements in 
control cell layers (no HA), plotted as functions of HA oligomer mixtures either surface-tethered or 
exogenously supplemented. [* denotes a p-value < 0.05] 
 
 
4.3.13 Ultrastructural Analysis of Elastin Matrix 
 TEM micrographs of cell layers cultured with exogenous and surface-tethered HA 
oligomer mixtures for 21 days contained multiple layers of elongated, aggregating elastin 
fibrils and clumps uniformly sandwiched between alternating cell layers (Figure 4.17A, 
B). These deeply staining microtubules surrounded the periphery of aggregating elastin 
fibrils (Figure 4.17D). TEM of HA oligomer surface-tethered cell cultures showed a 
denser elastin-fiber network than exogenous oligomer supplemented cultures. Control 
cell layers at 21 days could be distinguished from sample cell layers due to the presence 
of far fewer elastin fibrils and amorphous clumps (Figure 4.17C). Elastin fibrils appeared 
to laterally aggregate; symbolizing formation of thicker elastin fibers in both surface-
tethered and exogenous HA oligomer supplemented cultures (Figure 4.17A, B).  
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Figure 4.17 Matrix ultrastructure and fibrillin-mediated elastin deposition. Shown are representative 
transmission electron micrographs of 21 day-old cell layers cultured in the presence of HA oligomers, 
either exogenously supplemented (4 µg/ 5 ml; panel A), or surface-tethered (4 µg/ 5 ml; panel B) or in it’s 
absence (C). In each case, representative images were selected from nearly 20 captured micrographs. A 
qualitative comparison of the matrix within test (A, B) and control (C) cell layers reveals differences in the 
amount and nature of elastin deposited. Both HA oligomer-supplemented (A, B) and control cell layers (C) 
preserved normal fibrillin microtubule-mediated elastin deposition. These deeply staining microtubules 
surrounded the periphery of aggregating elastin fibrils (D). Magnification: A-C is 15,000×, D is 25,000×. 
 
 
4.4 Discussion 
 The long-term goal of our research is to develop HA-based scaffolds for vascular 
regeneration that will be conductive to the development of a normally functional luminal 
endothelium and stimulate SMCs to synthesize elastin. A healthy, confluent EC lining is 
crucial to maintaining the anti-thrombotic and anti-hyperplasic endothelial signaling 
pathways and the presence of elastin preserves homeostasis and provides the necessary 
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mechanical properties to blood vessels to accommodate blood flow. Both luminal ECs 
and elastin within the vessel wall are disrupted by injury or disease, therefore, the 
regeneration of these vascular elements are vital to the reinstatement of vascular 
homeostasis during treatment of vascular disease. 
 The choice of HA as a vascular implant material stems from it’s biocompatibility 
and non-immunogenicity, an outcome of the high degree of homology in its structure 
across species 18, and its potential, as a ECM component, to evoke native, non-
exaggerated responses from cultured vascular cells. HA has also been shown to exhibit 
angiogenic tendencies, although these effects, as with other phenomena observed with 
other cell types, appear to be highly specific to HA fragment size 19.  In our previous 
work, we have also seen that cells respond to HA oligomers more exuberantly than to 
larger sized HA, and show significant size-specificity in their responses, even within the 
oligomer size range. However, other studies have also shown HA fragments and HA 
oligomers to be capable of inducing inflammatory responses 18. Thus, the distribution of 
bioactive HA fragments and oligomers within an HA-based scaffold must be defined and 
optimized to elicit desired outcomes (i.e. functional endothelialization, SMC 
elastogenesis) and prevent unwanted ones (i.e. inflammation). We thus seek to 
comprehensively determine the specific fragment-size effects of HA on EC function and 
SMC elastin synthesis. 
 Prior studies 31 determined that a model of exogenous supplementation of 
scaffolding materials inadequately predicted cell responses to the same materials when 
presented as a substratum, likely due to the absence of continuous cell-material contact. 
 154
In addition, fragmented HA/ oligomers cannot by themselves be crosslinked into stable 
solid scaffolds to test their stand-alone impact. Therefore, we have developed a surface-
tethered model of HA to compare to the exogenous supplementation model. 
 Silane coupling agents are often used to durably link organic, and inorganic 
groups such as those present on glass. We chose to use a aminotrialkoxysilane due to its 
presentation of an exposed -NH2 group and its hydolytic stability 309. Trialkoxysilanes 
form 3D silane networks of bonded multilayers on the glass surface that restrict the 
infiltration of hydrolytic substances from solution. If necessary, however, silanes 
incorporating even more hydrolysis-resistant aromatic groups may be used in the future. 
Among the chemically reactive groups on HA (-OH, -COOH) 200, we targeted the 
carboxyl groups specifically due to their ability to react with primary amines. To do this, 
the carboxyl groups of the component HA disaccharide monomers were activated with 
EDC into the chemically reactive and unstable O-acylisourea. This complex can either 
react with a primary amine to form stable amide bonds or undergo hydrolysis in the 
presence of water to reform the carboxyl. To prevent the hydrolysis of O-acylisourea, 
NHS is added to the solution. NHS combines with O-acylisourea to form a semi-stable 
and amine reactive NHS-ester to increase the efficiency of EDC-mediated coupling 
reactions 310. In the past, some studies have used charged sulfo-NHS instead of NHS 
because of its increased solubility. No experiments were conducted to compare the 
solubility and relative reactivity of these molecules but NHS was found to readily and 
completely solubilize in aqueous solutions and therefore was used in these experiments. 
Although no concrete proof is available, one previous study expressed doubts in a similar 
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method of HA immobilization based on XPS results that deviated from the expected 
theoretical values. Therefore, we have presently characterized the created aminosilane 
and HA-tethered surfaces using various analytical techniques.  
 Analysis of the HA surfaces by fluorescence, SEM and AFM indicate that at the 
cellular scale (~10-20 µm), the HA coatings are highly homogeneous and continuous. 
Results of XPS analysis correctly reflected the changes in surface-elemental composition 
that might be expected to occur upon aminosilane treatment and HA immobilization. 
However, the relative content of these elements showed slight differences from that 
might be theoretically expected based on the stochiometry of HA, likely due to steric 
hindrance. Upon aminosilane treatment, an expected increase in nitrogen and carbon 
content was observed. The elemental profiles were similar to that theoretically expected 
APTMS. Assuming complete reaction of all tethered amine groups on the surface to the 
carboxyl groups on HA, the % elemental composition of HA-tethered substrates should 
be independent of their molecular weight. Yet, the XPS results show differences in 
elemental composition between HA 1500, HA 200, HA 20 and D1 surfaces. Specifically, 
as seen in Table 4.1, the % composition of nitrogen atoms on HA 1500- and HA 200-
tethered surfaces was somewhat higher than that of HA 20 and D1 (11.2%, 10.7% vs. 
5.0%, 8.3%). We believe that these differences stem from the greater gaps within the 
higher MW HA coatings and the less efficient binding to available tethered amine groups. 
High resolution XPS analysis confirms this since a higher % content of C-N and lower N-
C=O bonding functionalities were detected for HA 1500 and HA 200 relative to the other 
sized HA fragments. 
 156
When a single disaccharide unit of polymeric HMW HA binds to an APTMS 
amine, the remaining strand may effectively prevent other such strands from binding to 
the APTMS molecules in the local vicinity by directly binding to them or sterically 
inhibiting their interaction with other strands. As a result, binding of HMW HA to surface 
amines is less efficient. It is also possible that the large size of the HMW HA strands also 
causes substantial strand entanglement to produce a compact zone of HA close to the 
aminated surface, yet creating sporadic gaps devoid of HA. This theory was supported by 
our low magnification immunofluorescence micrographs which indicated areas of intense 
fluorescence, likely due to large HA strands stacked on top of one another, adjoining 
darker ones (gaps/ pores) less densely covered with HA. Such a distribution of HA could 
more easily permit the detection of un-reacted, exposed nitrogen containing amine groups, 
to thus increase the elemental concentration of nitrogen above that expected theoretically. 
With regard to shorter HA fragments, such entanglement and steric hindrance were 
apparently far less of an issue as evidenced by fluorescence detection of uniform intensity, 
and much lower levels of detection of APTMS amines and a higher degree of C-N=O 
structures by XPS, which suggest more efficient reaction between APTMS amines and 
HA. Also, when imaged under high magnification (SEM), a fibrous surface was revealed, 
with clustered short HA fibers. Likely, these fibers were concentrated around the APTMS 
amine functional groups preventing their detection. In support of these observations, 
AFM data indicate higher peaks on surfaces tethered with HA 20 and D1 than that 
tethered with HA 1500 and HA 200. This suggests the shorter HA fragments were not 
entangled with one another to create a compact zone, but rather individually attached to 
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the amines. 
 The FACE outcomes support our hypothesis that HA 1500 forms entangled 
networks on the surface, unlike shorter HA fragments and oligomers; indeed, the amount 
of HA 1500 immobilized on glass was far greater than that of HA 200, 20 or D1. Shorter 
HA fragments likely do not stably entangle with one another due to their smaller size. 
Thus excess fragments were released from the surface when rinsed immediately after 
preparation but just prior to incubation with medium. 
 FACE and the toluidine blue assay both confirmed the long-term (21 days) 
retention of the immobilized HA/ fragments/ oligomers but each used a different process. 
FACE directly measures the amount of enzyme-digested tethered HA, while the toluidine 
blue assay utilizes an indirect approach. Toluidine blue binds to carboxyl groups present 
on HA dissacharides 311. Since the number of disaccharides in each case is dependant on 
HA chain length, tethered amount between different HA size groups. However, for each 
HA size we can reliably monitor the retention of HA/ fragments / oligomers on the 
surface over time. 
Since cells cultured on an HA scaffold would encounter HA as a substratum and 
not freely diffusing HA molecules, we sought to create HA-substrates that would 
somewhat replicate this environment. Yet, the results indicate that almost all forms of HA, 
bound utilizing the available carboxyl functional groups, do not allow EC attachment. 
This may be due to the high charge densities and smooth surface topographies of larger 
HA fragments; both of which are known to inhibit cell adhesion 312,313.  The only 
fragment size that provided a surface that allowed EC attachment was the highly 
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concentrated oligomer digest (D2). This may result in altered physical attributes, 
increased surface roughness that provides greater opportunities for cell anchorage and 
lower anionic charge densities that render cell-surface interactions thermodynamically 
favorable, or receptor-ligand interactions. In addition, the D2-tethered surface supplied 
ECs with a substrate conducive to proliferation, similar to fibronectin, with the potential 
to support a confluent EC layer. However, the D2-tethered surface also incited an 
increase in inflammatory marker expression (ICAM-1, VCAM-1). These results are 
similar to what we observed in the exogenous study (chapter 3), indicating the exogenous 
model closely mimics EC responses to different fragments of HA when presented in 
scaffold form. It can be inferred from these results that derivatized HA oligomers 
immobilized on a surface and exogenous HA oliogmers interact with EC receptors in a 
similar manner. 
Although the reasons for the unique interactions of different-sized HA fragments 
with ECs is unclear, it is believed to be due to their differential interactions with cell 
surface receptors specific for HA. CD44 is a trans-membrane adhesion receptor found in 
several cell types, including ECs, and is the most studied among three cell membrane 
receptors for HA currently identified, the others being Receptor for HA-Mediated 
Motility (RHAMM), and Toll-Like Receptor 4 (TLR4) 232. Studies have shown that HA 
oligomers can incite very different cell responses when bound to CD44 receptors, than 
when HMW HA interacts with them, because HA oligomers can cause clustering of 
multiple CD44 receptors and thus alter intracellular responses 293. The stimulation of 
CD44 receptors by HA oligomers has also been suggested to enhance the production of 
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vascular EC growth factor (VEGF) and therefore promote EC proliferation 26.  The CD44 
receptor is also known to mediate cellular adhesion 314. This study shows that the 
interactions of HA oligomers and CD44 receptors are not altered by chemical 
derivatization and immobilization chemistries. In addition to their importance to EC 
function, CD44 receptor has also been shown to modulate vascular SMC behavior. 
Another concern of this study was the potential alteration of HA oligomers to 
stimulate an elastogenic response by SMCs when immobilized onto a surface. Previous 
studies have shown SMCs stimulated with exogenously supplemented D1 produce 
increased amounts of tropoelastin and crosslinked matrix elastin, and in this study we 
investigated whether this phenomenon was maintained when the oligomers were 
presented to SMCs in a modulated scaffold environment. FACE analysis found the D1  
digest of HA to contain 13.9 ± 3.6% HA 6mers and 8.0 ± 1.6% HA 12mers (chapter 3), 
while Matrix Assisted Laser Desorption/Ionization-Time of flight (MALDI-TOF) mass 
spectrometry suggests a 75.0  ± 0.4% HA 4mer content 31. The elastogenic responses of 
vascular SMCs to exogenous and surface-tethered D1 were directly compared. In specific, 
we sought to compare the quality, quantity and desmosine concentration of cultured 
elastin, generated by SMCs in presence of both exogenous and tethered D1. We selected 
the dose of exogenous D1 (4 µg) to be equivalent to the amount of surface-tethered D1 
(based on the FACE analysis) calculated as an average value (0.5 µg/ cm2; 8 cm2 total 
area) of the amount initially tethered onto the 1-chamber glass slide and the ultimate 
amount surviving hydrolysis over 21 days of culture. 
Comparing quantitative matrix synthesis outcomes of SMCs presently cultured 
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atop HA-oligomer-tethered surfaces or with exogenous HA oligomers, it is clear that 
silane coupling of HA oligomers preserves innate cellular responses to these fragments. 
The amounts of tropoelastin, total matrix elastin and alkali-insoluble matrix elastin in test 
cultures were dramatically up-regulated relative to non-HA control cell layers. In addition, 
the quantity of tropoelastin, total matrix elastin and alkali-insoluble matrix elastin was 
not particularly influenced by mode of presentation of HA oligomers to the cells. We can 
infer from this finding that D1 enhances SMC production of elastin precursor and final 
crosslinking into matrix elastin, irrespective of the method by which they are presented to 
SMC cultures. This strongly supports a hypothesis that HA oligomers enhance 
recruitment of soluble tropoelastin and facilitates it’s crosslinking into an insoluble 
matrix form. While this may be purely a charge effect wherein tropoelastin coacervates in 
presence of HA oligomers and is preferentially crosslinked, an alternate explanation 
might be that HA oligomers receptor interactions may have downstream effects such as 
increased activity and expression of lysyl oxidase (LOX), an important initiator of 
desmosine crosslinking. Yet another possibility is the absence of any effort to block 
endogenous elastase activity, wherein HA oligomer-cell interactions might instead 
interfere and affect elastase activity thus leading to enhanced elastin turnover, resulting in 
accumulation of matrix elastin.  
 An important difference between cell layers cultured with exogenous and surface-
presented HA oligomers, was with respect to their desmosine content. The amounts of 
desmosine synthesized by both groups, was higher than that in control cultures, and 
statistically different among themselves; surface-tethered D1 increased desmosine 
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synthesis relative to exogenously supplemented D1. This in turn suggests that intimate 
cellular contact with D1 may be responsible for enhanced desmosine crosslinking. This 
phenomenon may also be attributable to previous suggestions that surface-tethered D1 
attracts, coacervates and cross-links elastin deposited on its surface, thereby facilitating 
its crosslinking by lysyl oxidase into a more stable elastin matrix 315. This finding is also 
supported by observation from our previous studies 220 that cells atop HA crosslinked gel 
scaffolds cause enhanced crosslinking of elastin matrix due to a possible effect of highly 
anionic HA which possibly attract, and coacervate elastin on their surfaces. 
 TEM analysis provided conclusive evidence that tethered D1 prompted cells to 
lay down a matrix characterized by the presence of amorphous elastin clumps and 
numerous aggregating elastin fibers, the latter barely seen in control (non-HA) cultures. 
Although biochemical analysis indicated insignificant differences in elastin amounts 
within cell cultures incorporating exogenous and surface-tethered D1, there were some 
visual differences in the organization of elastin. In the surface-tethered cultures, fewer 
amorphous elastin clumps and more fibers were observed indicating a more stable form 
of elastin.  
 Thus, the results of this study strongly suggest that presentation of HA oligomers, 
either as an exogenous supplement or tethered onto a surface, does not alter its influence 
on EC functionality or SMC elastin synthesis, as would be deduced from EC proliferation 
and CAM expression, and quantitative analysis of SMC elastin production. However, the 
presentation of D1 immobilized on a cell substrate appears to somehow benefit the 
crosslinking of soluble elastin and facilitate its organization into elastin fibers. 
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 The results of our exogenous (chapter 3) and this surface-immobilized studies 
indicate that HA oligomers may stimulate modest inflammatory CAM expression, while 
HA 1500, in general, had a more limited effect. In order to limit the inflammatory 
response of ECs to HA oligomers we aim to incorporate moderate concentrations these 
HA oligomers into a more bioinert HA 1500 scaffold formed by crosslinking HA into a 
hydrogel. We believe these scaffolding materials composed of optimized ratios of HA 
oligomer and HA 1500 will diminish the inflammatory response of ECs to HA oligomers 
but maintain the ability of HA oligomers to stimulate ECs to growth, regenerating a 
normally functional endothelium on the hydrogel surface. 
 
4.5 Conclusions 
Two of the main obstacles in vascular graft development are the regeneration of a 
confluent EC layer on the luminal surface and restoration of a mature elastin matrix 
within the vessel wall. HA has been shown to be beneficial in this regard as an exogenous 
supplement but the utility of HA fragments/ oligomers as a scaffolding material is unclear. 
Therefore, we sought to immobilize HA fragments/ oligomers onto a surface to 
investigate if this effected their stimulation of EC function and SMC elastogenesis. In this 
study, we successfully chemically bound a wide range of HA fragment sizes onto glass 
chamber slides creating culture surfaces useful towards determining the size-specific 
cellular responses of surface-tethered HA. EC culture on these surfaces indicated that 
these cells only attached to HA surfaces composed of a highly concentrated digest of HA 
oligomers (D2), while larger sized fragments of HA deter cell adherence. The D2 
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surfaces also stimulated EC proliferation and CAM expression similarly to our 
observations with exogenous D2, in section 3. SMCs cultured on a less concentrated 
mixture of HA oligomers (D1) increased tropoelastin and crosslinked matrix elastin 
production similarly to exogenously supplemented D1. However, surface-tethered D1 
exhanced desmosine crosslinking and elastin fiber organization relative to exogenously 
supplemented D1. These results support the beneficial use of HA oligomers within HA-
based vascular scaffolding materials due to the maintenance of their function when 
immobilized onto a substrate. However, the enhanced CAM expression elicited by both 
exogenous and immobilized HA oligomers is a concern. Therefore, the next step in this 
project is to incorporate moderate concentrations of these HA oligomers into scaffolds 
composed of HA 1500 to reduce EC CAM expression, maintain their proliferative 
characteristics, and yet create a biomaterial with good handling properties.  
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CHAPTER 5 
THE IMPACT OF HA OLIGOMER CONTENT ON PHYSICAL, MECHANICAL, 
AND BIOLOGIC PROPERTIES OF DIVINYL SULFONE-CROSSLINKED HA 
HYDROGELS 
 
 
 
5.1 Introduction 
 To overcome the poor or, alternatively, exaggerated vascular cell responses to 
synthetic materials, there has been a recent shift toward the development and use of 
“natural or tissue-based” biomaterial scaffolds that could potentially evoke more 
appropriate, and accelerated regenerative/ healing responses by vascular cells. The 
extracellular matrix (ECM), once regarded simply as a structural scaffold, is now 
recognized as an important modulator of cell phenotype and function 263. From a tissue 
engineering perspective, it is thus increasingly apparent that the presence of ECM 
molecules is vital to developing a biomechanical and biochemical environment that 
mimics the cellular surroundings within native tissues. One class of ECM molecules that 
is increasingly studied in the context of designing regenerative materials are 
glycosaminoglycans (GAGs). One such GAG, hyaluronic acid (HA), occurs naturally in 
connective tissues (e.g. skin) as a simple, linear molecule consisting of repeating 
dissacharide units of N-acetyl-D-glucosamine and D-glucuronic acid 17. Most cells have 
the ability to synthesize HA at some point during their cell cycle, signifying that the 
molecule has vital function in several fundamental biological processes 18.  
 From a biomaterials standpoint, HA has been increasingly recognized as an 
appropriate biomolecule to modulate tissue regeneration, since it can be chemically 
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derivatized into biomaterials with little change to it’s inherent biologic properties. It is 
now known that HA, when  physiologically degraded into smaller-sized fragments, 
facilitates wound healing by promoting angiogenesis 19. HA fragments can, under 
specific circumstances, also incite early inflammation, which is critical to initiate wound 
healing, and then modulate later stages of the process to stabilize the matrix and reduce of 
long-term inflammation 18. In an uncrosslinked state, HA is also highly biocompatible 
and has been shown to poorly elicit a foreign-body response upon cross-transplantation 
due to the high degree of structural homology that HA exhibits across species and tissue 
types 18. In addition, HA is amenable to binding peptides, matrix proteins, and growth 
factors capable of further modulating cell responses 220,316. Although the modes of 
interaction between HA and the human body are still incompletely understood, the 
favorable characteristics outlined above have assured its extensive use as a scaffolding 
biomaterial for tissue engineering applications, most recently for cartilage 20 and dermal 
21 repair and regeneration. Our lab is currently investigating the potential use of HA as a 
vascular regenerative implant material. Since HA forms a significant (4-7% w/w) 
component of vascular ECM 22, we hypothesize that HA modified biomaterials will 
provide biomechanical and biochemical signals to vascular cells to ensure a healthy 
physiologic-like phenotype. 
 In previous sections (chapters 3, 4) we reported on the size-specific effects of HA 
on vascular ECs. Briefly, we found exogenous supplementation of a mixture of HA 
oligomers (D2), containing predominantly 6mers and 12mers, to stimulate EC 
proliferation, secretion of pro-angiogenic growth factors, and formation of a micro-
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vascular network. The chemical immobilization of these HA oligomer mixtures onto 2-D 
cellular substrates (glass) did not alter their impact on EC behavior differentially from 
when the same mixtures were exogenously delivered to ECs (see chapter 4). This 
reinforced our hypothesis that chemical derivatization of HA oligomers does not 
necessarily alter their cellular interaction and hence, could likely be incorporated into 
cell-contacting biomaterials, with little or no detriment. However, under both 
presentation modes, this pro-endothelial HA oligomer mixture somewhat elevated EC 
expression of inflammatory CAMs. In addition, when HA oligomers are crosslinked, the 
resulting biomaterials are fluid-like and exhibit very poor handling properties. One way 
to address these problems, is to incorporate the bioactive HA oligomers within 
mechanically robust constructs containing chemically-crosslinked, highly biocompatible 
and rather bioinert, high molecular weight (HMW) HA (MW > 1 × 106 Da). 
Previous studies with divinyl sulfone (DVS)-crosslinked HA hydrogels, 
composed of HMW HA alone, showed them to be bioinert and non-conducive to cell 
spreading and proliferation 306. However, it was shown that such gels could be bio-
activated by controlled surface-irradiation with UV light (λ = 254 nm), a process that 
randomly splices HMW HA to generate HA fragments of a range of sizes, including HA 
oligomers 306. It was observed that vascular cells readily attached, spread, proliferated 
and generally exhibited a healthy phenotype, and normal functionality when cultured atop 
these bio-activated gels. Since the effects of UV light can be difficult to control, and can 
potentially cause random ionizations that are structurally disruptive, a better approach is 
to create ‘bioactivated’ gels containing bio-inert long-chain HA, necessary to maintain 
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mechanical integrity and potentially provide a high degree of biocompatibility, and 
smaller, more cell-interactive HA fragments/ oligomers. In pursuing this approach, it is 
however important to incorporate optimally-sized HA fragments, and modulate their 
content within the HA biomaterial such as to evoke desired cell responses, and yet 
prevent exaggerated responses (e.g. inflammation) that can be potentially elicited by HA 
oligomers. At the time this study was conducted, the use of HA oligomers as biomaterials 
for enabling functional vascular endothelialization and tissue regeneration had not been 
thoroughly investigated. Particularly, the effects of crosslinking HMW HA/ HA 
oligomers to obtain HA scaffolds with good handling properties, and the densities at 
which bioactive HA oligomers need to be presented on these biomaterials to achieve the 
desired EC responses were unknown. In the current study we therefore specifically 
investigate the impact of crosslinking HMW HA and HA oligomer mixtures with divinyl 
sulfone (DVS) on the physical, mechanical and biological properties of the resulting 
material. 
 
5.2 Materials and Methods 
5.2.1 Preparation of HA Oligomer Mixtures 
As mentioned in section 3.2.1, HA 1500 (MW 1.5 – 1.8 × 106) was enzymatically 
digested to produce a mixture of HA oligomers (D2). Briefly, HA 1500 (5 mg/ ml) was 
digested with bovine testicular hyaluronidase, (4.5 mg/ ml; 439 U/mg) in a solution of 
digest buffer (37 °C) for 48 h. The enzyme was then precipitated, its activity terminated 
by boiling (2 min), and cooled on ice. Following centrifugation (2800 rpm, 10 min), to 
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separate the enzyme from the mixture, the supernatant was dialyzed in water (12 h) and 
then freeze-dried overnight to generate lyophilized HA oligomers. The mixture was 
analyzed by FACE and found to contain 33.3 ± 2.4% w/w of HA 6mers and 39.2 ± 2.7% 
w/w of HA 12mers, with oligomers of closely-related sizes forming the balance (see 
chapter 3). 
 
5.2.2 Hydrogel Formulation 
 HA hydrogels crosslinked with DVS (DVS-HA) were formulated using methods 
loosely based on a previously described protocol 317. Briefly, HA 1500 with added D2 (0, 
5, 10, 20% w/w) was completely dissolved at a concentration of 45 mg/ ml in a 1:4 v/v 
solution of 1M sodium hydroxide (NaOH; to maintain a high pH): 1M sodium chloride 
(NaCl; to increase the dissolution rate of HA), pH 13.0. Thorough mixing of the resulting 
viscous solution was achieved by repeated transfer of the mixture between two sterile 
syringes (Beckton Dickenson, Franklin Lakes, NJ) through a 3-way stopcock (Kimble 
Kontes, Vineland, NJ). The mixture was then centrifuged for 5 min at 1000 g to remove 
air bubbles and aliquoted into cylindrical molds (for rheology, compression: 2 cm2, 0.5 
ml; for all other analytical techniques: 0.79 cm2, 0.2 ml). The aliquoted mixtures were 
homogenously crosslinked by adding DVS (Sigma; Density = 1.177 g/ ml) directly into 
the aliquoted HA solutions at two concentrations (1:1 or 1:2 w/w DVS:HA), which 
translated to added volumes of 7.6 µl and 3.8 µl for the 0.79 cm2 mold. A spatula was 
used to mix DVS into the solution and the hydrogel was allowed to form (2 hr) through 
radical addition reaction between the vinyl groups of DVS and hydroxyl groups of HA 
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(Figure 5.1). The crosslinked gels were thoroughly washed in DI water (3 cycles; 2 hr/ 
cycle) to leach out unreacted DVS, and then finally equilibrated in sterile PBS. There 
were therefore a total of 8 formulations (4 oligomer concentrations × 2 crosslinker 
densities). The dimensions (height and diameter) of the swollen cylindrical hydrogels 
crosslinked in the 0.79 cm2 mold were measured with a digital caliper (Fisher, Pittsburgh, 
PA). 
Vinyl groups 
 
 
 
 
 
Figure 5.1 Chemical schematic of DVS-HA hydrogel formation. The vinyl groups of DVS combine with 
the hydroxyl groups of HA through radical addition. 
 
 
5.2.3 Fourier Transform Infrared Spectroscopy 
 Fourier transform infrared – attenuated total reflectance (FTIR-ATR) was 
performed to determine the chemical alternations induced by incorporation of DVS into 
the HA hydrogel. Crosslinked DVS-HA was freeze-dried and analyzed on a Varian 660-
IR FTIR spectrometer (Varian, Palo Alto, CA) and compared to uncrosslinked HA (n = 
3). The spectra were recorded in a frequency range between 400 cm-1 and 4000 cm-1 with 
a spectral resolution of 4 cm-1. A spectral library (Mentor Pro, Biorad, Hercules, CA) was 
used to identify the peaks and the corresponding bond vibrations. 
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5.2.4 Fluorescent Method to Detect Incorporation of HA Oligomers within Gels 
 HA oligomers (D2) were fluorescently labeled prior to incorporation within the 
hydrogel to evaluate their retention within the respective gels. D2 was dissolved (1.25 
mg/ ml) in a 0.0125 M solution of the fluorescent dye 2-aminoacridone (AMAC, Sigma) 
prepared in acetic acid/ DMSO (3:17 v/v), and incubated for 15 min in the dark. An 
equivalent amount of 1.25 M sodium cyanoborohydride (Sigma) was then added and 
incubated (37 °C, 16 h, dark). The fluorescently labeled-D2 was then recovered and 
purified by precipitation in acetone and re-dissolution in DI water (3 cycles), and finally 
precipitated in acetone and freeze-dried in the dark. Fluorescent D2 was then 
incorporated into DVS crosslinked hydrogels, as described in section 5.2.2, and the 
fluorescence intensities (λ = 365 nm) of the gels (n = 4), was monitored at regular 
intervals over 21 days of incubation in PBS (37°C) using a FluorChem 8900 (Alpha 
Innotech, San Leandro, CA). Gels were imaged with a constant exposure time of 200 
msec. 
 
5.2.5 Apparent Crosslinking Density 
 The structural integrity of DVS-HA is primarily maintained by DVS crosslinks, 
bonding the HA strands to one another and limiting their freedom of motion. The 
incorporation of HA oligomers may reduce the effectiveness of these crosslinks, 
diminishing the overall mechanical properties of the gel. In addition, the crosslinking 
efficiency of DVS may not be 100%. Accordingly, we deemed it necessary to define the 
apparent crosslinking parameter, which in essence represents the effective crosslinking 
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within each gel formulation. Uniaxial compression testing was performed to calculate the 
apparent crosslinking density within the gels. Cylindrical gel samples (8 mm diameter) 
were punched out of a larger gel using a 8-mm-diameter corneal trephine (BRI, Malden, 
MA) and were compressed without constraining the edges (unconfined compression 
testing) on a DMA Q800 (TA Instruments, New Castle, DE). The gels were subject to an 
initial force of 0.05 N and were then compressed at a rate of 20% strain/ min (n = 8). All 
tests were performed in air, though the gels were kept hydrated in PBS while being 
compressed. Stress/ strain curves were developed according to the following formula 
developed by Flory 318. 
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⎛ −⎟⎟⎠
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⎛= 23/1,23/2,2 1ααφφ
υσ sx
o
e
V
RT    (Eq 5.1) 
 
where σ – uniaxial compressive stress (Pa), Ρ – universal gas constant (J/ mol K), Τ – 
temperature (K), φ2,x – polymer volume fraction post-crosslinking, φ2,s – polymer volume 
fraction swollen, νe/Vo – apparent crosslinking density (mol/ cm3), and α – compressed 
fraction. This formula was developed for fully hydrated samples and water within DVS-
HA was forced out of the gel during compression. Therefore, the initial slope of the curve 
(0 – 30% strain) was used to estimate the apparent crosslinking density of the gel. 
 
5.2.6 Rheology 
 To further characterize the impact of crosslinking and oligomer incorporation on 
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hydrogel mechanics, rheological oscillatory shear stress experiments were performed. 
The strength or stiffness was experimentally determined by measuring the storage (G’) 
and loss (G”) moduli. An AR G2 rheometer (TA Instruments, New Castle, DE) was used 
in the parallel plate geometry, with a 25-mm plate and constant normal force of 0.2 N. A 
deformation angle of 1 mrad was maintained throughout each frequency sweep of 0.01–
10 Hz (n = 4). 
 
5.2.7 Swelling Ratio 
 Swelling tests were performed to study the effects of HA oligomer content and 
DVS concentration on the bulk hydrodynamic properties of the gels. Fully hydrated gels 
were blotted to remove excess PBS and the weight of the swollen samples were recorded 
using a sensitive balance (OH AUS, Pine Brook, NJ). The gels were then freeze-dried 
and weighed again. The swelling ratio was calculated by the following formula (n = 4). 
 
d
s
W
WtioSwellingRa =     (Eq 5.2) 
 
where Ws is the swollen mass of the gel (mg), and Wd is the dry mass of the gel (mg). 
 
5.2.8 Scanning Electron Microscopy 
 SEM was performed to determine whether D2/ DVS concentration alters the 
surface morphology of the gel. In preparation for SEM, swollen gels were dehydrated 
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with acetone and the dried gel samples were coated with gold for 4 min using a SPI-
Module Sputter Coater (Structure Probe, Inc., West Chester, PA) and imaged on an SEM 
( Jeol 100-JSM 5410 LV, Pleasanton, CA) at 150× magnification (n = 3). 
 
5.2.9 In Vitro Degradation 
 In vitro enzymatic degradation of the hydrogels was measured as a function of 
time by incubating the gels in testicular hyaluronidase and monitoring the remaining dry 
mass of the hydrogel. The gels were initially soaked in digest buffer (150 mM NaCl, 100 
mM CH3COONa, 1 mM Na2-EDTA, pH 5.0) overnight to reach swelling equilibrium. 
Bovine testicular hyaluronidase (Sigma-Aldrich) in digest buffer (2 mL of 50 U/ ml) was 
then added to each gel and incubated for 8 h at 37°C with mild mixing on a platform 
shaker. The dry masses of the gels were determined at 0, 2, 4, 6, and 8 h, and the enzyme 
solution replaced at each analysis time point (n = 3). This degradation profile was fitted 
according to first-order degradation kinetics using non-linear regression to estimate gel 
degradation rates. 
 
kt
oeCtC
−=)(      (Eq 5.3) 
 
where, C(t) is the dry mass of the gel at time t (mg), Co is the initial dry mass of the gel 
(mg), k is the degradation rate (h-1), t is time (h). 
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5.2.10 In Vivo Biocompatibility 
 The biocompatibility of the hydrogels was determined by subcutaneous 
implantation in rats. Prior to implantation, hydrogels were sterilized in 95% v/v ethanol 
(Sigma) for 2 h and then re-hydrated in sterile 1× PBS overnight. Sprague-Dawley rats 
(~250 g) were anesthetized (0.01 ml/ g intramuscular injection of 4% chloral hydrate), 
shaved, and a 5-cm incision made in the skin along the spine. Blunt dissection was used 
to form a pocket between the skin and muscle, and muscle surface was cleared of fascia. 
Hydrogels and matrigel (Sigma) were placed directly into these pockets (8 implants/ 
animal; n = 7), as shown in Figure 5.2. After implantation, the surgical incision was 
closed with 4-0 silk suture with a FS-2 cutting needle (Ethicon, Piscataway, NJ). 
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Figure 5.2 Illustration of subcutaneous implantation scheme of DVS-HA in the back of rats. All DVS-HA 
formulations were implanted into the same rat. Due to the lack of space, matrigel controls were implanted 
in separate rats. 
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 At 3 weeks, the hydrogels and the adherent tissue capsules were explanted from 
the subcutaneous pockets, fixed in 4% v/v paraformaldehyde and soaked for 1 h intervals 
in 30% w/v sucrose, 1:1 30% sucrose: optimal cutting temperature (OCT; Sakura, 
Torrance, CA) compound and finally pure OCT. The explants were then embedded 
within OCT , frozen on dry ice and stored at -80°C. Prior to sectioning, frozen blocks 
were acclimated to -20°C (overnight) and cryosectioned perpendicular to the skin and 
muscle surfaces. The 8-µm thick sections were transferred onto HistoBond® glass slides 
(VWR) and stained with Haematoxylin and Eosin to detect inflammatory cell infiltration 
towards or within the implant. The tissue sections were imaged on a Leica DM IRB 
microscope equipped with a JVC TK-C1380 color camera. In addition, 
immunofluorescence methods were used to detect the collagen, and hence presence of a 
fibrous capsule within the tissue mass surrounding the implant. Sections, 15 µm thick, 
were initially quenched with 1% v/v phosphomolybdic acid to eliminate autofluorescence 
from collagen and then incubated with a primary antibody for collagen I for 1 h (rbt vs. 
rat col I; 1:100 in PBS; Chemicon, Temecula, CA). A solution of donkey serum (5% v/v 
in PBS) was added to the sections as a blocking agent (20 minutes) to prevent nonspecific 
binding of the secondary antibody. The sections were then treated with a FITC-
conjugated secondary antibody (dky vs. rbt IgG; 1:500 in PBS; Chemicon) for 1 h. Draq 
5 (1:2000 in PBS, 10 min; Biostatus, Leicestershire, UK) was used to fluorescently label 
the cell nuclei and visualize the cell density in the region surrounding the implant. 
Fluorescently labeled sections were imaged on a TCS SP2 AOBS confocal microscope 
(Leica, Allendale, NJ) using the z-axis function to image 5 µm sections, which were then 
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compressed into a single image. 
 
5.2.11 Cell Culture 
 Hydrogels were initially sterilized in 95% v/v ethanol (2 h) and re-equilibrated in 
sterile PBS prior to EC seeding onto the gel surfaces. As stated in section 3.2.4, rat aortic 
ECs (passage 6-8) were cultured in MCDB-131 medium supplemented with 10% v/v 
FBS (Invitrogen), 1% v/v penicillin-streptomycin (Invitrogen), 50 µg/ ml EC growth 
supplement (BD), 4 mM L-glutamine (Invitrogen), and 30 U/ ml heparin (Sigma). Spent 
medium was replaced thrice weekly. Due to the high water content and anionic charge of 
these gels, adherent ECs may be unable to fully spread and remain rounded on the gel 
surface failing to achieve a natural morphology. We sought to address this by adsorbing a 
mixture of adhesive proteins (matrigel: laminin, collagen IV), similar to the composition 
of the vascular basement membrane, onto the hydrogel surfaces by incubating each gel in 
3 ml of a sterile matrigel/PBS solution (10 µg/ ml; 4 h) prior to EC seeding. ECs were 
cultured for 2 wks on both matrigel-free and matrigel-adsorbed gels, and imaged on a 
phase contrast microscope to monitor their morphology. The gel condition (matrigel-free 
or matrigel-adsorbed) that was determined to support ECs exhibiting a spread 
cobblestone morphology was used in further culture experiments. 
 
5.2.12 Protein Adsorption Assay 
 The protein content in the bulk solution of matrigel incubated with each HA 
hydrogel was quantified by a DC protein assay (Bio-Rad, Hercules, CA). Via this method, 
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we estimated the amount of protein lost by adsorption onto the HA hydrogels. Briefly, 
100 µl of bulk solution was combined with 500 µl of reagent A and 4 ml of reagent B of 
the assay kit, and incubated for 15 min. A 200-µl aliquot of the reacted sample solutions 
was pipetted into micro-well plates and their absorbances were measured at λ = 750 nm.  
Background absorbance from control wells containing PBS without matrigel was 
subtracted from the sample absorbance measurements. The detected absorbances (n = 4) 
were compared to standards prepared with bovine plasma gamma globulin (Bio-Rad) to 
determine the depletion of proteins from the matrigel stock solution, and thus calculate 
the total amount of protein deposited onto the DVS-HA hydrogels. 
 
5.2.13 Fluorescent Detection of Cell Viability 
 As stated in section 4.2.11, calcein AM was used to fluorescently detect live cells 
and determine their morphology when cultured on HA hydrogels. ECs were seeded onto 
the HA gel surfaces at a concentration of 2 × 104 cells/ gel and cultured for 1 week prior 
to calcein AM detection. Surface adherent ECs were imaged on a TCS SP2 AOBS 
confocal microscope (Leica) using the z-axis function to image 5 µm sections on the 
concave surface of the gels (n = 4). These sections were then compressed into a single 
image. 
 
5.2.14 MTT Assay for EC Proliferation 
 EC proliferation on gels was quantified using a colorimetric MTT assay, 
described previously by Denizot and Lang 319. The MTT reagent is reduced by the 
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mitochondria of live attached cells to yield a blue formazan product, which can be 
extracted, and quantified by absorbance spectroscopy. ECs were seeded onto the gels at a 
density of 1 × 104 and cultured for 2 wks. The number of live, attached cells on each set 
of samples was quantified at 1 and 14 days, respectively, after seeding. At the end of the 
culture period, medium was aspirated from the wells, and the gels with adherent cells 
were transferred to fresh wells. Gels were briefly rinsed with 1× PBS to remove 
unattached cells. A 2-ml aliquot of 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) reagent (1 mg/mL in phenol red-free DMEMF12) was added to each gel 
and incubated for 3 h at 37°C. Each sample was then overlaid with 2 ml of n-propanol 
and mixed for 15 min on a rotary shaker. The formazan product produced by cells was 
extracted by the propanol, 200 µl of the extract was pipetted into micro-well plates, and 
the absorbance was measured at λ = 550 nm (n = 4). Background absorbance from 
control wells containing no cells was subtracted from the sample absorbance 
measurements. For use as standards, between 5 × 103 and 3 × 105 ECs were seeded in 6-
well polystyrene culture plates and allowed to attach overnight before they were 
quantified. 
 
5.2.15 Immunolabeling for EC CAM Expression 
 Expression levels of CAM (ICAM-1, VCAM-1) by ECs cultured on HA 
hydrogels were compared by immunofluorescence and quantified by calculating the mean 
fluorescence intensity (MFI) on a per cell basis. ECs were seeded onto the gels at 2 × 104 
and cultured for 1 wk prior to analysis. The cells were then fluorescently labeled for 
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CAM expression, as described in section 4.2.12, and imaged on a TCS SP2 AOBS 
confocal microscope (Leica) using the z-axis function to image 5 µm sections on the 
concave surface of the gels (n = 9) at a constant gain and offset (FITC - 650, 0.8). Draq 5 
(1:2000 in PBS, 10 min; Biostatus) was also used to fluorescently label the cell nuclei. 
These sections were then compressed into a single image prior to MFI per cell 
calculations using Image J. 
 
5.2.16 Statistical Analysis 
All experiments were performed in triplicate with triplicate samples/ cultures per 
formulation, unless otherwise mentioned. Statistical significance between and within 
groups was determined using Microsoft Excel’s statistical function for t-tests, assuming 
unequal variance and two-tailed distribution. Differences were considered statistically 
significant at p < 0.05.  Quantitative results are reported as mean ± standard deviation. 
 
5.3 Results 
5.3.1 Crosslinked HA Hydrogels 
 HMW HA and HA oligomers (D2) were combined into hydrogels by crosslinking 
with DVS, resulting in 8 total gel formulations: 2 crosslinking concentrations (1:1, 1:2 
w/w DVS:HA) × 4 oligomer concentrations (0, 5, 10, 20% w/w D2/HA). Figure 5.3 
shows the swollen hydrogels crosslinked in 0.79 cm2 molds and their measured 
dimensions. The HA oligomer (D2) content appeared to minimally affect hydrogel size 
with limited increases in height (h) and diameter (d). On the other hand, increasing the 
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DVS content drastically reduced the size of the gels resulting in more compact strands of 
HA and an opaque coloration. 
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Figure 5.3 Size of swollen DVS-HA hydrogels. Increasing the amount of DVS within the gels resulted in 
reduced gel sizes and an opaque coloration. Measuring the dimensions of the DVS-HA hydrogels showed 
that both height (h) and diameter (d) of the cylindrical gels also slightly increased with HA oligomer 
content. The ruler marks cm increments. 
 
 
5.3.2 FTIR Spectroscopy 
 FTIR-ATR spectra of dried DVS-HA and the corresponding starting material of 
uncrosslinked HA were measured. Spectra were taken of HA, and DVS-HA with all 
concentrations of D2 (0, 5, 10, 20% w/w) and DVS (1:1, 1:2 w/w), but, due to their 
similarity, Figure 5.4 shows only a spectrum representative of all DVS-HA formulations 
in comparison to uncrosslinked HA. The spectrum of HA agrees well with that provided 
by the American Society for Testing of Materials (ASTM). The most significant 
difference between DVS-HA and HA is the higher intensity of the absorption band at 
1284.14 cm-1 in the DVS-HA spectrum, which corresponds to the presence of sulfonyl 
groups 320. 
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Figure 5.4 FTIR-ATR spectra of DVS-HA (A) and uncrosslinked HA (B). The most significant difference 
between HA and DVS-HA is the higher intensity absorption band at 1284.14 cm-1 in the DVS-HA spectra 
indicating the presence of sulfonyl groups, specific to DVS.  
 
 
5.3.3 Hydrogel Oligomer Content 
 D2 oligomers were tagged with AMAC prior to crosslinking within DVS-HA in 
order to verify that the relative differences in HA oligomer content within DVS-HA were 
maintained upon crosslinking. By this method, we sought to monitor the retention of 
these oligomers within the hydrogels in their swollen state, and upon their further, long-
term incubation in PBS. Higher D2 content within the DVS-HA gels corresponded with 
increased fluorescence intensity, in gels of both crosslinker concentrations (Figure 5.5). 
However, 1:1 w/w DVS-HA gels fluoresced to a greater degree than 1:2 w/w DVS-HA 
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gels and their fluorescence intensity was relatively stable over 21 days of incubation in 
PBS. Gels containing 1:2 w/w ratios of HA to DVS showed a sharp increase in 
fluorescence intensity between day 0 and 1, and a mild decrease in fluorescence intensity 
was observed between day 1 and 14 but remained constant thereafter. 
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Figure 5.5 Fluorescence intensities of HA oligomers (D2) embedded within DVS-HA. The number of 
oligomers within 1:1 w/w DVS-HA (A) appeared to remain constant, whereas the oligomer content of 1:2 
w/w DVS-HA (B) decreased slightly before reaching a plateau. However, within both DVS concentration 
groups, the differences in oligomer content were maintained. [* denotes a p-value < 0.05 in comparison to 
day 1] 
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5.3.4 Hydrogel Crosslinking 
 The apparent crosslinking density and swelling ratio of DVS-HA were used to 
estimate the degree of crosslinking within the hydrogels. The results show apparent 
crosslinking density (Table 5.1) and swelling ratio (Figure 5.6) were dependant on both 
concentrations of DVS and presence of D2. For a given crosslinker to HA ratio, the 
addition of D2 into the hydrogel construct increased the swelling capacity of the gels 
over gels composed only of HA 1500 though the extent of swelling did not appear to 
depend on the D2 concentrations. On the other hand, the apparent crosslinking density 
decreased in direct correlation with increases in concentration of D2, when other 
formulation parameters were unchanged. For each D2 concentration, increasing the 
incorporated amounts DVS within the gels reduced their ability to swell and increased 
their apparent crosslinking density. The differences in apparent crosslinking density, for 
each D2 concentration, was maintained at approximately a factor of 3. However, the 
measured crosslinking density was much lower than the calculated theoretical value, 
assuming 100% DVS reaction, resulting in an overall crosslinking efficiency of 10 – 15% 
for 1:1 w/w DVS-HA and 15 – 20% for 1:2 w/w DVS-HA. 
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Table 5.1 Apparent crosslinking density of DVS-HA determined from the uniaxial compression data and 
Eq 5.1. Overall, 1:1 DVS-HA (A) exhibited a higher apparent crosslinking density than 1:2 DVS-HA (B). 
The addition of D2 into the hydrogels reduced the apparent crosslinking density and these values were 
approximately 10 – 20% of the estimated theoretical values assuming 100% DVS bonding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Swelling ratios of DVS-HA. The incorporation of D2 within the DVS-HA hydrogel mildly 
increased their swelling capacity irrespective of the crosslinking density. The swelling ratio was 
dramatically increased by a greater concentration of DVS within the gel. [* denotes a p-value < 0.05 in 
comparison to 0%] 
 
 
5.3.5 Hydrogel Stiffness and Resistance to Degradation 
 Rheological analysis provided the quantitative evaluation of the viscous and 
elastic responses of DVS-HA with varying concentrations of D2 and DVS providing 
information on their stiffness. In general, both the storage moduli (G’) and loss moduli 
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(G”) for all cases were independent of frequency and G’ values were always higher than 
G”, as seen in Figure 5.7. As expected, a greater crosslinking density increased the 
hydrogel stiffness (G’), however, the addition of D2 within the hydrogel decreased its 
stiffness. 
 To determine the biodegradability of the DVS-HA hydrogels, we tested the 
sensitivity of the gels to a super-physiologic concentration of bovine testicular 
hyaluronidase. The degradation profiles of the stronger (less stiff) 1:1 w/w DVS-HA 
(Figure 5.8A, Table 5.2A) resulted in lower degradation rates than 1:2 w/w DVS-HA 
(Figure 5.8B, Table 5.2B), indicating a greater resistance to enzymatic digestion. Greater 
concentrations of D2 also increased the degradation rates of the hydrogels. 
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Figure 5.7 Viscoelastic properties of DVS-HA. The storage moduli (G’) in all cases are greater than the 
loss moduli (G”). Increasing the concentration of DVS within the hydrogel, 1:1 w/w (A) vs. 1:2 w/w (B) 
DVS-HA, resulted in a greater G’ and overall stiffness of the gels. The addition of D2, however, reduced 
the storage moduli indicating lowered stiffness of the hydrogels. 
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Figure 5.8 Degradation of DVS-HA in vitro. Hydrogels with a greater concentration of DVS, i.e., 1:1 w/w 
(A), vs. 1:2 w/w (B) DVS-HA, exhibited greater stability against degradation by testicular hyaluronidase. 
However, increasing the concentration of D2 within each of these gel formulations enhances the 
degradation rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 Degradation rate of DVS-HA in vitro. A greater DVS concentration, i.e. 1:1 w/w of DVS to HA 
(A) vs. a 1:2 w/w ratio (B) within DVS-HA gels, and increasing the D2 content, resulted in a higher rate of 
degradation when incubated with testicular hyaluronidase enzyme. 
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5.3.6 Hydrogel Surface Morphology 
 SEM shows the change in surface morphology of hydrogels that were dehydrated. 
The dehydration process resulted in ripple formation on the surface of the gels (Figure 
5.9). However, increases in DVS and/or HA oligomer (D2) content appeared to reduce 
the formation of these ripples. Also, hydrogels with a higher concentration of D2 
possessed a surface topography that appeared more granular, potentially forming a 
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surface with a greater roughness. 
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Figure 5.9 Surface morphology of DVS-HA. The dehydration process resulted in the development of 
ripples on the surfaces of the hydrogels, with bulkier ripples visible on 1:2 w/w DVS-HA gels (B) than on 
1:1 w/w DVS-HA gels (A). The addition of D2 reduced ripple formation and rendered the surface more 
granular. 
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5.3.7 Hydrogel Biocompatibility 
 In all cases, H&E staining revealed a distinct ring of cellularized tissue around the 
defect created by the implant. The thickness of this highly cellularized region appeared to 
increase with increases in DVS concentration and with HA oligomer content (Figure 
5.10). Since the cells were not flattened, and did not show alignment with collagen fibers, 
typical of fibroblasts, it is highly likely that these were inflammatory cells. Additionally, 
the fact that these cells were present around all implants and indeed were far more 
numerous around select gels, with a reduced presence of collagen (Figure 5.11), 
strengthens our hypothesis that these cells are inflammatory and not fibroblasts. As can 
be seen in Figures 5.10, the gels containing the greater concentration of DVS crosslinker 
(panels A in both figures) stimulated much greater inflammatory cell recruitment (see 
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darkened region near defect) than the less robustly crosslinked gels (panels B). The cells 
distributed farther from the implants appeared more flattened, and aligned with matrix 
fibers, and are thus likely to be fibroblasts. Immunofluorescence studies (Figure 5.11) 
confirmed these results in that greater cellularity (blue) was noted in the region 
immediately surrounding all the implants, than further afield, and that the thickness of 
this layer was greater around gels that contained (a) greater DVS content and (b) higher 
oligomer content. These studies also confirmed a depletion in collagen (green) 
immediately surrounding the defect region. Very little tissue infiltration was observed 
within DVS-HA, as compared to the matrigel control (Figure 5.12). The defect 
containing 1:1 w/w DVS-HA gel implant was consistently void of any inward tissue 
projections. However, some tissue projections were observed for 1:2 w/w DVS-HA gels.  
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Figure 5.10 Biocompatibility of DVS-HA. In all cases, a distinct, darkened ring of inflammatory cells (see 
arrows) surrounded the implant and the thickness of this highly cellular region appeared to be increase with 
DVS concentration. Hydrogels with a greater DVS concentration, 1:1 w/w (A) vs. 1:2 w/w (B), stimulated 
an enhanced inflammatory response from the surrounding tissue that was greater than the matrigel control. 
Likewise, gels containing greater HA oligomer (D2) content, appeared to incite a greater inflammatory 
response, though these effects were muted compared to the impact of DVS crosslinking. 
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Figure 5.11 Immunofluorescence analysis collagen I surrounding implant. Gels containing greater 
crosslinker (DVS) content (A) prompted greater cellularity in the region surrounding the gels than the gels 
in panel B, or controls. However, the collagen I (green) content appeared depleted immediately 
surrounding the implant. The recruitment of the inflammatory cells (blue) appeared to be enhanced by 
increasing HA oligomer (D2) content. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Tissue infiltration into DVS-HA. Very little tissue infiltration was observed within DVS-HA, 
as compared to the matrigel control. The implant region of DVS-HA 1:1 w/w (A) remained consistently 
void of inward tissue projections. However, some tissue projections (see arrows) were observed in DVS-
HA 1:2 w/w (B). 
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5.3.8 EC Morphology and Protein Adsorption 
 Upon seeding ECs on uncoated DVS-HA hydrogels, we found that ECs attached 
readily and the incorporation of D2 within the gels appeared to enhance the extent of 
attachment. However, these ECs exhibited a rounded morphology even 2 weeks after 
seeding, different from those ECs cultured on polystyrene (PS), which exhibited a more 
typical cobblestone shape (Figure 5.13). Therefore, the cell-adhesive proteins of matrigel 
were adsorbed onto the surfaces of the DVS-HA gels. The total protein content within the 
bulk matrigel-coating suspention decreased following incubation with DVS-HA gels 
indicating successful adsorption of protein onto the hydrogel surfaces (Figure 5.14). The 
total amount of protein adsorbed onto 1:2 w/w  DVS-HA gels was greater than the 1:1 
w/w DVS-HA gels but when adjusted for increased swelling, and therefore increased 
surface area (SA), of 1:2 w/w DVS-HA (SA = 3.8 ± 0.3 cm2 for 1:2 w/w DVS-HA gels 
vs. 2.4 ± 0.1 cm2 for 1:1 w/w DVS-HA gels) we found the adsorbed protein density was 
the same on gels containing both crosslinker densities. Likewise, regardless of 
crosslinker amounts, matrigel adsorption on the gels was independent of the content of 
incorporated HA oligomers (D2), see Figure 5.14. ECs cultured atop these matrigel-
adsorbed DVS-HA gels appeared more spread, and exhibited a natural cobblestone 
morphology (Figure 5.15). Therefore, all further culture studies were performed only 
with matrigel-adsorbed DVS-HA hydrogels. This spread cobblestone morphology of ECs 
cultured atop matrigel-adsorbed gels was more readily apparent when visualized after 
calcein AM staining (Figure 5.16). ECs appeared as isolated clusters on 1:2 w/w DVS-
HA gels (B), while on 1:1 w/w DVS-HA gels (A) ECs were more homogeneously 
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distributed. 
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Figure 5.13 Attachment and morphology of ECs cultured on DVS-HA gels. Very little difference in the 
attachment and morphology of ECs was observed between 1:1 w/w (A) and 1:2 w/w DVS-HA. The 
addition of D2 clearly increased the number of adherent ECs; however, the cells remained rounded 
exhibiting an abnormal rounded morphology. 
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Figure 5.14 Matrigel adsorption onto DVS-HA gel. A drop in protein content within the bulk coating 
suspension was observed indicating protein adsorption onto the gel surfaces. Calculations revealed that 
protein was the same on all DVS-HA gels, regardless of crosslinker density. [* denotes a p-value < 0.05 in 
comparison to no gel] 
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Figure 5.15 EC morphology atop DVS-HA gels with surface-adsorbed matrigel. The addition of matrigel 
allowed the ECs to spread and assume a more native-like cobblestone morphology and enhanced 
attachment to some extent as well. No difference in cell morphology was observed between 1:1 w/w (A) 
and 1:2 w/w (B) DVS-HA gels. 
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Figure 5.16 Morphology of ECs cultured on matrigel-adsorbed DVS-HA gels. The incorporation of D2 
enhanced EC adherence on the gels. The ECs appeared to spread and exhibited a natural cobblestone 
morphology similar to cells cultured on fibronectin. ECs appeared as isolated clusters on 1:2 w/w DVS-HA 
(B), while on 1:1 w/w DVS-HA (A) ECs were more uniformly distributed. 
 
 
5.3.9 EC Proliferation 
 All gel formulations, irrespective of DVS and D2 content adsorbed identical 
amount of matrigel on a per unit area basis, therefore, any proliferation differences were 
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purely an affect of oligomer content and/or DVS concentration. In absence of any 
oligomers, EC proliferation on 1:1 DVS-HA hydrogels was greater than the less 
crosslinked 1:2 w/w DVS-HA gels (Figure 5.17). This difference was maintained even 
when the HA oligomers were incorporated into the gels. Within each crosslinking group, 
EC proliferation increased in direct correlation with incorporated D2 amounts. However, 
even on the gels incorporating the highest amounts of D2 (i.e. 20%), EC proliferation 
over 14 days of culture was much lower relative to those ECs cultured on matrigel and 
fibronectin substrates. 
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Figure 5.17 Proliferation of ECs cultured on DVS-HA. 1:1 w/w DVS-HA stimulated greater EC 
proliferation than 1:2 DVS-HA, as did increased D2 concentration within either gel type. In all cases, the 
ECs were able to interact with the embedded oligomers enhancing proliferation. However, EC proliferation 
levels on these gels were lower than that attained by ECs cultured on matrigel and fibronectin substrates. [* 
denotes a p-value < 0.05 in comparison to 0%] 
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5.3.10 EC CAM Expression 
 It is apparent from the fluorescent images that the ICAM expression levels 
(Figure 5.18) of ECs cultured on matrigel-coated DVS-HA are similar to ECs grown on 
fibronectin substrates and matrigel surfaces, and much lower than TNF-α-stimulated ECs. 
Quantification of these expression levels confirmed this observation and additionally 
showed ICAM expression to remain unchanged upon incorporation of D2 into DVS-HA 
(Figure 5.20). VCAM-1 expression levels (Figures 5.19, 5.20) were also unaffected by 
D2 content within DVS-HA gels and remained much more attenuated in comparison to 
TNF-α stimulated ECs. However, VCAM-1 expression of ECs was slightly elevated 
beyond ECs cultured on pure matrigel and fibronectin substrates. 
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Figure 5.18 ICAM-1 expression of ECs cultured on DVS-HA. Similar ICAM-1 expression was detected on 
all DVS-HA formulations and the degree of expression appeared similar to the fibronectin and matrigel 
controls, and much lower than TNF-α stimulated ECs. 
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Figure 5.19 VCAM-1 expression of ECs cultured on DVS-HA. Similar VCAM-1 expression was detected 
on all DVS-HA formulations and remained below TNF-α stimulated ECs, however, the expression level 
appeared elevated beyond that of the fibronectin and matrigel controls. 
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Figure 5.20 Quantification of ICAM-1 and VCAM-1 expression of ECs cultured on DVS-HA. This 
confirms the fluorescence intensity of each EC CAM remained the same on all DVS-HA formations. While 
the fluorescence intensity of ICAM-1 (A) was suppressed to similar levels as fibronectin and matrigel, 
VCAM-1 (B) expression was slightly elevated compared to the controls. Both ICAM-1 and VCAM-1 
expression levels did not reach that of TNF-α stimulated cells. [* denotes a p-value < 0.05 in comparison to 
fibronectin] 
 
 
5.4 Discussion 
 In order to create a long-term HA implant, it must be converted into a stable, 
biocompatible, insoluble biomaterial with good handling properties and mechanics 
appropriate to the site of implantation. Chemical modification has been well recognized 
as a means to enhance the biostability and mechanical properties of native HA. Two 
possible methods to modify HA are through derivatization and cross-linking, both of 
which can be achieved through reactions between the available functional groups of HA 
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(-COOH, -OH). In the current study, we chose to use DVS to crosslink the hydroxyl (-
OH) groups on the HA chains under alkaline conditions to yield stable hydrogels 
containing sulfonyl-bis-ethyl linkages, as has been shown in Figure 5.1. Such 
crosslinking produces a network of HA chains that is no longer water-soluble. Limited 
studies have suggested that crosslinked HA gels containing a low concentration of DVS-
HA retain the biologic characteristics of un-crosslinked HA, especially their high 
biocompatibility 321. DVS-HA exhibit significant flexibility in their mechanical properties 
and rheology, ideal for a wide variety of medical applications. For this reason, a number 
of clinical products approved by the Food and Drug Administration based on this 
formulation have been generated for use as post-surgical anti-adhesive films, ocular 
fillings, and joint lubricants, among others 322,323. However, it is to be noted that all these 
applications do not involve substantial cell interactions with the biomaterial, and instead 
capitalize on the poor cell binding properties of DVS-HA. In other words, the 
applications have capitalized on the physical and mechanical properties of these gels 
rather than their biologic interaction with host cell types. 
 Previous studies have suggested that DVS-HA gels containing long-chain HA 
(MW>1 × 106 Da) interact poorly with cells and exhibit poor mechanics, both of which 
are detrimental to our intended use of them as cellular scaffolds for tissue regeneration 
306,324. This has been attributed variously to their physical properties (porosity, pore size, 
extreme hydrophilicity), chemical characteristics (anionicity, degree of hydration, 
crosslinker), and biologic composition (long-chain vs. fragmented HA). Of these 
parameters, the size of component HA chains seem to most critically influence cell 
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response. Native long-chain HA has been implicated in cell excluding mechanisms, 
whereas HA fragments, especially HA oligomers, elicit enhanced cell responses, 
although these may be exaggerated and undesirable 325. The use of HA gels as tissue-
engineering scaffolds may thus necessitate a need to optimize gel composition, 
derivatization and crosslinking chemistries, and post-formulation tailoring strategies to 
more closely modulate the physical and biologic characteristics to elicit ideal cell 
responses specific to target cell type on one hand and maintain material biocompatibility 
on the other. To enhance cell attachment, we have previously developed two techniques 
to micro-texture the gel surface by controlled exposure to UV light and γ-irradiation 
220,317. We demonstrated that both UV treatment and γ-irradiation alter the surface 
topography to create a less-uniform and ridged surface, more conducive to cell adherence 
and spreading. However, the greater impetus to ready cell adherence and proliferation on 
these irradiated gels was found to be due to shorter sized HA fragments generated on the 
gel surfaces by splicing of long-chain HA by random ionization caused by irradiation. 
Since the effects of UV and γ-irradiation are highly variable, such methods are neither 
closely replicatable nor easily controlled, so that gels with predictable and bioactivity and 
other biologic and physical properties are difficult to create. Accordingly, we decided to 
explore the possibility of directly incorporating HA oligomers into DVS-HA scaffolds 
thereby influencing cell behavior in a predictable and controlled manner. 
 In this study we explore the concept of incorporating bioactive HA oligomers into 
DVS-crosslinked mixtures of long-chain HA, to create standalone biomaterials for use as 
vascular scaffolds capable of functional and complete endothelialization. As mentioned 
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above, studies have shown that DVS-crosslinked HA containing only HMW HA do not 
support cell attachment due to the extremely hydrophilic nature and anionicity of HMW 
HA which renders the surface thermodynamically unfavorable for cell adherence and 
spreading. In an attempt to reduce the anionicity of these gels, we sought to incorporate 
HA oligomers to potentially enhance cellular attachment to the gel surface. As described 
in chapter 3, we demonstrated exogenous supplements of a mixture of HA oligomers 
(D2), containing predominantly 6mers and 12mers, stimulated proliferation, angiogenesis 
and the secretion of angiogenic growth factors by cultured ECs in vitro. Further, 
immobilization of derivatized D2 mixtures onto 2-D cellular substrates did not alter their 
modulation of EC behavior, reinforcing our hypothesis that HA oligomers may be 
chemically derivatized, as often required for formulating biomaterials, and yet retain their 
innate biologic properties. However, under both presentation modalities (exogenous vs. 
surface-immobilized), this HA oligomer mixture somewhat elevated EC expression of 
inflammatory CAMs. To circumvent these problems, we reason in the current study that 
incorporation of these oligomers within crosslinked constructs containing bioinert, HMW 
HA would temper the inflammatory effects of HA oligomers, while stimulating the 
adhesion and proliferation of ECs. In addition, the presence of HMW HA in crosslinked 
form would allow us to create solid biomaterials that may be handled easily, unlike the 
fluid mixtures that result when HA oligomers alone are crosslinked. 
 FTIR analysis found the stretching bands of carboxyl (-COOH) and acetamido 
groups (CH3COONH) in DVS-HA were identical to those in HA, indicating that the 
carboxyl group is not involved in the crosslinking reaction. The retention of the carboxyl 
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groups is considered essential to maintaining the polyanionic character of HA, and 
therefore it is important to preserving its natural physicochemical and biological 
properties. Aside from the sulfonyl group absorption band, the infrared spectrographs of 
DVS-HA were indistinguishable from HA implying the basic structure of HA and hence 
its function was maintained as DVS-HA. However, the ability of DVS to stably crosslink 
HA oligomers (D2) into the bulk material of the hydrogel was still unknown and of 
concern. 
 In order to determine the initial incorporation and long-term retention of D2 
within DVS-HA, the intensity of fluorescently-labeled D2 was monitored. Greater D2 
concentrations within the gels resulted in higher fluorescence intensities at all analysis 
time points indicating that a difference in D2 content was maintained between the 
difference formulations. A difference in fluorescence intensity between 1:1 w/w and 1:2 
w/w DVS-HA gels was noted, which is likely due to a difference in UV penetration 
through gel during imaging. 1:2 w/w DVS-HA swelled to greater degree than 1:1 w/w 
DVS-HA resulting in gels with a higher water content and, therefore, lower polymer 
density. During the 200 ms exposure time that was adopted for all gels, the 
transluminating UV light was able to penetrate farther through these low density gels 
stimulating more oligomers to fluoresce. This idea is reinforced by the fluorescence data 
of 1:2 w/w DVS-HA between day 0 and 1. Directly after crosslinking (day 0), the 
fluorescence levels of 1:2 w/w DVS-HA are similar to 1:1 w/w DVS-HA. However, upon 
incubation in PBS, 1:2 w/w DVS-HA swelled allowing more UV penetration and 
increased fluorescence. In case of 1:1 w/w DVS-HA gels, the fluorescence intensity was 
 204
maintained constant through the entire period of incubation in PBS, suggesting 
significant retention of the incorporated HA oligomers. On the other hand, an overall loss 
in fluorescence was observed from the 1:2 w/w DVS-HA gels over time. We believe that 
the lower DVS concentration within these gels may be insufficient to chemically 
crosslink all of the added D2 and that the un-reacted D2 was merely physically entrapped 
within DVS-HA during the crosslinking process. Upon incubation within PBS, un-
reacted D2 began to elute out of the hydrogel leaving only chemically-crosslinked D2 
within the hydrogel after 14 days.  
 Materials fabricated from naturally occurring molecules are more susceptible to 
degradation within the body due to presence of enzymes that specifically target these 
molecules. The turnover of HA within the body is relatively rapid compared to other 
ECM molecules (33% weight loss per day). The half-life of HA circulating in the blood is 
5 minutes and that in the skin epidermis is half a day, while collagens have half-lives of 
several weeks 30,224. High molecular weight HA (HMWHA) is degraded extracellularly 
through both enzymatic and non-enzymatic processes. Enzymatic degradation occurs 
physiologically through the action of hyaluronidases, chondroitinases and 
hexosaminidases. Non-enzymatic degradation of HA, on the other hand, occurs almost 
solely following tissue injury and during inflammation, and involves mediation of 
reactive oxygen species (ROS), hydrogen peroxide (H2O2) and hydroxyl radicals (OH-) 
225,226. In this study we hoped that DVS crosslinking of HA would decelerate and possibly 
inhibit its natural breakdown. However, we found DVS-HA to still be susceptible to 
degradation. Therefore, we investigated the impact of incorporated oligomer content and 
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extent of crosslinking on the rate of degradation of DVS-HA gels when exposed to a 
super-physiologic concentration of testicular hyaluronidase in vitro. The degradation 
rates of these gels were influenced by the hydrogel swelling capacity (and thereby 
enzyme concentration within the gels) and apparent crosslinking density (or HA bonding 
with the gels). DVS-HA containing higher concentrations of DVS (1:1 w/w DVS-HA) 
and a lower D2 content exhibited reduced capacity for hydration, and thus, lower 
swelling ratios, which restricted the entry of enzymes from the bulk solution into the gel 
interior. The greater amount of bonding within these hydrogels (measured by the 
apparent crosslinking density) also required the enzymes to work longer to breakdown 
these gels, as is clear from the data presented in Figure 5.8. 
 Rheological analysis provided a quantitative evaluation of the viscous and elastic 
responses of DVS-HA. Both the storage moduli (G’) and loss moduli (G”) are 
independent of frequency and G’ values are always higher than G”, which is typical of a 
“strong hydrogel”, whose answer to oscillating frequency is more similar to a solid than a 
liquid. By increasing the concentration of DVS within these gels we were able to obtain 
G’ (1400 – 3000 Pa) and G” (10 – 40 Pa) that were much higher than commercially 
available DVS-HA products for soft tissue augmentation; the G’ and G” of Hylaform (a 
dermal filler) are 185 Pa and 21 Pa, respectively, at 3.0 Hz 321. However, vascular 
regenerative applications demand far more resilient biomaterials then does skin due to the 
dynamic and strenuous environment of blood vessels. A completely sulfated form of 
hyaluronic acid (Hyaff), which has shown potential as a regenerative vascular grafting 
material (but yet not particularly conducive to endothelialization), possesses G’ and G” 
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values on the order of 420 kPa and 17 kPa, respectively, at 1 Hz 256,326. The high strength 
of this and other successful vascular grafting materials indicates that our DVS-HA 
hydrogels would not by themselves be suitable for use as a vascular scaffolding materials, 
but rather must be composited with other existing natural or synthetic graft materials, at 
least from the standpoint of surviving the forces experienced in a vascular environment. 
 SEM was used to evaluate the changes in surface morphology of dehydrated 
hydrogels as a function of D2 and crosslinker content. Dehydration itself caused the gels 
to shrink, drawing the HMW HA strand toward one-another and the appearance of 
ripples on the gel surface. Higher concentrations of DVS (i.e., 1:1 w/w DVS-HA) 
restricted the movement of the HA 1500 strands to a greater degree, preventing ripple 
formation. The addition of D2 enhanced the ability of the hydrogel structure to compact, 
avoiding the need to create folds on the surface. Also, hydrogels with a higher 
concentration of D2 possessed a surface topography that appeared more granular, 
potentially forming a surface with a greater roughness and more conducive to cell 
attachment. Previous studies 327 showed that surface roughness, both at the level of cell 
adhesion (1 µm) and the level of protein adsorption (50 nm), can stimulate cell 
attachment. Likely, in our case, these physical changes to the gel surface must contribute 
in some manner to enhanced cell adherence to gels with incorporated D2 oligomers, 
although the predominant effect may be due to cell signaling. 
 In all cases, a distinct ring of inflammatory cells surrounded the implant and the 
thickness of this highly cellular region appeared to be dependant on DVS concentration. 
Hydrogels containing greater DVS-crosslinker densities stimulated an enhanced 
 207
inflammatory response from the surrounding tissue. Free-form DVS is known to be toxic, 
though, it has been shown to be biocompatible when used as a crosslinker for HA at low 
concentrations 328. Here we show that the higher DVS concentrations, required from the 
standpoint of imparting good biomaterial handling properties and improved mechanics, 
results in an exaggerated inflammatory tissue response. The region around the implants 
also contained less collagen I than further afield, strongly suggesting that the dense 
population of cells in this region are inflammatory, and not collagen-producing 
fibroblasts. The primary cell types that respond to subcutaneous implants are typically 
fibroblasts and inflammatory cells. Fibroblast attempt to isolate the implant by 
surrounding it with a collagen I-rich fibrous capsule, while inflammatory cells degrade/ 
digest the implant. The lack of collagen I adjacent to the implant indicates an absence of 
fibroblastic activity. In addition, very little tissue infiltration was observed within DVS-
HA, as compared to the matrigel control. The defect containing 1:1 w/w DVS-HA gel 
implant remained consistently void of inward tissue projections, though, some tissue 
projections were observed in 1:2 w/w DVS-HA gels, possibly due to the lower 
crosslinking density (lowered stiffness), which enables cells to readily infiltrate. 
 The goal of this work was to incorporate HA oligomers into a DVS-crosslinked 
gel containing HMW HA in order to promote EC attachment/proliferation on the 
hydrogel surface, while tempering the inflammatory cell response to HA oligomers by 
the presence of HMW HA. We found that ECs, cultured in vitro, attached onto gels with 
incorporated D2, and the D2 content appeared to enhance this attachment. However, the 
EC maintained a rounded morphology throughout the culture period. Two factors 
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influence cell morphology are surface charge and substrate hydrophilicity. Negatively-
charged cells adhere far less strongly to substrates containing acidic or neutral groups 
than to those with basic (positively charged) groups 329. In addition, the DVS-HA gels are 
very hydrophilic in nature and therefore contain a high water content. Previous studies 
have shown that extremely hydrophilic surfaces are thermodynamically unfavorable for 
cell attachment 330. As a cell-binding ligand and via its ability to enhance surface 
roughness, D2 was able to promote EC adherence but the extreme anionicity of HMW 
HA and exuberant water content of DVS-HA gels dissuaded the ECs from spreading. 
Matrigel is a mixture of predominantly laminin and collagen IV, a substrate similar to the 
natural basement membrane of blood vessels. In order to promote EC spreading, a low 
concentration of matrigel was adsorbed onto the hydrogel surfaces, which allowed the 
ECs to exhibit their natural morphology while interacting with the HMW HA and HA 
oligomers also present on the hydrogel surface. Matrigel was successfully adsorbed onto 
the hydrogel surfaces and the Dc protein assay showed the concentration remained 
constant (~12 µg/ cm2) on all hydrogel formulations. The natural cobblestone 
morphology of ECs on matrigel adsorbed DVS-HA indicate the adsorption process did 
not alter the conformation of laminin and collagen IV, a common problem with synthetic 
materials (i.e. polymethylmethacrylate). However, ECs remained fairly clustered in 
isolated locations on 1:2 w/w DVS-HA. This is likely due to the higher water content and 
anionicity of 1:2 w/w DVS-HA isolating cell attachment to specific regions of the 
hydogel surface. It is interesting to note that compared to ECs cultured on pure matrigel, 
those cultured on matrigel-coated HA gels, free of HA oligomers, exhibited much lower 
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levels of proliferation. This suggests that matrigel surface coatings of low density on the 
HA gels primarily influenced cell adherence and morphology, not proliferation. However, 
EC adherences and proliferation enhanced as a direct function of D2 content. This 
suggests that the ECs were able to interact with the embedded oligomers and as a result, 
up-regulate proliferation. Therefore, we can conclude that the incorporation of HA 
oligomers into vascular scaffolding constructs is beneficial to endothelialization by the 
promotion of EC proliferation. We believe the level of proliferation did not attain that of 
fibronectin and matrigel due to the vast excess of HMW HA on the hydrogel surface, 
which suppresses the effects of the HA oligomers. The level of ICAM-1 expression by 
the ECs was also suppressed by HMW HA. HA oligomers elevated both ICAM-1 and 
VCAM-1 expression of ECs when presented as an exogenous supplement or immobilized 
surface but when these oligomers were embedded within HMW HA, EC ICAM-1 
expression remained similar to DVS-HA without HA oligomers and the fibronectin 
control. VCAM-1 expression, on the other hand, was elevated on all DVS-HA hydrogels 
irrespective of HA oligomer concentration. Possibly, this may be due to the high 
concentration of DVS within these hydrogels, which was also found to stimulate an 
exaggerated inflammatory response in the subcutaneous in vivo model. 
 
5.5 Conclusions 
 In this study, we successfully developed hydrogels composed of high molecular 
weight HA and its oligomers, as potential biomaterials for the regeneration of luminal 
ECs of blood vessels. We showed the mechanical (degradation, viscoelasticity) and 
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physical (crosslinking density, surface structure, swelling) properties of these hydrogel 
can be adjusted by varying the crosslinker and oligomer densities within them. However, 
the overall strength of these hydrogels is too low for vascular applications as a stand-
alone material and therefore, may only be used as a composite material. The presence of 
oligomers within DVS-HA seemed to enhance EC attachment and proliferation, 
supporting the notion that HA oligomers are more conducive to EC growth than other 
forms of HA. However, the high concentration of DVS, required to impart good handling 
properties of these gels, appeared to be somewhat toxic resulting in enhanced 
subcutaneous inflammatory response and VCAM-1 expression by ECs. Therefore, 
another crosslinker may be more appropriate to use, which could result in better 
mechanics and improved biocompatibility. In the case of such a formulation too, the HA 
oligomers would provide the stimulus for functional endothelialization. If no such 
crosslinker exists, a better approach might be to abandon the idea of a standalone HA 
vascular graft materials, and, as discussed in chapter 4, chemically derivatize and 
immobilize both HA oligomers and HMW HA in a controlled manner onto the lumenal 
surface of synthetic or tissue engineered grafts already in use, so that improved, 
predictable, and functional endothelialization may be achieved, while eliminating the 
need to address the biomechanics of the graft material at large. This method would also 
eliminate the need for crosslinking HA, which would likely circumvent the problems 
associated with crosslinker-mediated toxicity or inflammation. 
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CHAPTER 6 
THE IMPACT OF HA OLIGOMER CONTENT ON PHYSICAL, MECHANICAL, 
AND BIOLOGIC PROPERTIES OF GLYCIDYL METHACRYLATE -
CROSSLINKED HA HYDROGELS 
 
 
6.1 Introduction  
 As mentioned in chapter 2, tissue engineering is an emerging interdisciplinary 
field of bioengineering that aims to regenerate diseased or injured tissues using the 
building blocks of cells, growth factors and scaffolding cues. The field has gradually 
transitioned from one of synthetic scaffolds to the use of extracellular matrix (ECM), a 
naturally occurring cell scaffolds. These natural materials provide cells inherent 
biological instructive cues to guide their proliferation and differentiation. In addition, 
they have some remarkable advantages over synthetic materials including selective cell 
adhesion, mechanical properties similar to that exhibited by native tissues, and 
biodegradability, which allows complete re-sorption of the matrix after tissue 
regeneration is complete. A class of ECM molecules that are increasingly studied in the 
context of regenerative materials are glycosaminoglycans (GAGs). One such GAG, 
hyaluronic acid (HA), occurs naturally in connective tissues (e.g. skin) as a simple linear 
molecule consisting of repeating dissacharide units of N-acetyl-D-glucosamine and D-
glucuronic acid 17. Most cells have the ability to synthesize HA at some point during their 
cell cycle, signifying that the molecule has vital function in several fundamental 
biological processes 18.  
 In recent years, HA has been recognized as a potential biomaterial for effective 
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tissue regeneration. Biologically, HA has three known molecular functions: (1) It 
encompasses a large hydrodynamic domain, permitting it to form a physical barrier 
around cells shielding them from disturbances, or alternatively, creating an uninhibited 
pathway for migrating cells. (2) It interacts with HA-binding proteins, proteoglycans, and 
other structural molecules to form composite ECM structures that act as macromolecular 
cues for cellular synthesis and organization of tissues. (3) It binds to cell surface 
receptors (CD44, RHAMM) to help mediate important intracellular signaling pathways. 
As a result, HA is a critical regulator in many biological phenomina including embryonic 
development, tissue organization, wound healing, and angiogenesis. HA is also highly 
biocompatible and does not elicit a foreign-body response upon cross-transplantation due 
to the preserved structural homology of HA across species 18. For the same reason, HA 
meant for clinical use can be derived from many sources including bacterial fermentation 
and synthesized in large quantities 331. Though HA is enzymatically degraded in vivo by 
hyaluronidases 332, and completely resorbed via several metabolic pathways, it can be 
chemically derivatized and/or crosslinked into stable hydrogels or solid biomaterials 
253,256. Although the modes of interaction between HA and the human body are still 
incompletely understood, the favorable characteristics outlined above have recently 
prompted an investigation into its utility as a scaffolding biomaterial for tissue-
engineering applications, such as cartilage 20 and dermal 21 repair and regeneration. In 
this line of thinking, our lab is currently investigating the potential use of HA as an 
implant material for vascular regeneration. Since HA forms a significant (4-7% w/w) 
component of vascular ECM 22, we hypothesize that HA-derived biomaterials will mimic 
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the in vivo environment and provide healthy biomechanical and biochemical signals to 
cultured vascular cells.  
 Elastin is a critical structural protein in the medial layer of blood vessels, which 
facilitates their elastic recoil and provides the resilience necessary for cyclic distension 
and contraction 333,334. It is secreted as a soluble protein precursor (tropoelastin) by SMCs, 
recruited onto a microfibrillar template (fibrillin), and crosslinked by desmosine mediated 
by lysyl oxidase (LOX) 335. In addition to providing tissue elasticity, elastin also 
mechano-transduces SMC behaviour (e.g. proliferation) through binding to cell surface 
elastin–laminin receptors 6 to regulate SMC activity 42, particularly during vascular 
morphogenesis 336. Thus, disruption of elastin due to inflammatory diseases 42,337, direct 
mechanical injury 211 or its malformation in congenital and inherited conditions can 
encourage SMC hyperproliferation and medial thickening, leading to reduced arterial 
compliance and hypertension 338. In such cases, vascular elastin must be restored or 
regenerated as a priority. 
 Studies conducted by our group 31,32 have shown that HA oligomer mixtures (D1,  
see chapter 3) dramatically enhance elastin matrix deposition by adult SMCs; the 
extremely anionic high molecular weight (HMW) HA (> 1 × 106 Da) did not cause such 
up-regulation but appeared to benefit matrix deposition and fiber formation, possibly by 
causing physical coacervation of elastin precursors to facilitate their crosslinking. We 
also showed immobilization of the oligomers onto 2-D cellular substrates (i.e. glass) did 
not alter its stimulation of SMC elastin production (chapter 4), reinforcing our hypothesis 
that HA oligomers, when chemically derivatized, retain their innate biologic signaling 
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characteristics, and are thus amenable to formation of biomaterials. In addition, we 
reported successful synthesis and recruitment of elastin by SMCs seeded atop 
bioactivated HA hydrogels whose surface contained a mixture of bioinert HMW HA and 
shorter, more bioactive HA fragments and oligomers 220 generated in situ by prolonged 
UV irradiation of the gels. However, since the effects of UV light can be difficult to 
control and replicate, and potentially cause random ionizations that can be structurally 
disruptive, a better approach is to create ‘bioactivated’ gels containing bio-inert long-
chain HA, necessary to maintain mechanical integrity and potentially provide a high 
degree of biocompatibility, and smaller, more cell-interactive HA oligomers. In addition, 
it has been hypothesized that cells embedded within 3D scaffolds interact with each other 
and the surrounding scaffold in a more natural tissue environment than 2D culture and 
thus expected to more closely evoke native cell responses 339. To examine the efficacy of 
stimulating elastin regeneration by cells encapsulated in a 3D space, we propose to 
generate photo-crosslinked HA 264 hydrogels containing HA oligomers, encapsulate 
SMCs within them, and investigate their ability to regenerate elastin matrix. 
To date, the use of HA oligomers as biomaterials for enabling SMC mediated 
vascular elastin regeneration/ remodeling have not been thoroughly investigated. Also, 
the densities at which bioactive HA oligomers should be presented within such scaffolds 
to elicit the desired matrix regenerative responses, and yet not adversely impact gel 
handling, mechanics, and biocompatibility, are unknown. Therefore, in this chapter, we 
investigate the mechanical properties, biocompatibility, and elastin production of SMC 
elastogenesis encapsulated within oligomer-embedded HMW HA hydrogels crosslinked 
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with GM. 
 
6.2 Materials and Methods 
6.2.1 Preparation of HA Oligomer Mixtures 
 As mentioned in section 3.2.1, HA 1500 (MW = 1.5 × 106 Da) was enzymatically 
digested to produce a mixture of HA oligomers (D1). Briefly, HA 1500 (5 mg/ ml) was 
digested with bovine testicular hyaluronidase, (0.45 mg/ ml; 439 U/mg) in a solution of 
digest buffer (37 °C) for 18 h. The enzyme was then precipitated, its activity terminated 
by boiling (2 min), and cooled on ice. Following centrifugation (2800 rpm, 10 min), to 
separate the enzyme from the mixture, the supernatant was dialyzed in water (12 h) and 
then freeze-dried overnight to generate lyophilized HA oligomers. The mixture was 
analyzed by FACE and found to contain a broad range of oligomers (D1), specifically 
13.9 ± 3.6% w/w of HA 6mers and 8.0 ± 1.6% w/w of HA 12mers. 
 
6.2.2 Hydrogel Fabrication 
 HA hydrogels were crosslinked with glycidyl methacrylate (GM-HA) using a 
method based on one previously described (Figure 6.1) 264. Briefly, HA 1500 with added 
D1 (0, 5, 10, 20% w/w) was dissolved (10 mg/ ml) in DI water, then mixed with 
triethylamine (3.6% v/v; Sigma; a chemical catalyst), glycidyl methacrylate (GM, 3.6% 
v/v; Sigma; a crosslinker), and tetrabutyl ammonium bromide (3.6% w/v; Sigma; a phase 
transfer catalyst). The batch reaction was allowed to continue overnight (18h, 23°C) and 
finally completed by incubation of the mixture for 1 h at 60 °C. The aqueous product 
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(GM-HA) was recovered/ purified by precipitation in acetone, re-dissolved in DI water (3 
cycles), and finally precipitated in acetone (Sigma). The GM-HA precipitate was finally 
freeze-dried, and stored at -20 °C. To create hydrogels, GM-HA was dissolved in PBS 
(45 mg/ ml), and mixed with Irgacure 2959 (0.01% w/v; Ciba, Basel, Switzerland; a 
photo-initiator). Thorough mixing of the viscous solution that resulted was achieved by 
repeated transfer of the mixture between two sterile syringes (Beckton Dickenson, 
Franklin Lakes, NJ) through a 3-way stopcock (Kimble Kontes, Vineland, NJ). The 
mixture was then centrifuged for 5 min at 1000 g to remove air bubbles and aliquoted 
into cylindrical molds (for rheology, compression: 2 cm2, 0.5 ml; for all other mechanical 
analytical techniques: 0.79 cm2, 0.2 ml; for cell culture: 0.32 cm2, 0.1 ml). The aliquoted 
solution was then exposed to UV light (λ = 365 nm, ~22 mW/ cm2) for 1.11 min/ mg HA 
(2 cm2 mold: 25 min; 0.79 cm2 mold: 10 min; 0.32 cm2 mold: 5 min). The dimensions 
(height and diameter) of the swollen cylindrical hydrogels, which were crosslinked in the 
0.32 cm2 mold, were measured with a digital caliper (Fisher, Pittsburgh, PA). 
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Figure 6.1. Crosslinking chemistry of GM HA. GM-HA hydrogels were prepared by a two step process. 
HA was initially incubated with GM, a chemical catalyst (TEA) and phase transfer catalyst (TBAB) in a 
batch reaction combining the glycidyl units of GM and hydroxyl units of HA to create the uncrosslinked 
GM-HA product. A GM-HA solution was then combined with a  photoinitiator (I2959) and treated with 
UV to stimulate the radical reaction of the methacrylate units of  GM-HA. 
 
 
6.2.3 Fourier Transform Infrared Spectroscopy 
 Fourier Transform Infrared – Attenuated Total Reflectance (FTIR-ATR) was 
performed to determine the chemical alterations induced by the initial incorporation of 
GM onto the HA backbone and its UV-induced transition into a crosslinked GM-HA 
hydrogel. Freeze-dried samples of crosslinked GM-HA were analyzed on a Varian 660-
IR FTIR spectrometer (Varian, Palo Alto, CA) and compared to uncrosslinked GM-HA 
and the HA starting material (n = 3). The spectra were recorded in a frequency range 
between 400 cm-1 and 4000 cm-1 with a spectral resolution of 4 cm-1. A spectral library 
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(Mentor Pro, Biorad, Hercules, CA) was used to identify the peaks and the corresponding 
bond vibrations. 
 
6.2.4 Apparent Crosslinking Density 
 The structural integrity of GM-HA is primarily maintained by GM crosslinks, 
which link the HA strands to one another and limit their freedom of motion. The 
incorporation of HA oligomers may reduce the effectiveness of these crosslinks, 
diminishing the overall mechanical properties of the gel. In addition, the efficiency of 
GM-HA derivatization and UV-induced crosslinking of GM may not be 100%. 
Accordingly, we deemed it necessary to define an apparent crosslinking parameter, which 
in essence represents the effective crosslinking within each gel formulation. Uniaxial 
compression testing was performed to calculate the apparent crosslinking density within 
the gels. Cylindrical gel samples (8-mm diameter) were punched out of a larger gel using 
a 8-mm-diameter corneal trephine (BRI, Malden, MA) and were compressed without 
constraining the edges (unconfined compression testing) on a DMA Q800 (TA 
Instruments, New Castle, DE). The gels were subject to an initial force of 0.05 N and 
were then compressed at a rate of 20% strain/ min (n = 8). All tests were performed in air, 
though the gels were kept hydrated in PBS while being compressed. Stress/ strain curves 
were developed according to Equation 6.1 developed by Flory 318 and the initial slope of 
the curve (0 – 30% strain) was used to estimate the apparent crosslinking density of the 
gel. 
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where σ – uniaxial compressive stress (Pa), Ρ – universal gas constant (J/ mol K), Τ – 
temperature (K), φ2,x – polymer volume fraction post-crosslinking, φ2,s – polymer volume 
fraction swollen, νe/Vo – apparent crosslinking density (mol/ cm3), and α – compressed 
fraction. 
 
6.2.5 Rheology 
 To further characterize the impact of crosslinking and oligomer incorporation on 
hydrogel mechanics, rheological oscillatory shear stress experiments were performed. 
The gel stiffness was experimentally determined by measuring the storage (G’) and loss 
(G”) moduli. An AR G2 rheometer (TA Instruments, New Castle, DE) was used in the 
parallel plate geometry, with a 25-mm plate and constant normal force of 0.2 N. A 
deformation angle of 1 mrad was maintained throughout each frequency sweep of 0.08–
10 Hz (n = 4). 
 
6.2.6 Swelling Ratio 
 Swelling tests were performed to study the effects of HA oligomer content on the 
bulk hydrodynamic properties of the GM-HA gels. Fully hydrated gels were blotted to 
remove surface liquid. The weight of the swollen gel samples were recorded using a 
sensitive balance (OH AUS, Pine Brook, NJ). The gels were then freeze-dried and 
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weighed again. The swelling ratio was calculated by the following formula (n = 4). 
 
d
s
W
WtioSwellingRa =      (Eq 6.2) 
 
where Ws is the swollen mass of the gel (mg), and Wd is the dry mass of the gel (mg). 
 
6.2.7 Scanning Electron Microscopy 
 SEM was performed to determine how incorporating HA oligomers (D1), and 
their concentrations alter the interior pore structure of the gels. In preparation for SEM, 
swollen gels were dehydrated with acetone, snap-fractured and the interior surface coated 
with gold for 4 min using a SPI-Module Sputter Coater (Structure Probe, Inc., West 
Chester, PA) and imaged on an SEM ( Jeol 100-JSM 5410 LV, Pleasanton, CA) at 150× 
magnification (n = 3). 
 
6.2.8 In Vitro Degradation 
 In vitro enzymatic degradation of the hydrogels was measured as a function of 
time by incubating the GM-HA gels in a solution of testicular hyaluronidase, and then 
monitoring the dry mass of the samples that remained un-degraded at various time points. 
The gels were initially soaked in digest buffer (150 mM NaCl, 100 mM CH3COONa, 1 
mM Na2-EDTA, pH 5.0) overnight to reach swelling equilibrium. Gels were then 
incubated in a solution of bovine testicular hyaluronidase (Sigma-Aldrich), prepared in 
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digest buffer (2 mL of 50 U/ ml), for 6 h at 37°C with mild mixing on a platform shaker. 
At 0, 2, 4, and 6 h of digestion, the surviving dry masses of the gels were measured (n = 
3). The enzyme solution was replaced after each analysis time point. The HA mass 
degradation profile was fitted according to first-order degradation kinetics using non-
linear regression to estimate gel degradation rate constant (k). 
 
kt
oeCtC
−=)(       (Eq 6.3) 
 
where, C(t) is the dry mass of the gel at time t (mg), Co is the initial dry mass of the gel 
(mg), k is the degradation rate (h-1), t is time (h). 
 
6.2.9 In Vivo Biocompatibility 
 The biocompatibility of the hydrogels was determined by their subcutaneous 
implantation in rats. Prior to implantation, the hydrogels were sterilized in 95% v/v 
ethanol (Sigma) for 2 h and then re-hydrated in sterile 1× PBS overnight. Sprague-
Dawley rats (~250 g) were anesthetized (0.01 ml/ g intramuscular injection of 4% chloral 
hydrate), shaved, and a 5-cm incision made in the skin along the spine. Blunt dissection 
was used to form a pocket between the skin and muscle. The muscle surface was then 
cleared of fascia. GM-HA hydrogels of different formulations and matrigel (Sigma) were 
placed directly into these pockets (5 implants/ animal; n = 7), as shown in Figure 6.2. 
After implantation, the surgical incision was closed with 4-0 silk suture with a FS-2 
cutting needle (Ethicon, Piscataway, NJ). 
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Figure 6.2 Illustration of subcutaneous implantation scheme of GM-HA in the back of rats. All GM-HA 
formulations and matrigel controls were implanted into the same rat. 
 
 
 At 3 weeks, the hydrogels and the adherent tissue capsules were explanted from 
the subcutaneous pockets, fixed in 4% v/v paraformaldehyde and soaked for 1 h intervals 
in 30% w/v sucrose, 1:1 30% sucrose: optimal cutting temperature (OCT; Sakura, 
Torrance, CA) compound, and finally in pure OCT. The explants were then embedded 
within OCT, frozen on dry ice, and stored at -80°C. Prior to sectioning, the frozen blocks 
were acclimated to -20°C (overnight) and cryosectioned perpendicular to the skin and 
muscle surfaces. The 8-µm thick sections were transferred onto HistoBond® glass slides 
(VWR) and stained with Haematoxylin and Eosin to detect inflammatory cell infiltration 
towards or within the implant. The tissue sections were imaged on a Leica DM IRB 
microscope equipped with a JVC TK-C1380 color camera. In addition, 
immunofluorescence methods were used to detect the collagen, and hence presence of a 
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fibrous capsule within the tissue mass surrounding the implant. The 15 µm thick tissue 
sections were initially quenched with 1% v/v phosphomolybdic acid to supress 
autofluorescence due to collagen, and then incubated with a primary antibody for 
collagen I for 1 h (rbt vs. rat col I; 1:100 in PBS; Chemicon, Temecula, CA). A solution 
of donkey serum (5% v/v in PBS) was added to the sections as a blocking agent (20 
minutes) to prevent nonspecific binding of the secondary antibody. The sections were 
then treated with a FITC-conjugated secondary antibody (dky vs. rbt IgG; 1:500 in PBS; 
Chemicon) for 1 h. Draq 5 (1:2000 in PBS, 10 min; Biostatus, Leicestershire, UK) was 
used to fluorescently label the cell nuclei and visualize the cell density in the region 
surrounding the implant. Fluorescently labeled sections were imaged on a TCS SP2 
AOBS confocal microscope (Leica, Allendale, NJ) using the z-axis function to image 5 
µm sections, which were then compressed into a single image 
 
6.2.10 Cell Culture 
 Neonatal rat aortic smooth muscle cells (NRASMCs) were harvested from the 
aortae of 3-day-old rat pups using methods previously described by Oakes et al. 340. 
Aortae from Sprague–Dawley rat pups were excised and split longitudinally in sterile 
PBS (with 2mM Ca2+, 4°C). The collagen-rich matrix was digested with collagenase 
(type II, 2 mg/ ml in serum-free medium; Worthington Chemical Corporation, Lakewood, 
NJ) for 10 min at 37°C. DMEM: F12 culture medium, containing 10% v/v FBS and 1% 
v/v penicillin-streptomycin, was added to the digested segments. After scraping off the 
endothelium, the aortal segments were minced into 0.5-mm-long pieces and explanted 
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within culture plates pre-wetted with DMEM:F12 culture medium. The explants were 
removed after 1 week of culture and the primary cells were cultured to confluence and 
passaged to expand the culture. Only low passage (P6-8) cells were used in this study. 
 The pre-gelation solution of uncrosslinked GM-HA was initially sterilized by 
syringe filtration, added to the wells of a sterile mold (0.32 cm2 ,0.1 ml) and combined 
the rat aortic SMCs (3 × 106 cells/ ml) isolated from neonatal rats. GM-HA was then 
crosslinked by UV exposure (5 min) and the resulting hydrogels with encapsulated SMCs 
were cultured in DMEM: F12 containing 10% v/v FBS and 1% v/v penicillin-
streptomycin. Spent medium was replaced thrice weekly during the duration of culture. 
 
6.2.11 Fluorescent Detection of Cell Viability 
 As stated in section 4.2.11, calcein AM was used to fluorescently detect live 
SMCs within GM-HA and determine their ability to endure the extent UV treatment 
necessary for crosslinking GM-HA. SMCs were encapsulated in GM-HA with 0% w/w 
HA oligomer content using UV exposure times of 3, 5, 7 and 10 min, and cultured for 4 h 
prior to calcein AM detection. Draq 5 (1:2000 in PBS, 10 min; Biostatus) was also used 
to fluorescently label the cell nuclei. Encapsulated SMCs were imaged on a TCS SP2 
AOBS confocal microscope (Leica) using the z-axis function to image 80 µm within each 
gel in 8 µm sections (n = 4). These sections were then compressed into a single image. 
 
6.2.12 Immunolabeling of Elastin 
 The elastin produced by SMCs cultured within the GM-HA hydrogels were 
 225
compared by immunofluorescence and quantified by calculating the volumetric mean 
fluorescence intensity (MFI) on a per cell basis. Encapsulated SMCs were cultured for 3 
wks prior to preparation for cryosectioning. The cryo-frozen samples were sectioned with 
a 15-µm thickness, in a direction perpendicular to the radial axis of the cylindrical GM-
HA gels. The sections were transferred onto HistoBond® glass slides (VWR) and 
fluorescently labeled for elastin. To do this, briefly, the sections were quenched with 1% 
v/v phosphomolybdic acid to supress autofluorescence due to collagen and then 
incubated with a primary antibody for elastin for 1 h (rbt vs. rat elastin; 1:100 in PBS; 
Chemicon, Temecula, CA). A solution of donkey serum (5% v/v in PBS) was added to 
the sections as a blocking agent (20 minutes) to prevent nonspecific binding of the 
secondary antibody. The sections were then treated with a FITC-conjugated secondary 
antibody (dky vs. rbt IgG; 1:500 in PBS; Chemicon) for 1 h. Draq 5 (1:2000 in PBS, 10 
min; Biostatus) was used to fluorescently label the cell nuclei. Fluorescently labeled 
sections were imaged on a TCS SP2 AOBS confocal microscope (Leica) using the z-axis 
function to image 5 µm sections at a constant gain and offset (FITC – 600, 0.9). These 
sections were then compressed into a single image (n = 9) prior to MFI per cell 
calculations using Image J. 
 
6.3 Results 
 6.3.1 Crosslinked HA Hydrogels 
 HMW HA and HA oligomers (D1) were combined into hydrogels by crosslinking 
with GM, resulting in a total of 4 gel formulations. Briefly, these formulations contained 
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oligomer concentrations of 0, 5, 10, 20% w/w D1/HA. Figure 6.3 shows the hydrated 
hydrogels following crosslinking within the 0.32 cm2 mold, and their measured 
dimensions. The HA oligomer (D1) content minimally affected the size of the fully-
hydrated hydrogels with limited increases observed in their height (h) and diameter (d). 
Irrespective of their composition, and the gels remained fairly transparent. 
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Figure 6.3 Size of hydrated GM-HA hydrogels. The height (h) and diameter (d) of the cylindrical GM-HA 
hydrogels slightly increased with increases in HA oligomer content. The transparency of the gels was 
maintained. The ruler marks indicated 1-cm increments. 
 
 
6.3.2 FTIR Spectroscopy 
 FTIR-ATR spectra of lyophilized crosslinked GM-HA containing various 
concentrations of D1 (0, 5, 10, 20% w/w), uncrosslinked HA and uncrosslinked GM-HA 
(both HA 1500 and D1) were measured. Due to the similarity within each tested group of 
samples, Figure 6.4 shows only a representative spectrum of formulations in each stage 
in the formation process of GM-HA. The spectrum of uncrosslinked HA (A) agreed well 
with that provided by the American Society for Testing of Materials (ASTM). Upon 
adding GM to the HA backbone, the emergence of absorption bands at 936.12 and 
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1492.06 cm-1 (B) indicated the presence of the methacrylate carbon-to-carbon double 
bonds 320 and the successful derivatization of HA and HA oligomers (D1) with GM. UV 
exposure resulted in bonding between methacrylate groups, the radical breakdown of 
their carbon-to-carbon double bonds and the disappearance of the absorption bands at  
936.12 and 1492.06 cm-1 within crosslinked GM-HA (C). 
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Figure 6.4 FTIR-ATR spectra of HA (A), uncrosslinked GM-HA (B), and crosslinked GM-HA (C). The 
initial addition of GM to HA resulted in an absorption band at 936.12 cm-1 identifying the carbon-to-carbon 
double bond of GM methacrylate. This absorption band disappeared upon UV exposure signifying the 
successful crosslinking between the methacrylate groups. 
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6.3.3 Hydrogel Crosslinking 
 The apparent crosslinking density and swelling ratio of GM-HA hydrogels were 
used to estimate the degree of crosslinking within them. Table 6.1 and Figure 6.5 show 
the apparent crosslinking density and swelling ratio, respectively, were dependant on the 
presence of D1. The addition of D1 into the hydrogels constructs increased the swelling 
capacity of the gels over gels composed only of HA 1500, though the extent of swelling 
did not appear to depend on the D1 content. On the other hand, apparent crosslinking 
density showed an inverse correlation to D1 content. The measured crosslinking density 
was much lower than the calculated theoretical value. Assuming 100% GM 
derivatization of HA (uncrosslinked GM-HA) and 100% UV crosslinking of derivatized 
GM-HA (crosslinked GM-HA), the apparent crosslinking density was calculated to be 
roughly of 1 – 2% of that theoretically calculated. 
 
 
20%
10%
5%
0%
D1 Conc.
1035.80
1171.18
1325.72
1378.52
Theoretical
νe (mol/ cm3 x 106)
0.88 ± 0.05
1.31 ± 0.81
2.14 ± 0.15
2.66 ± 0.24
Measured
νe (mol/ cm3 x 106)
 
 
 
 
 
Table 6.1 Apparent crosslinking density of GM-HA determined from the uniaxial compression data and Eq 
5.1. The addition of D1 into the hydrogels reduced the apparent crosslinking density. These values were 
approximately 1 – 2% of the estimated theoretical values. 
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Figure 6.5 Swelling ratios of GM-HA gels. The incorporation of D1 within the GM-HA hydrogel mildly 
increased their swelling capacity. These increases were, however, not statistically significant except at high 
D1 content. [* denotes a p-value < 0.05 in comparison to 0%] 
 
 
 6.3.4 Hydrogel Strength and Resistance to Degradation 
 Rheological analysis quantified the viscous and elastic responses of GM-HA with 
varying concentrations of D1, thus providing information on their stiffness. In general, 
irrespective of their formulation, both the storage moduli (G’) and loss moduli (G”) of 
the gels were independent of frequency, with the G’ values constantly higher than G” 
(Figure 6.6). The addition of D1 within the GM-HA gels decreased both G’ and G”, 
indicating reduced hydrogel stiffness. To investigate the biodegradability of the GM-HA 
hydrogels, we tested the sensitivity of the gels to a super-physiologic concentration of 
bovine testicular hyaluronidase. The weaker (less stiff) GM-HA gels containing greater 
concentrations of D1 also exhibited steeper degradation profiles (Figure 6.7) 
corresponding to increased gel degradation rates (Table 6.2). 
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Figure 6.6 Viscoelastic properties of GM-HA. The storage moduli (G’) in all cases was greater than the 
loss moduli (G”). The addition of D1 reduced the storage moduli, suggesting lowered gel stiffness of the 
hydrogels. 
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Figure 6.7 Degradation of GM-HA in vitro. Increasing the concentration of D1 within the gels reduced 
their resistance to degradation by testicular hyaluronidase and enhanced the degradation rate. GM-HA 
hydrogels containing oligomers were completely degraded after 6 h exposure to the super-physiologic 
concentration of the enzyme. 
 
  
 
 
 
 
 
 
 
Table 6.2 Degradation rate of GM-HA in vitro. Increasing the D1 content, resulted in a higher rate of 
degradation of GM-HA gels when incubated with a super-physiologic concentration of testicular 
hyaluronidase enzyme. 
 
 
6.3.5 Hydrogel Interior Morphology 
 SEM, in Figure 6.8, shows the change in interior morphology of dehydrated GM-
HA hydrogels. In the absence of incorporated oligomers, the process of dehydration 
resulted in a collapse of the HA strands within the GM-HA gels, to create a solid and 
M
as
s 
R
m
a
g 
(
Time (hrs)
%
)
in
in
e
0.0260.584220%
0.0120.416110%
0.0180.33585%
0.0170.26960%
pvaluek (h-1)HA-o Conc.
 232
minimally porous mass. However, upon incorporation of D1 oligomers, the interior 
structure of GM-HA was rendered increasingly porous. 
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Figure 6.8 Interior morphology of GM-HA. The addition of HA oligomers into GM-HA gels resulted in 
enhanced porosity of the gels. 
 
 
6.3.6 Biocompatibility of GM-HA Hydrogels 
 In all cases, H&E staining revealed limited cellularity immediately around the 
defect created by the GM-HA implants, as compared to that around the DVS-HA (see 
chapter 5); the cellularity of the tissue, however, appeared to increase slightly with 
increases in HA oligomer content (Figure 6.9). Most of the cells in the tissue surrounding 
the implants were flattened and aligned with the collagen fibers, suggestive of fibroblasts. 
However, the cluster of cells immediately around the gels were nonaligned, and in 
greater number around GM-HA gels containing higher concentrations of HA oligomers; 
likely these cells are inflammatory in nature. Thus, GM-HA gels containing a greater 
content of D1, elicited enhanced inflammatory responses relative to gels that contained a 
lower content of D1. However, even in gels containing 20% w/w of D1, the 
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inflammatory cell recruitment was very limited compared to DVS-HA (see Figure 5.9). 
A significant amount of tissue infiltration (see arrows in Figure 6.10), similar to that 
observed within matrigel controls, was observed within GM-HA gels. However, HA 
oligomer content did not appear to affect tissue infiltration into the gels. 
Immunofluorescence studies (Figure 6.11) confirmed the increases in cellularity (blue) in 
the tissue immediately surrounding implants that corresponded with a greater HA 
oligomer content in the implanted gels. These studies also indicated the distribution of 
collagen (green) surrounding the defect region was fairly homogeneous. 
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Figure 6.9 Biocompatibility of GM-HA. Very few inflammatory cells (see arrows) surrounded the implant 
but their density appeared to increase slightly with HA oligomer concentration. 
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Figure 6.10 Tissue infiltration into GM-HA. A significant amount of tissue infiltration (see arrows) was 
observed within GM-HA similar to that of the matrigel control, and did not appear to be affected by HA 
oligomer content. 
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Figure 6.11 Immunofluorescence analysis collagen I surrounding implant. The cellularity (blue) in the 
region immediately surrounding implants increased slightly with a greater HA oligomer content and the 
distribution of collagen I (green) surrounding the defect region was fairly homogeneous. 
 
 
6.3.7 SMC Survival 
 Fluorescence detection of calcein AM-labeled SMCs encapsulated within GM-
HA gels showed that a majority of the cells survived UV-induced crosslinking for UV-
exposure times of 0.67 – 2.22 min/ mg HA (Figure 6.12), which corresponds to 3 – 10 
min for hydrogels crosslinked in 0.32 cm2 molds. At this time (4 h of culture), the SMCs 
continued to retain a rounded phenotype. 
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Figure 6.12 SMCs survival of UV crosslinking. Most of the embedded cells survived all exposure times of 
UV radiation, indicated by the overlaying of nuclei (blue) and live cell (green). 
 
 
6.3.8 Elastin Production by Encapsulated SMCs 
 It is apparent from the fluorescent images in Figure 6.13, that the elastin content 
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(green) within GM-HA containing HA oligomers was visibly higher than the hydrogels 
that did not incorporate HA oligomers (Figure 6.13). Quantification of the volumetric 
fluorescence intensities of elastin and comparison between the gel formulations, 
confirmed this observation and additionally showed that increases in HA oligomer 
content do not enhance elastin production (Figure 6.14). Furthermore, the elongated 
appearance of cell nuclei in all cases suggests that the SMCs acquired a spread 
morphology quite different from the rounded nuclei observed at early culture time points 
(e.g. 4 h; see Figure 6.12). 
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Figure 6.13 SMC elastin production within GM-HA. The elastin content (green) within GM-HA gels 
containing HA oligomers was higher than the hydrogels without HA oligomers. The nuclei of the 
embedded SMCs appeared elongated and, therefore, may have attained a natural spread morphology. 
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Figure 6.14 Quantification of volumetric fluorescence intensities due to elastin synthesized by SMCs 
cultured within GM-HA. The fluorescence intensity due to elastin was enhanced by the addition of HA 
oligomers into the GM-HA gel. The amount of elastin synthesized, however, was independent of the 
concentration of HA oligomers within the GM-HA gels. [* denotes a p-value < 0.05 in comparison to 0%] 
 
 
6.4 Discussion 
 In the past, the relative bioinertness of natural polysaccharides such as HA, has 
prompted their extensive study as biocompatible biomaterials and bio-interfaces for 
clinical use 257,341. As a vital component of tissue ECM, which contributes to 
sequestration 342 and prolonged release of cytokines and other growth factors, useful to 
direct cell behavior, HA with its multiple functional groups available for chemical 
derivatization, is also useful as a drug delivery vehicle/ carrier 267. HA, particularly its 
fragmented forms (e.g., oligomers) also play prominent regulatory roles in wound healing 
in vivo, and thus would be potentially useful as raw materials for fabricating cellular 
scaffolding biomaterials for enabling tissue regeneration in vitro or in vivo. Many unique 
properties of HA, including its viscoelasticity and lack of immunogenicity, have made it 
an appealing cell scaffold platform for tissue engineering applications 343-345.  
M
FI
/ C
el
l
*
*
*
 238
 In order to create HA scaffolds capable of surviving prolonged periods of 
implantation, it must be converted into a stable, biocompatible, insoluble biomaterial with 
good handling properties and mechanics appropriate to the site of implantation. Chemical 
modification has been well recognized as a means to enhance the biostability and 
mechanical properties of native HA. Two possible methods to modify HA are through 
derivatization and crosslinking, both of which can be achieved through reactions between 
the available functional groups of HA (-COOH, -OH, -CH3COONH). The crosslinking 
scheme described in the present study involves incorporation of photo-polymerizable 
methacrylate groups on the HA chain. This strategy presents several advantages over 
other crosslinking methods. Specifically, photo-polymerization avoids the disadvantages 
stemming from reactions that occur immediately upon solution mixing (non-uniform 
gelation) and those that depend on pH, ionic strength, or temperature (non-physiologic, 
detrimental to cells). With photo-polymerization, the solutions can be completely mixed 
prior to exposure to the appropriate wavelength of light required to trigger crosslinking, 
so that rapid, controllable, and minimally invasive crosslinking occurs 346,347. 
Furthermore, since photo-polymerization can be performed under physiological 
conditions, it permits the co-polymerization of biomolecules that would retain their native 
activity thereafter, and incorporation of cells that would remain viable. In vivo, cells are 
exposed to a 3-D architectural microenvironment wherein the behavior is regulated by 
their interactions with other cells, ECM, and growth factors. HA hydrogels resemble the 
physical characteristics of the ECM 122 and can thus be used to encapsulate cells to 
provide a more in vivo-like microenvironment to cultured cells.  
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 Previous studies have suggested that HA hydrogels containing long-chain HA 
(MW>1 × 106 Da) interact poorly with cells, which is detrimental to our intended use of 
these gels as cellular scaffolds for vascular tissue regeneration 306,324. This has been 
attributed variously to their physical properties (small and random pore size, extreme 
hydrophilicity, smooth surface topography), chemical characteristics (anionicity, need for 
chemical derivatization/ crosslinking), and biologic composition (HA chain length). Of 
these parameters, the size of component HA chains appears to most critically influence 
cell response. Native long-chain HA has been implicated in cell-excluding mechanisms, 
whereas HA fragments, especially HA oligomers (< 20mers), are recognized to be more 
bioactive 325. Investigation of size-specific effects of HA on matrix regeneration 
outcomes, particularly of hard-to-regenerate elastic fibers by adult SMCs, has been a 
major focus of research in out lab. We previously showed that elastogenesis and elastin 
matrix synthesis by SMCs was up-regulated by exogenous supplements of an HA digest 
containing a broad range of HA oligomers. FACE analysis found this digest (D1) to 
contain 13.9 ± 3.6% HA 6mers and 8.0 ± 1.6% HA 12mers (chapter 3), while Matrix 
Assisted Laser Desorption/Ionization-Time of flight (MALDI-TOF) mass spectrometry 
suggests a 75.0  ± 0.4% HA 4mer content 31. Previous studies have shown SMCs 
stimulated with exogenously supplemented D1 produced increased amounts of 
tropoelastin and crosslinked matrix elastin 31. This upregulatory phenomenon was 
maintained when the oligomers were presented to SMCs as a surface-immobilized 
substrate wherein HA was chemically derivatized, but not crosslinked (chapter 4). In 
addition, we reported successful synthesis and recruitment of elastin by SMCs seeded 
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atop bio-activated HA hydrogels containing a surface-mixture of bioinert HMW HA and 
shorter, more bioactive HA fragments and oligomers 220 generated by UV-induced 
scission of the HMW HA. However, since the effects of UV light can be difficult to 
control, and potentially cause random ionizations that can be structurally disruptive, a 
better approach is to create ‘bio-activated’ gels containing bio-inert long-chain HA, 
necessary to maintain mechanical integrity and potentially provide a high degree of 
biocompatibility, and smaller, more cell-interactive HA oligomers of defined sizes, that 
would specifically evoke the desired cell responses. Therefore, in this study we sought to 
explore the concept of incorporating bio-active HA oligomers into photo-crosslinked 
mixtures of GM-derivatized long-chain HA, to create standalone biomaterials for use as 
vascular regenerative scaffolds capable of directing encapsulated SMCs to exhuberantly 
synthesize mimics of native elastic matrix structures. 
 The synthesis of GM-HA relied on the reaction of glycidyl methacrylate (GM) 
with HA in the presence of a catalyst, triethylamine. An excess of GM relative to HA was 
also used because of the limited solubility and hydrolysis of GM in aqueous medium.For 
the same reason, tetrabutyl ammonium bromide was used to facilitate the transfer of GM 
into the aqueous phase and thus enhance it’s reactivity with HA. It has been suggested 
that during this derivatization, two reactions occur simultaneously at pH 7.4. The first is a 
reversible trans-esterification that occurs through the primary hydroxyl group and the 
second, an irreversible ring-opening conjugation that occurs through the carboxylic acid 
group toward the highest substituted carbon of the epoxide 348. However, as the reaction 
proceeds, there is a decline in the amount of trans-esterification products and a parallel 
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increase in the concentration of ring-opening products. This suggests that the reaction of 
HA with GM requires a long reaction time (5-10 days) to promote ring-opening vs. 
generation of trans-esterification products. Due to the relatively short reaction time (18 h) 
utilized in this study, we believe the GM-HA produced primarily included the trans-
esterification product (Figure 6.1). In addition, the initial derivatization of HA by GM 
was conducted in a solution that was highly viscous due to the presence of HMW HA, 
and was therefore less-conducive to reaction between GM and HA. Thus, the amount of 
crosslinking induced with GM-HA gels (apparent crosslinking density) was lower (1-2%) 
than that of DVS-HA (10-20%; chapter 5). 
 FTIR analysis was unable to confirm the primary mechanism of the reaction 
between HA and GM but it was able to show the presence of the carbon-carbon double 
bond of the methacrylate group (absorption bands 936 and 1492 cm-1) indicating the 
successful derivatization of HA with GM. The main difference registered between the 
FTIR spectra performed before and after UV irradiation was the disappearance of the 
absorption bands (936 and 1492 cm-1) corresponding to the of the carbon-carbon double 
bonds in the irradiated polymer. The disappearance of these bands suggests that the 
crosslinking reaction was complete following UV irradiation of HA for 1.11 min/ mg HA. 
After UV irradiation, the infrared spectrographs of GM-HA were indistinguishable from 
HA implying that GM-HA retained the basic structure of HA and hence its function.  
 In this study, we hoped that GM crosslinking of HA would decelerate and 
possibly inhibit its natural breakdown. However, we found GM-HA to still be susceptible 
to degradation. Therefore, we investigated the impact of incorporated oligomer content 
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on the rate of degradation of GM-HA gels when exposed to a super-physiologic 
concentration of testicular hyaluronidase in vitro. The degradation rates of these gels 
were influenced by the hydrogel swelling capacity (and thereby enzyme concentration 
within the gels). Hydrogels containing a higher D1 content exhibited a slightly higher 
capacity for hydration, and thus, higher swelling ratios, which allowed greater entry of 
enzymes from the bulk solution into the gel interior. The degradation rates of GM-HA 
gels were much higher than that observed for DVS-HA gels; likely due to the decreased 
apparent crosslinking density and higher swelling ratios. 
 Rheological analysis provided a quantitative evaluation of the viscous and elastic 
responses of GM-HA. Both the storage moduli (G’) and loss moduli (G”) were 
independent of frequency and G’ values were always higher than G”, which is typical of 
a “strong hydrogel”, whose response to oscillating frequency more closely resembles a 
solid than a liquid. The G’ and G” values of GM-HA gels that did not incorporate any D1 
oligomers were similar to that exhibited by other commercially available HA hydrogel 
products for soft tissue augmentation; the G’ and G” of Hylaform (a dermal filler) are 
185 Pa and 21 Pa, respectively, at 3.0 Hz 321. However, vascular regenerative applications 
demand far more resilient biomaterials then does skin due to the dynamic and strenuous 
nature of blood vessels. A completely esterified form of HA (HYAFF), which has shown 
potential as a regenerative vascular grafting material (but yet not shown to be conducive 
to elastogenesis of SMCs), possesses G’ and G” values on the order of 420 kPa and 17 
kPa, respectively, at 1 Hz 256,326. The high strength of this and other successful vascular 
grafting materials indicates that our GM-HA hydrogels would not by themselves be 
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suitable for use as a vascular scaffolding materials, but rather must be composited with 
other existing natural or synthetic graft materials, at least from the standpoint of surviving 
the forces experienced in a vascular environment. 
 SEM was used to evaluate the changes in interior morphology of dehydrated 
hydrogels as a function of D1 concentration. Dehydration itself caused the gels to shrink, 
drawing the HMW HA strand toward one-another resulting in the appearance of very 
solid non-porous material in the absence of HA oligomers. The addition of D1 resulted in 
the emergence of a more porous gel containing a higher quantity and more uniformly-
sized pores. The addition of HA oligomers into GM-HA gels decreased their apparent 
crosslinking density and enhanced their swelling capacity. This, likely, resulted in a 
looser polymer matrix with greater porosity. Dehydration reduced the degree of porosity  
of the GM-HA gels from that of the hydrated state, however, it is evident that the 
increase in porosity of gels with a greater HA oligomer content was maintained. This 
increase in porosity could provide opportunities for encapsulated cells to adhere, spread 
and migrate within these gels. 
 Acetone precipitation, to remove excess GM, a known cytotoxic chemical, from 
the GM-HA conjugates, was used since dialysis procedures used in other methods tended 
to be lengthy and laborious 195. The subcutaneous implant studies show the GM involved 
in the crosslinking of GM-HA to be exceedingly biocompatible. Very few inflammatory 
cells surrounded the implant-tissue interface suggesting GM-HA elicited a much lower 
inflammatory response than DVS-HA. The collagen density in the region around the 
implants and further afield appeared uniform, indicating the lack of  exaggerated fibrous 
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capsule formation. The primary cell types that respond to subcutaneous implants are 
typically fibroblasts and inflammatory cells. Fibroblast attempt to isolate the implant by 
surrounding it with a collagen I-rich fibrous capsule, while inflammatory cells degrade/ 
digest the implant. The lack of an accumulation of collagen I and inflammatory cell 
adjacent to the D1 oligomer-free GM-HA gels indicates a very biocompatible material. 
The addition of D1 oligomers into GM-HA stimulated a moderate increase in 
inflammatory cell recruitment, though still much lower than DVS-HA with the same 
content of D1. The only difference between GM-HA and DVS-HA was the amount and 
type of crosslinker; therefore, we can conclude that the toxicity observed in DVS-HA 
(chapter 5) was due to the DVS content. In addition, similar to the matrigel control, a 
greater amount of tissue infiltration was observed within GM-HA, as compared to the 
DVS-HA. Tissue projections into the defect site were observed for all formulations 
possibly due to the lower crosslinking density (lowered stiffness) as compared to DVS-
HA, which enables cells to readily infiltrate. 
 The goal of this work was to incorporate HA oligomers into photo-crosslinked 
GM-HA gels containing predominantly HMW HA, in order to provide greater bioactivity, 
and specifically enhance elastogenesis of encapsulated SMCs. It is possible that photo-
initiator concentration, duration of UV exposure for crosslinking, and HA oligomer 
concentration may affect the viability of cells encapsulated within the photopolymerized 
hydrogels 349. Therefore we used calcein AM to determine whether SMCs survived the 
encapsulation process, under these conditions to fabricate GM-HA. We found that the 
SMCs were able to endure UV exposure times that were twice the dosage we deemed 
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necessary for gel solidification via crosslinking (2.22 vs. 1.11 min/ mg HA) and remained 
viable in the presence of 0.01% w/v I2959 photo-initiator. After 3 weeks of culture of 
encapsulated SMCs, elastin was detected within the GM-HA gels; the presence of HA 
oligomers doubled elastin matrix deposition. SMCs do produce enzymes that degrade 
HA; therefore, it is possible that in the absence of D1 oligomers encapsulated SMCs were 
stimulated to produce elastin by the HA fragments generated by cellular degradation of 
long-chain HA within the gels. However, given the increase in elastin production 
observed with exogenous and immobilized HA oligomers (see chapters 3, 4), and GM-
HA gels incorporating D1, it must be concluded that the presence of HA oligomers is 
primarily responsible for the increase in elastin production. One way in which HA 
impacts cellular events is through interaction with cell surface receptors that, in turn, 
transduce intracellular signals. One such receptor is CD44, a widely distributed cell 
surface glycoprotein that is expressed as numerous iso-forms that are, however, not active 
on all cell types 350. The intracellular domain of CD44 interacts with cytoskeletal proteins 
and regulates signaling, thereby providing a direct link between extracellular HA and the 
cell cytoskeleton 351. HA oligomers are capable of binding to cell surface receptors in a 
monovalent manner, possibly allowing HA–bound receptors to cluster and/or multiple 
HA molecules to bind to a single receptor resulting in the stimulation of specific cell 
signaling cascades 233. Binding of HA oligomers to CD44 has been shown to activate 
intracellular signaling pathways that significantly alter cell proliferation and motility 351 
and may also promote the production of elastin. HA plays a prominent role in the 
synthesis and organization of microfibrils (fibrillin), a precursor for elastic fiber 
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deposition 27-29. HA has also been implicated to play key roles in the synthesis 352, 
organization, and stabilization 353 of elastin by SMCs. In addition, HA has been suggested 
to play an indirect role in elastogenesis through its intimate binding of versican, which in 
turn interacts with microfibrillar proteins (fibulin-1, 2) and elastin-associated proteins to 
form higher-order macromolecular structures important for elastic fiber assembly 27-29. 
Recent studies provide evidence that some GAGs (e.g., HA) coacervate soluble 
tropoelastin molecules on their highly anionic surfaces, to facilitate LOX- mediated 
crosslinking into an insoluble matrix 354, and stabilize elastin fibers against degradation 
by elastases. Therefore, both HMW HA and HA oligomers may play significant roles in 
the production of elastin within GM-HA. 
 
6.5 Conclusions 
 In this study, we successfully developed hydrogels composed of HMW HA and 
its oligomers, derivatized with UV-crosslinkable glycidyl methacrylate, as potential 
biomaterials for regeneration of the elastin-rich tunica media layer of blood vessels. We 
showed the mechanical (degradation, viscoelasticity) and physical (crosslinking density, 
surface structure, swelling) properties of these hydrogels can be modulated by varying 
the oligomer content within. However, the overall strength of these hydrogels is too low 
for them to be used as stand-alone biomaterials/cell scaffolding for in vivo tissue 
regeneration, and therefore, must be composited with other more robust biomaterials with 
a proven record of survival in the rigorous mechanical environment exhibited by blood 
vessels. Using this crosslinking scheme we were able to encapsulate SMCs directly into 
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the gel forming a 3-D cellularized scaffold. The embedded cells survived the UV-induced 
crosslinking process, and extended culture periods (3 weeks). The presence of oligomers 
within GM-HA enhanced elastin matrix deposition, supporting the notion that HA 
oligomers are more conducive to SMC elastogenesis than other forms of HA. Upon 
subcutaneous implantation, GM-HA gels appeared very biocompatible, eliciting a very 
mild inflammatory cell responses and minimal fibrous capsule formation. Overall, we 
have demonstrated that HA oligomers are a useful tool to incorporate within crosslinked 
HA gels and quite possibly other synthetic or natural biomaterials for the purpose of 
upregulating elastogenesis by vascular SMCs encapsulated in a 3-D space. Though these 
stand-alone materials do not fulfill the requirements for vascular implantation from a 
mechanical standpoint, they may be certainly used for in vitro vascular and other tissue 
regeneration using tissue engineering principles, and quite possibly composited with 
other more mechanically robust biomaterials to provide greater bioactivity and 
elastogenic cues for vascular matrix regeneration in situ and disease blood vessels in vivo. 
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CHAPTER 7 
 
CONCLUSIONS, STUDY LIMITATIONS, AND FUTURE DIRECTIONS 
 
 
 
7.1 Conclusions 
 Over the past 6 years, our lab has reported extensively on the use of HA as a 
biomolecular agent for the regenerative repair of vascular tissue. HA has been shown to 
beneficially impact two key aspects of vascular regeneration, namely functional 
endothelialization and elastin matrix repair/ regeneration, both of which are crucial to 
restore vascular homeostasis following trauma or disease. Our previous efforts showed 
the elastogenic effects of exogenous HA fragments on SMCs to be depend on HA size 
31,32. Only supplements of broad HA oligomer mixtures (D1), containing a lower 
concentration of 6mers and 12mers, up-regulated elastin synthesis by adult SMCs, and 
enhanced the formation of an elastin fiber-rich matrix. This project was initiated to 
investigate the ability of HA to promote surface endothelialization of intravascular 
implants/ grafts, and thereafter apply this, and previously acquired information on the 
HA-induced elastogenesis of vascular SMCs, to the development of HA biomaterials, in 
the form of surface coatings and hydrogels, for vascular tissue engineering. To achieve 
this goal, the project was divided into four modules. Module 1, investigated the size-
specific effects of exogenous HA on EC behavior, and used this information to identify 
the HA fragment sizes or combination thereof , which would be needed to be presented at 
biomaterial surfaces to elicit complete and functional endothelialization when implanted 
intra-vascular. In module 2, we immobilized different-sized HA fragments onto culture 
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surfaces to determine if the immobilization process, which involved derivatization of HA 
without incorporation of a crosslinker, would altered the size-specific responses of ECs 
and SMCs to HA, as identified in module 1. Such a culture model also simulated the use 
of HA as a scaffold coating material. Modules 3 and 4 involved the development of 3-D 
HA scaffolds and their ability to promote endothelialization and SMC elastogenesis, 
respectively, and also permitted assessment of the effects of incorporated crosslinks and 
HA oligomers on the physical, chemical and biologic properties of the formulated 
hydrogels. 
 The initial objective of module 1 was to generate enzymatic digests of HMW HA 
containing low (D1) and high (D2) concentrations of HA oligomers, and to further test 
EC responses to these digests, HMW HA, and larger commercially available pure 
oligomer preparations. In this manner, we demonstrated that both HA oligomers (D2) and 
HMW HA interact with ECs in a positive manner; D2 enhanced EC proliferation, and 
angiogenesis, while HMW HA significantly alternated platelet attachment to ECs and 
their futher aggregation and activation. However, D2 also stimulated modest 
inflammatory cytokine production and CAM expression, while HMW HA, in general, 
limited this effect. From this data we concluded that HA oligomers are capable of 
stimulating an angiogenic response by ECs but may also elicit mild inflammatory 
reaction in vivo or cell activation in vivo, while HMW HA can act as a protective barrier 
to exclude potentially harmful blood components from interacting with the ECs. These 
studies thus stressed on the importance of including both forms of HA within HA 
biomaterials so as to achieve optimal biocompatibility and biologic responses. 
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 In module 2, we investigated the utility of HA fragments/ oligomers as bioactive 
surface coatings for biomaterials that would enhance their recruitment, sustenance, and 
functional guidance of a confluent layer of ECs. To do this, we immobilized the 
fragments/ oligomers onto a culture substrate via a strategy that involved chemical 
derivatization of HA, but not crosslinking. We then investigated if these HA fragements/ 
oligomers stimulated EC function and SMC elastogenesis as did their exogenously-
supplemented counterparts. We found that we were able to successfully chemically bind 
a wide size range of HA fragment onto glass slides. When ECs were seeded on these 
surfaces, the cells only attached to those surfaces immobilized with a highly concentrated 
digest of HA oligomers (D2) containing predominantly HA 6mers and 12mers; the 
larger-sized HA fragments detered cell adherence and/or spreading. The D2-tethered 
surfaces also stimulated EC proliferation and slightly enhanced CAM expression similar 
to what we observed with exogenous D2. SMCs cultured on substrates of a differently 
composed HA oligomers digest (D1), which contained a lower concentration of HA 
6mers and 12mers, enhanced cellular tropoelastin synthesis and deposition of crosslinked 
matrix elastin similar to that induced by exogenous D1 mixtures 31; however, surface-
tethered D1 was more effective in enhancing in desmosine crosslinking and elastic fiber 
organization. These results attest to the utility of HA oligomers as coatings on the surface 
or within the interior lattices of various vascular regenerative scaffolding materials, 
natural or synthetic, for the purpose of modulating behavior and matrix production by cell 
seeded thereupon. However, the enhanced CAM expression elicited by both exogenous 
and immobilized HA oligomers is of concern. Therefore, the next step in this project was 
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to incorporate these bioactive HA oligomers into scaffolds composed predominantly of 
relatively bioinert HMW HA, to temper EC CAM expression, and create a biomaterial 
with good handling properties. However, in order to ensure the benefits of HA oligomers 
were not lost and that the physical and mechanical properties of the composite gel 
scaffolds were not compromised, we deemed it necessary to determine the optimal 
content of bioactive HA oligomers within these gel scaffolds. Moreover, creation of such 
a gel would necessitate the use of chemical crosslinking which could by themselves alter 
cell response to HA/ oligomers or compromise biocompatibility. We thus sought to 
assess the impact of crosslinker content on gel biocompatibility and physical properties. 
 In module 3, we successfully developed hydrogels composed of DVS-crosslinked 
HMW HA and HA oligomers, as potential biomaterials for the regeneration of the 
vascular endothelium. We showed the mechanical (degradation, viscoelasticity) and 
physical (crosslinking density, surface structure, swelling) properties of these hydrogels 
can be adjusted by varying the crosslinker and oligomer densities within them. However, 
the overall strength of these hydrogels was too low for their use as standalone materials 
for vascular applications. Therefore, our study recommends that these DVS-crosslinked 
gels, composed of relatively bioinert HMW and bioactive HA oligomers, be composited 
with other existing and mechanically appropriately vascular graft/ implant materials to 
modulate vascular cell behavior to achieve a faithful regenerative response. The presence 
of HA oligomers within DVS-HA seemed to enhance EC attachment and proliferation, 
supporting our hypothesis that crosslinked HA oligomers would retain the biologic 
signaling characteristics of uncrosslinked HA oligomers, and they would be more 
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conducive to EC growth than longer sized fragments of HA. However, the high 
concentration of DVS, required to impart good handling properties to these gels, 
appeared to stimulate mild inflammation in vivo and EC activation in vitro. Therefore, 
another crosslinker may be more appropriate to use, which could result in better 
mechanics and improved biocompatibility. To investigate this, we altered the mechanism 
of crosslinking within the hydrogels, focusing on the development of UV-
photocrosslinked gels based on glycidyl methacrylate-derivatized HMW HA and HA 
oligomers. Since this crosslinking mechanism was amenable to encapsulating and 
sustaining cells, we investigated the impact of incorporated GM-derivatized HA oligomer 
mixtures on elastogenesis by encapsulated SMCs. 
 Thus, in module 4, we continued with our idea of combining HMW HA and its 
oligomers into biomaterials but changed the crosslinking scheme (UV crosslinkable 
glycidyl methacrylate) and the cell type investigated. As with DVS-HA, the mechanical 
(degradation, viscoelasticity) and physical (crosslinking density, surface structure, 
swelling) properties of GM-HA could also be modulated by varying oligomer densities 
within them. However, the overall strength of GM-HA was even lower than DVS-HA, 
suggesting that the formulation also be necessarily composited with existing scaffolding 
biomaterials (synthetic or natural) that would be mechanically compliant with the 
vascular tissue material for vascular applications. The role of oligomer-containing GM-
HA within these composite scaffolds would be to recruit and sustain SMCs within, and 
elastogenically upregulate these cell types that are poorly capable of synthesizing elastin, 
to regenerate a functional elastic tissue as the scaffold degrades.  
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 Using this photocrosslinking scheme we were able to encapsulate SMCs directly 
into the gel to form a 3D cellularized scaffold. The embedded cells survived extended 
periods of UV exposure necessary to initiate crosslinking of GM-HA. The presence of 
oligomers within GM-HA enhanced elastin matrix deposition by SMCs, supporting our 
hypothesis that GM-HA oligomers would retain the pro-elastogenic properties of 
uncrosslinked HA oligomers. GM-HA gels were more biocompatible/ less inflammatory 
than DVS-HA when implanted subcutaneously in rats. Overall, we showed that HA 
oligomers are useful to incorporate within existing, mechanically appropriate vascular 
biomaterial scaffold, either as surface-immobilized coatings or as hydrogels composited 
with the scaffolds, to promote endothelialization and elastic tissue regeneration. Our 
studies also indicate that incorporation of HMW HA is also necessary to temper adverse 
cell responses to HA oligomers (e.g., CAM expression) and provide mechanical stability/ 
ease of handling to the gels. Therefore, future studies will focus on the development of 
other more mechanically appropriate materials with known cell adhesive or elastogenic 
properties that may benefit from the incorporation of HA oligomers. 
 
7.2 Study Limitations 
Despite the perceived potential advantages of developing vascular biomaterials 
with HA oligomers for the promotion of endothelialization and SMCs elastogenesis, 
limitations pertaining to this study must be addressed prior to their application to tissue 
engineering systems.  These limitations are outlined below. 
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1. All hydrogels were produced in cylindrical molds composed of polystyrene or 
plexiglass, which resulted in surface tension-induced liquid migration along the 
mold-hydrogel interface prior to crosslinking. This produced hydrogels that 
possessed concave surfaces. Somewhat crude Caliper measurements were use to 
determine the dimensions of the hydrogels and did not take this concavity into 
account. Therefore, the surface area and protein deposition calculations may not 
be exact. It is to be noted however, that concavity was not extreme and was only 
percieved when attempting to image cells on the hydrogel surface. Therefore, we 
believe our methods were adequate for the purposes of this study. 
2. The HA oligomers used in this study were obtained by enzymatic digestion of 
HMW HA, using optimized protocols developed in our lab.  These oligomeric 
mixtures contained predominantly 6mers and 12mers, with other oligomers 
forming the balance.  However, any changes in digestion conditions (time, 
concentrations, temperature, source of HMW HA, etc) can alter the composition 
of the HA oligomer mixtures, which might significantly alter the cellular response 
to these mixtures. Thus, high level of quality control in the preparation of these 
oligomer mixtures is warranted. 
3. We used a protein assay to determine the amount of matrigel deposited onto 
DVS-HA. The accuracy of measurement using the Dc Bio-Rad protein assay is 
greatest for standards and sample concentrations within the range of 0.2-1.5 µg/ 
ml. In our studies, the protein concentrations often were lower than 0.2 µg/ ml. 
This brings the accuracy of our results into question. However, the calibration 
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curves generated with standards within our concentration range of interest, 
continued to be linear, as with standards within the recommended range. We also 
measured a significant decrease of protein within the applied bulk protein solution, 
following incubation with the gel surfaces. Therefore, the results strongly suggest 
that this assay is useful for measuring protein concentration outside the range 
recommended by the manufacturer. 
4. For study of interior pore-structures, GM-HA hydrogels were dehydrated prior to 
imaging by SEM. Therefore, the images generated do not necessarily represent 
the interior structure of the hydrated hydrogels. Nevertheless, since our interest 
lies not in elucidating the actual interior morphology of GM-HA, but rather, 
determining the effects of HA oligomer incorporation on the morphology, the 
inferences we have drawn by a comparison of the images obtained for each of the 
gel formulation are likely reliable. However, to investigate the true interior 
topography of the gels in a hydrated state, in the future, using freezing drying or 
osmium tetroxide methods is recommended. 
5. Neonatal vascular SMCs were embedded within the GM-HA gels as opposed to 
adult SMCs used in the exogenous and surface tethered studies. Neonatal cells 
inherently produce a much more exuberant amount of matrix (including elastin) 
than adult cells. We found that elastin production of these neonatal cells is 
upregulated when encapsulated within GM-HA containing HA oligomers. 
However, this may differ from adult SMCs and must be investigated in the future. 
6. Upon explanting the hydrogels from subcutaneous implantation, only a small 
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amount of the tissue surrounding the implant was removed with the implant. 
Therefore, only a minimal view of the tissue reaction to the implant was observed. 
In the future a greater amount of the tissue surrounding the implant must be 
explanted in order to compare the conditions near and distant from the implant 
and fully diagnose the tissue reaction at the biomatial interface. 
7. Most studies use a constant gap distance between the parallel plates of the 
rheometer when performing a frequency sweep. However, due to the malleability 
of our gels we decided to utilize a constant normal force. During the application 
of the normal force, the rheometer constantly recalculated the plate gap involved 
in the calculation of G’ and G”. Therefore, we believe the numbers we obtained 
are accurate. 
8. The sterilization process of GM-HA prior to SMC encapsulation required syringe 
filtration of an extremely viscous solution using a very high back pressure. HA, 
though solubilized, may have been lost during this process reducing the amount of 
HA within each gel and hence may have limited its toxicity. 
9. Many rheology analysis techniques exists, however, we had to limit our studies to 
simple frequency sweeps using a very small deformation angle (1 mrad) due to 
the limited contact between the HA hydrogels and the parallel plates of the 
rheometer. These hydrogels were composed of a very hydrophilic molecule and 
high water content and, even with the use of sandpaper on the plate face, 
contorting the gels was very difficult due to slippage. However, this technique has 
been published as a valid analytical tool for HA hydrogels and therefore, we 
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believe our results are both meaningful and useful in the design of HA materials. 
 
7.3 Future Directions 
 Despite the numerous positive outcomes listed above, the long-term realization of 
the project objectives is contingent on elucidating several unknowns, which have not yet 
been explored in this project and will be addressed by others in our group. Thus, future 
studies can investigate: 
 
Endothelial Cell Studies 
1. Response of ECs to HA oligomers incorporated within a known cell adhesive 
base material with appropriate mechanical properties. 
2. Response of ECs to HA oligomers immobilized on a known vascular grafting 
materials (i.e. ePTFE, Dacron). 
3. Effects of dynamic-conditioning (i.e. shear force) of ECs seeded on HA oligomer-
incorporating scaffolds. 
 
Smooth Muscle Cell Studies 
4. Elastogenesis of adult vascular SMCs encapsulated within GM-HA incorporating 
HA oligomers (D1). 
5. Overall production of elastin precursors, and the yield, stability, and organization 
of elastin matrix generated by SMCs encapsulated within GM-HA, incorporating 
HA oligomers. 
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6. Effects of dynamic-conditioning (i.e. cyclic distension) of SMC-ecapsulated GM-
HA scaffolds incorporating HA oligomers on elastin gene expression, precursor 
synthesis, matrix deposition and maturation, and fiber organization. 
7. Identification of cell signaling pathways of SMC elastogenesis modulated by HA 
oligomers. 
8. Generation of a functional elastic tissue in tissue culture, that can meet the 
mechanical and biologic requirements for implantation in vivo. 
 
Other Studies 
9. Generation of a fully functional blood vessel in vitro by encapsulating SMCs 
within GM-HA loaded with HA oligomers, growth factors and adhesive 
molecules and seeding ECs on the surface. 
10. Utility of HA oligomer-containing GM-HA gels in other relevant areas of tissue 
engineering such as wound healing, cosmetic/ dermal regeneration. 
11. Development of a biodegradable oligomer/ growth factor-loaded scaffold capable 
of delivering properly sized HA oligomers and specific growth factors to an 
elastin deficient tissue (i.e. damaged skin, aneurismal blood vessel) at an 
optimized rate. 
12. The mechanical and biological properties of HA oligomer-embedded GM-HA 
with an added synthetic polymer to enhance mechanical strength and cellular 
interaction. 
13. Mesenchymal stem cell differentiation/ in vivo delivery within GM-HA gels 
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containing HA oligomers for soft tissue (i.e. dermal, etc.) regeneration 
applications. 
14. Generation of photocrosslinkable HA microspheres for the injectable local 
delivery of drugs/ growth factors/ cells. 
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APPENDIX 
 
1. Molecular Content of HA-Immobilized Surfaces 
 In Chapter 4, we immobilized HA onto culture surfaces in order to determine their 
capacity for regenerating the vascular endothelium and vascular SMC elastogenesis. 
Upon quantifying the amount of HA on all surfaces we found that the content of HA 
1500 was much higher than HA 200, HA 20 and D1. However, converting the HA 
content to a molecule basis revealed many more molecules of low MW HA (HA 20, D1) 
attached to the surface than higher MW HA (HA 1500, HA 200). We believe this is due 
to steric hindrance of the larger molecules preventing further HA deposition near the area 
of their attachment. The immunofluorescence images showed higher MW HA to deposit 
on the APTMS functionalized glass surfaces in a less uniform manner and high resolution 
XPS indicated less efficient binding of high MW HA to the amines of APTMS. This data 
confirms the isolated and less efficient binding of higher MW HA to the glass surfaces. 
The molecular weight of D1 was approximated based on the FACE data in chapter 3 and 
found to contain an average MW of 6709 g/ mol. 
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Figure App 1. FACE analysis of HA surfaces on a molecule basis. More molecules of HA 1500 and HA 
200 were present on the surface than the lower molecular weights of HA. The amount of HA 1500 and HA 
200 was similar, while the content of HA 20 and D1 was approximately the same. In all cases, the amount 
of HA was stable on the surfaces throughout the 21 days. [* denotes a p-value < 0.05 in comparison to day 
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